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 Rio2 is required for small subunit ribosomal RNA (rRNA) maturation.  It is 
specifically involved in site D cleavage of the 20S rRNA to produce the mature 18S 
rRNA.  Loss of Rio2p is lethal and a decrease of Rio2p activity results in 20S 
accumulation in the cytoplasm.  One of the goals of this thesis was to crystallize Rio2 
from a eukaryotic organism in order to determine the structural differences between 
eukaryotic and archaeal versions.  Another goal was to define the importance of 
individual domains.  Yeast Rio2 was the first eukaryotic protein purified, but it 
formed only microcrystals.  Human Rio2 was purified next, but the solubility was too 
low to set up crystal trays.  Finally, Rio2 from Chaeotomium thermophilum was 
purified and crystals were obtained.  The structure revealed a possibly inhibitory 
alpha helix blocking the active site.  The role of the N-terminal winged helix domain 
of Rio2 in yeast was investigated and found not to be necessary for binding of Rio2p 
to the ribosome.  
The crystal structure of the first N-acetylglutamate synthase (NAGS) was also 
determined.  The crystal structure of NAGS complexed with acetyl-CoA and with 
CoA plus N-acetylglutamate was determined at 2.5 and 2.6-Å resolution.  Each 
NAGS consists of an N-terminal amino acid kinase domain (AAK) domain and a C-
terminal N-acetlyltransferase (NAT) domain connected by three amino acids.  The 
monomers form a six membered ring with a trimer of dimers symmetry.  The AAK 
domains form two dimeric contacts with other AAK domains.  Each AAK domain 
interacts with the NAGS domain of another monomer at the polar ends of the ring.  
The NAGS domain contains the active site.  The AAK domain is believed to bind 
arginine and also helps to bind acetyl-CoA.   Structural insights suggest a one step 
mechanism in which both substrates bind and the acetyl group is directly passed from 
acetyl-CoA to the alpha amino group of gluatamate. 
In addition, collaborative work on the structural characterization of the 
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Chapter 1:  Introduction 
1.1:  Importance of Ribosome Biogenesis in Tumor Growth and Cancer Progression 
Ribosome biogenesis is the process of making ribosomes.  It involves the 
coordinated function of over 200 proteins in the synthesis and processing of the four 
rRNAs, as well as assembly of those rRNAs with the ribosomal proteins.  Ribosome 
biogenesis is critical for cell cycle progression and cellular proliferation in both normal 
cells and cancer cells (1-4).  Ribosomal RNA (rRNA) processing occurs in the nucleoli 
(located within the nucleus) where ribosome production occurs (5).  Nucleoli undergo 
enlargement in two types of cells: rapidly proliferating normal cells and cancer cells (6).  
In cancer cells, the average size of nucleoli is larger and occurs with a decreased cell 
doubling time (7).  The size of the nucleoli is also directly correlated with the amount of 
rRNA transcription.  Data show that the expression of nucleolar proteins involved in 
rRNA transcription control and rRNA processing is directly correlated to the nuclear size 
and the cellular proliferation rate (7).  Thus, the size of a nucleus is an indicator of the 
rate of cellular proliferation.  The enlarged nucleoli in cancer cells are associated with an 
enhanced ribosome production.  For a proliferating cell to produce new daughter cells, an 
increase in the concentration of ribosomes is required.  The enlarged nucleoli and the 
increase in rRNA production is a marker for conversion to a metastatic state in cancer 
cells (8, 9).  Although ribosome biogenesis is an important part of cancer progression, the 
molecular details of how it occurs are not known. 
1.2:  Ribosome Biogenesis is Highly Controlled in Normal Cells but Becomes 
Deregulated in Tumorigenesis 
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Most of the energy of a proliferating cell is devoted to ribosome production (10).  
Ribosome production is a highly regulated process that is controlled by nutrient level 
changes and growth signals.  The transcription of ribosomal genes is carried out by RNA 
Polymerase I (5, 11).  An increase in production of rRNA occurs when the upstream 
binding factor 1 (UBF1) binds to the upstream control element (UCE) and the core 
promoter of the 35S rRNA gene in response to external stimuli (3).  Binding of UBF1 to 
DNA is regulated by phosphorylation of the C-terminus (12-15).  In nonproliferating 
cells, UBF1 is not phosphorylated and does not activate rRNA gene transcription (15).  
When UBF1 becomes phosphorylated by a kinase such as CDK4-cyclin D or CDK2-
cyclin E, UBF1 binds to the DNA and directly interacts with Pol1, resulting in gene 
transcription (13, 14).  Therefore, in order to control ribosome biogenesis, UBF1 has to 
be carefully regulated.  Caesin Kinase II, ERK1/2 kinases and CDK-cyclin complexes 
have all been shown to phosphorylate UBF1 at the C terminus (14).  These kinases are 
upregulated in many cancers.  Retinoblastoma (Rb) is a tumor suppressor and interacts 
with UBF1 to prevent it from binding to the DNA promoter (16-18).  Rb thereby inhibits 
the production of rRNA to regulate cell growth and proliferation.  A point mutation in Rb 
in small cell lung carcinoma prevents it from interacting with UBF1 (19, 20) .  The 
regulation of ribosome biogenesis must be understood in order to learn how to control 
this process in cancer cells. 
1.3:  RIO Kinases and Their Involvement in Ribosome Biogenesis 
Rio2 protein kinases are atypical serine kinases that are required for the cleavage 
of 20S rRNA to 18S rRNA (21-23).  Since, the yeast model of ribosome biogenesis is 
less complex and amenable to genetic manipulation, it has been used to study ribosome 
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assembly.  rRNA synthesis begins with transcription of a 35S rRNA by RNA polymerase 
I.  This 35S rRNA transcript contains 5.8S, 18S, and 25S rRNA, separated by internal 
transcribed spacers ITS1 and ITS2, and external transcribed regions 5’ and 3’ to the 
rRNA.  (The transcription of 5S rRNA by RNA polymerase III occurs on a separate 
transcriptional unit).  
The extra ribosomal proteins that assemble onto the 35S pre-rRNA cause it to 
sediment at 90S on a sucrose gradient.  Proteins are assembled onto 35S rRNA for 
ribosomal protein loading, rRNA folding modifications, and mainly to direct cleavage of 
the rRNA to produce 20S rRNA.  Cleavage first occurs at sites A0 and A1 on the 5’ 
external transcribed spacer of the 35S rRNA.  This is followed by cleavage at A2 in ITS1 
to release the 20S rRNA particle needed for the 40S small ribosomal subunit.  Proteins 
such as Enp1p, Dim1p, Nob1p, Hrr25p, Rrp12p, Rio2p, Trs1p and Yor145p associate 
with the pre40S ribosomal subunit (37).   Further processing of the 20S rRNA in yeast is 
performed in the cytoplasm by cutting at site D in ITS1 to release the 18S rRNA (Figure 
1.1).  Once the cleavages are completed, these ribosomal assembly factors dissociate.  
40S rRNA processing is abrogated by mutations in 60S rRNA processing.  However, the 
reverse is not true (24-26). 
1.4:  Rio2 is an Atypical Protein Kinase 
Protein kinases phosphorylate serine and threonine residues or tyrosine residues 
(27, 28).  All protein kinases contain a conserved kinase domain of 250-300 amino acids 
in length containing conserved secondary structures (27-29).  RIO proteins are serine 
kinases that contain very few of the conserved residues of typical protein kinases. Thus 
they are labeled as atypical protein kinases (21).  The RIO kinases consist of four 
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subfamilies of proteins, Rio1, Rio2, Rio3, and RioB.  Rio1 and Rio2 are found in species 
from archaeal to human, while Rio3 is found only in multicellular eukaryotes (21).  RioB 
is found only in eubacteria (30, 31).  The RIO family of proteins consists of a RIO kinase 
domain with C and N terminal extensions specific to each subfamily of proteins.  As seen 
from the structure of Rio1 and Rio2, the RIO domain consists of an N-terminal lobe 
containing a twisted β sheet and a long α helix that serves as the back of the ATP binding 
pocket, a hinge region, and a C-terminal lobe which houses the metal binding loop and 
the catalytic loop (32-34) (Figures 1.2 and 1.3).  Rio2 contains a winged helix domain at 
the N-terminus, archaeal Rio1 contains three extra α helices, and the structure of the N-
terminal extension of Rio3 is not yet known as no crystal structure has been determined 
(32-34).  RioB does not contain an N-terminal extension to the RIO domain or a C-
terminal extension.   
Each RIO subfamily member contains unique sequence variations in the RIO 
domain.  Distinct from eukaryotic protein kinases (ePKs), RIO proteins contain an 
insertion of 18-27 amino acids between αC and β3 called the flexible loop because in 
Rio2 this region is disordered (32-34).  In addition, RIO kinases only contain three of the 
α helices of canonical ePKs in the C-lobe.  In contrast to the structure of cAMP-
dependent protein kinase (PKA), RIO proteins lack an activation loop (subdomain VIII) 
and lack subdomains X and XI (32-34).  These subdomains are usually used by ePKs to 
bind to the peptide substrate.  As such, the mode of binding to the peptide substrate of 
RIO kinases is unknown.   
1.5:  Rio2p Associates with the 40S Preribosome and is Involved in Cleavage of the 
20S rRNA 
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Studies in which Rio2 was tagged on the C-terminus by a Tandem Affinity 
Purification (TAP) tag allowed identification of proteins associated with Rio2 in the cell.  
Mass spectrometry identified several proteins required for late 40S maturation such as 
Trs1p, Rrp12p, and Dim1p (35-37).  As such Rio2p was found to be stably associated 
with the 40S preribosome and tagged Rio2p could be used to specifically pull down the 
40S preribosome (35-37). 
Rio2p can shuttle between the nucleus and cytoplasm and thus most likely 
attaches in the nucleus and accompanies the 43S sub-complex to the cytoplasm (21, 22, 
40).  After the loss of Rio2p activity, 20S rRNA accumulates in the cytoplasm with a 
reduction in 18S rRNA (38).   
As Rio2p has serine kinase activity in vitro, its function might be strictly 
enzymatic. The low concentration of Rio2p required to sustain growth in glucose from a 
leaky Gal promoter of the wild type Rio2p, supports the conclusion that Rio2p might be 
used catalytically, rather than stoichiometrically, to effect cleavage at site D (37).   
Another RIO protein, Rio1p, is also important for cleavage of site D, but its 
activity cannot replace that of Rio2p (39).  Tandem affinity purification (TAP) of Rio2p 
does not pull down Rio1p.  There is no evidence for direct attachment of Rio1p to the 
43S preribosomal particle.   
1.6:  The Winged Helix Domain is Structurally Similar to DNA Binding Proteins 
 The structure of Rio2 from archaeobacteria, Archaeoglobus fulgidus, (afRio2) has 
been solved in complex with ATP or ADP and Mn
2+
, the former at 1.84Å and the latter at 
1.75Å (32, 34).  The N-terminal domain of afRio2 contains a winged helix motif.  This 
motif consists of four α helices, followed by two β strands which are followed by a fifth α 
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helix.  The connecting strand between the second and third α helix is a small β strand and 
forms a β sheet with the other two β strands.  The loop between the second and third β 
strand is called a wing—leading to the term winged helix turn helix (32, 34) (Figure 1.4).   
 The winged helix motif is usually found in transcription factors that bind DNA 
such as MarR, SlyA, and the histone linker protein GH5.  Although the root mean square 
difference (rmsd) between these structures is 1.2-1.3Å, they only share 7% to 14% 
identity (34).  These proteins bind to DNA in two ways.  The first way is through the 
amino acids in helix 3 interacting with the major groove of the DNA.  This mode of DNA 
binding was first found in the crystal structure of HNF-3 with DNA (41).  The second 
way of binding to DNA is through the amino acids in W1, β2, and β3 interacting with the 
major groove of DNA.  This mode of DNA binding was first found in the crystal 
structure of hRFX1 and DNA (42).  MarR and SlyA probably bind the major groove of 
DNA via helix 3 and histone H5 probably binds the major groove of DNA via W1, β2, 
and β3 (43, 44).  Rio2 is closer to the structure of SlyA than with histone H5.  Similar to 
SlyA, Rio2 has a fourth helix in the place of the second wing.  Also the electrostatic 
surface of the winged helix domain is most closely identical between Sly A and afRio2.  
Furthermore, supporting a role for afRio2 in nucleic acid binding, the amino acids in 
helix 3 are positively charged (34).  
1.7:  Structure of Rio2p RIO Domain and Insights into Catalysis 
The RIO domain consists of two lobes, the N-terminal lobe and the C-terminal 
lobe separated by a hinge region.  The N-lobe of afRio2 is used to bind and position ATP 
for attack on the γ phosphate by a serine hydroxyl group.  Like traditional kinases, afRio2 
contains a ‘DFG’ loop to bind metal ions.  It also contains a ‘P-loop’, which binds the 
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phosphate groups of ATP and contains the conserved sequence GXGXXS (GVGKES).  
The C-terminal lobe houses the catalytic loop, which contains the conserved N223 and 
D218 residues required for catalysis and metal binding (Figure 1.5).  However, unlike 
traditional ePKs, afRio2 lacks an activation loop also known as sub-domain-VIII.  In 
Erk2, upon phosphorylation of Y185, the loop changes conformation to allow the 
substrate to bind and to position the catalytic residues.  Sub-domain IX, and X in ePKs 
are used for peptide substrate binding.  As part of its classification as an atypical kinase, 
afRio2 lacks these sub-domains.  Thus its mode of peptide substrate binding is still 
unknown (28, 29, 32, 34).  
Upon co-crystallization of afRio2 with ATP and Mg
2+
, a different conformation 
of the γ phosphate is seen than is seen in canonical protein kinases.  When ATP binds 
between the N and C lobes, it causes a large movement of the two lobes with regards to 
each other causing the γ phosphate of ATP to be buried in a deep pocket.  ATP binds 
deep underneath the nucleotide binding loop, and in this position, the γ phosphate is 
shifted away from the center of the active site.  The distance between the catalytic base 
D218 and the phosphorus atom is 5.8Å in afRio2.  In support of its role in catalysis, the 
mutation of D218 produces a largely inactive afRio2.  In order for catalysis to take place, 
the γ phosphate may have to be unburied by a large conformational change of the enzyme 
(32, 34). 
Further conformational changes to the enzyme might occur either upon binding of 
the peptide or upon allosteric changes when an unknown serine/threonine residue is 
phosphorylated by some other kinase present in yeast.   In the case of Rio1p, kinase 
assays demonstrate that phosphorylation by Casein Kinase 2 (CK2) to the c-terminal 
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domain of Rio1p, increases its activity about twofold using a heterologous substrate (45).  
As previously mentioned for ePKs, phosphorylation of the activation loop tends to 
activate the kinase activity (29).  AfRio2 is autophosphorylated at S128, but its effect on 
catalysis had not been investigated (32). 
1.8:  Specific Aims 
The aim of my research towards this thesis was to expand the knowledge of Rio2 
catalysis and to analyze how Rio2 from archaea differs from Rio2 from eukaryotes.  The 
structure of the eukaryotic Rio2 needs to be elucidated as it contains features in addition 
to those of the archaeobacteria Rio2.   
The winged helix domain (wHTH) appears to be an important feature in Rio2.  
The wHTH might bind to the RNA of the ribosome.  The structures closest to wHTH 
found with the DALI server are the transcription factors MarR and SlyA and the histone 
linker protein GH5, all of which are known to interact directly with DNA.   
The specific aims included: 
1. To purify, crystallize and determine the x-ray crystal structure of a eukaryotic 
version of Rio2. 
2. To determine the role of the winged helix domain in yeast Rio2. 
In addition to the specific aims listed above that defined my thesis project, I have 
included the work on two additional crystallography projects completed during my tenure 
here that are considered part of my graduate work.  They are listed below: 
1.  Determination of the x-ray crystal structure of MphR(A), a repressor protein of 
the MphA operon, in collaboration with Dr. Ashton Cropp.  This is presented in 
Chapter 7. 
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2.  Determination of the first x-ray crystal structure of a N-acetyl glutamate 
synthase (NAGS) protein in the laboratory of Dr. Norma Allewell.   
Purification and crystallization of Rio2, the main topic of this dissertation, has been 
discussed in Chapters 2-6.  The x-ray crystal structure of Mphr(A) has been described in 
Chapter 7 and the x-ray crystal structure of NAGS has been presented in Chapter 8.  

















Figure 1.1:  Ribosomal RNA Processing in Eukaryotes.  
 Cleavages at A0, A1 and A2 release the precursor of the small subunit ribosomal rRNA, the 20S rRNA.  In 
the cytoplasm, the 20S rRNA is processed by cleavage at site D to produce the 18S small subunit rRNA.  
Cleavages at A3, B0, and C2 release the precursor rRNAs of the large ribosomal subunit which undergo 
further processing to produce the mature 5.8S and 25S rRNAs. 
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Figure 1.2:  Crystal Structure of AfRio2 
The crystal structure of afRio2 shows a bilobal kinase domain (brown and red) connected to a N-terminal 
winged helix domain (blue).  The green “hinge” region connects the N- and C- terminal lobes of the kinase 
domain.  The ATP binding loop “P-loop”, metal binding loop used to bind Mg, and catalytic loop which 
contains the catalytic D218 are indicated by arrows.  Electron density was not observed for the flexible 





























Figure 1.3:  Crystal Structure of AfRio1 
The crystal structure of afRio1 shows a bilobal kinase domain (magenta and green) connected to three N-
terminal  alpha helices (yellow and red).  The ATP binding loop “P-loop”, metal binding loop used to bind 
Mg, and catalytic loop which contains the catalytic D218 are indicated by arrows.  The cartoon 







Figure 1.4:  Structure of the Winged Helix Domain of AfRio2 
The winged helix domain consists of four alpha helices followed by two beta sheets.  A fifth alpha helix 
(αR) is part of the RIO domain. The wing is labeled W1 and is in magenta.  This cartoon representation was 






Figure 1.5:  Structural Alignment of Rio2 with Eukaryotic Protein Kinases 
Structure-based sequence alignment of the kinase domains of Rio1 and Rio2 from A.fulgidus (AFRio2 and 
AFRio1), Rio2 from S.cerevisiae (ScRio2), eukaryotic protein kinases, Protein Kinase A (PKA) and casein 
kinase (CK1).  Residues highlighted in green are identical in all kinases.  Residues highlighted in yellow 
are identical in Rio2 and Rio1 but not all kinases. The sequences of the ATP binding loop “P-loop”, metal 
binding loop used to bind Mg, and catalytic loop which contains the catalytic D218 are indicated by x’s. 
  
                                                                                                                          P-loop  
                                                                                                        xxxxxx 
AFRio2  48 RNILKYLSDLRVVQN-RQKDYEGSTFTFIGLSLYSLHRLVRSGKVDAIGKLMGEGKESAVF---NCYSEK-FGEC 
AFRio1   5 KKIESYLDKLRIKEK-DGEERKIYAEVLDGRTLKTLYKLSAKGYITAMGGVISTGKEANVFYADGVFDGK-PVAM 
ScRio2  50 NRAISDLAKLSLISKMRNVKYDGYRLTYNGIDYLALKTMLNRDTVYSVGNTIGVGKESDIY---KVSDKN-GNPR 
PKA     15                  VKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVM---LVKHKETGNHY 
CK1      6                                    NVVGV----HYKVGRRIGEGSFGVIF---EGTNLLNNQQV 
 
AFRio2 118 VVKFHKVGHTSFKKVKEKRDYGD-------LHFSVLAIRSARNEFRALQKLQ--GL-AVPKVYAWEG----NAVL 
AFRio1  78 AVKIYRIE-TSEFDKMDEYLYGDERFDMRRISPKEKVFIWTEKEFRNLERAKEAGV-SVPQPYTYMK----NVLL 
ScRio2 121 VMKIHRLGRTSFHSVRNNRDYLKKSNQG--ANWMHLSRLAANKEYQFMSMLYSKGF-KVPEPFDNSR----HIVV 
PKA     70 AMKILDKQKVVKLKQIEH----------------------TLNEKRILQAV---NFPFLVKLEFSFKDNSNLYMV  
CK1     40 AIKFEPRRSDAPQ---------------------------LRDEYRTYKLLA--GCTGIPNVYYFGQEGLHNVLV 
                                                                 Catalytic 
                                                                                                                                xxxxxx 
AFRio2 179 MELIDAKEL---------YRVRV------ENPDEVLDMILEEVAKFYHRG-IVHGDLSQYNVLVSE-------EG 
AFRio1 147 MEFIGEDELPAPTLVELGRELKE------LDVEGIFNDVVENVKRLYQEAELVHADLSEYNIMYID-------K- 
ScRio2 189 MELIEGYPM---------RRLRK-----HKNIPKLYSDLMCFIVDLANSG-LIHCDFNEFNIMIKDKLEDENDCG 
PKA    120 MEYVPGGEMFSH-----LRRI--G-RFSEPHARFYAAQIVLTFEYLHSLD-LIYRDLKPENLLIDQ------QGY  
CK1     85 IDLL-GPSLEDL-----LDLC--GRKFSVKTVAMAAKQMLARVQSIHEKS-LVYRDIKPDNFLIGRPNSKN-ANM 
                        Metal      
                       xxxxx 
AFRio2 231 IWIIDFPQSVEVGEEG---------------------------WREILERDVRNIITYFSRTYRT---------- 
AFRio1 208 VYFIDMGQAVTLRHPM---------------------------AESYLERDVRNIIRFFSK-YGV---------- 
ScRio2 248 FVVIDFPQCISIQHQD---------------------------ADYYFQRDVDCIRRFFKKKLKY---------- 
PKA    180 IQVTDFGFAKRVKGRTWXLCG----------TPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFFA---D  
CK1    150 IYVVDFGMVKFYRDPVTKQHIPYREKKNLSGTARYMSINTHLGREQSRRDDLEALGHVFMYFLRGSLPWQGLKAA 
 
AFRio2 269 EKDINSAIDRILQE 
AFRio1 245 KADFEEMLKEVKGE 
ScRio2 287 EPKPDSSMLDTEGFGDGYKYAYPDFKRDVKRTDNLDELVQASGFSKKH  
PKA    242 QPIQIYEKIVSGKVR-----FPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFATTDWIAIYQRKV  
CK1    225 TNKQKYERIGEKKQSTPLRELCAGFPEEFYKYMHYARNLA----FDATP--DYDYLQGLFSKVLERLNTTE---  
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Chapter 2:  Purification and Crystallography of Rio2p 
2.1:  Introduction to the Purification of Yeast Rio2 (Rio2p) 
 
The main goal of this project is to better understand the role of Rio2 in eukaryotic 
rRNA processing.  The details of the the molecular function of Rio2p is not known.  For 
instance, it is not known how Rio2p recognizes its peptide substrate.  Traditional ePKs 
use subdomains IX and X to recognize and bind their peptide substrate.  Rio2p lacks 
these domains (28, 29, 32, 34).  The eukaryotic version of Rio2p differs from the archaeal 
version in that it contains an extended C-terminus (Figure 2.1).  It can be hypothesized 
that the extended C-terminus of eukaryotic Rio2p proteins might be used to recognize the 
peptide substrate for specificity and binding.  Alternatively, the extended C-terminus 
might be used for some allosteric or inhibitory role.  Several attempts were made to 
obtain a structure of a eukaryotic version of Rio2p to determine how eukaryotic Rio2 
functions and whether it functions differently from the archaeal version.  Towards this 
goal, Rio2 from yeast (Sacchoromyces cerevisae), human, and Chaetomium 
thermophilum (ctRio2) were purified and screened for crystallization.  Table 2.1 briefly 
outlines the problems and successes encountered with each protein.  
 In this chapter, the purification of eukaryotic Rio2p is described.  During this 
process, I encountered the following difficulties: (a) Rio2p is rapidly degraded by 
proteases in the lysate;  
(b) Rio2p binds to RNA nonspecifically; and  (c) Rio2p exhibited poor solubility in the 
absence of solubilizing agents.  To circumvent these problems, I purified two different 
constructs containing His tags either on the N-terminus or the C-terminus of the protein; 
added ATP to buffer solutions to solubilize Rio2; and added RNases to the lysate to 
degrade RNA that would otherwise bind to Rio2p. 
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2.2:  Design 
Two constructs were designed to determine which gave the best results in 
purification from degradation products (Figure 2.2).  The first construct contained a N-
terminal 6x His tag followed by a 2kDa linker and a TEV cleavage site (N-Rio2p).  This 
construct was cloned into pDEST 527 and transformed into Rosetta (pLysS cells).  The 
second construct contained a C-terminal 6x His tag directly attached to Rio2p (C-Rio2p).   
2.3:  Methods 
 
2.3.1:  Subcloning of C-Rio2p 
 
A Rio2p construct with the C-terminal 6x His tag (C-Rio2p) (Figure 2.2B) 
yielded the most purifiable product.  To accomplish this, a full length Rio2p gene was 
cloned in an E. coli expression plasmid that contained IPTG inducible promoter.  C-
Rio2p was amplified from the pDEST527 plasmid, which already contained an insert for 
the Rio2p gene which was obtained from Dr. Nicole LaRonde LeBlanc from her work at 
NCI.  Two PCR reactions were performed to make the new construct.  The first PCR 
used a forward primer to add a necessary ribosomal binding site (RBS) next to the 5’ 
initiation codon of the Rio2p gene, because the vector does not contain a RBS.  The first 
PCR also used a reverse primer to add the 6x His tag and two stop codons to the 3’end of 
the Rio2p gene.  The second PCR used a forward primer to add the attB1 site to the 5’ 
end of PCR1 and used a reverse primer to add the attB2 site to the 3’ end of PCR1.  The 
forward and reverse primers for the two PCR reactions are diagrammed in Figure 2.3.  
The PCRs were performed using KOD polymerase (Novagen).  PCR products from both 
reactions were run on a 1% agarose gel shown in Figure 2.4. 
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  The Gateway
TM
  system was used to clone C-Rio2p  into pDEST 14, which is a 
bacterial T7 expression vector with no tags.  The Gateway
TM
  system relies on 
recombination between the vector and insert.  The process requires two cloning steps.  
First a cloning vector contained attP1 and attP2 sites known as an entry vector is 
recombined with the PCR product containing  attB1 and attB2 sites  inserted by PCR 
with primers containing the sequence (in the PCR product described above).  This 
recombination produces a vector containing attL1 and attL2 sites on either side of the 
insert.  Another recombination reaction was used to transfer the insert from the entry 
vector to the destination vector, pDEST 14, which contains attR1 and attR2 sites.  The 
resulting vector was then used for protein expression. 
To test the resulting clones for expression, Rossetta
TM
 cells were transformed with 
the pDEST 14 plasmid containing the C-Rio2p insert.  Four individual colonies were 
grown in 5 mL cultures until the colonies reached an O.D.600 of 0.8 and were then 
induced overnight at 18°C with 1mM isopropyl-β-D-thiogalactopyranoside (IPTG).  
Cells were pelleted by centrifugation and lysed with 5x SDS loading dye.  Lysates of the 
four cell cultures, before and after induction, were run on a SDS-PAGE gel.  All four 
colonies revealed expression of Rio2p.  Cells were also lysed with 0.3x Bugbuster
TM
, 
centrifuged, and the supernatants run on the SDS-PAGE gel.  Solubility was not evident 
in supernatant without ATP (Figure 2.5). 
2.3.2  Purification of C-Rio2p 
 
 The construct design for C-Rio2p is shown in Figure 2.9B.  The optimized 
procedures for C-Rio2p expression in E. coli and the purification steps are described 
below.  The pDEST 14-C-Rio2p vector, transformed into E. coli Rosetta
TM
 DE3 (pLysS) 
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cells, was used to inoculate an overnight culture in 100 mL of LB with 100 ug/ml 
ampicillin and 34 ug/ml chloroamphenicol.  The culture was grown overnight at 37°C in 
a shaking incubator.  4 L of LB in four 4 L flasks with ampicillin and chloromphenicol 
were inoculated with the overnight cultures of Rosetta
TM 
 cells in 1/100 dilution and 
grown at 37°C in a shaking incubator at 250 rpm.  At O.D.600 of 0.6 the flasks were 
transferred to a 20°C shaking incubator to cool.  At O.D.600 of 0.8, the cultures were 
induced with 1 mM IPTG and incubated overnight.  The next day, the cultures were 
centrifuged at 5000 rpm for 30 minutes.  The cell pellet was collected and frozen at -
80°C.  The frozen pellet was resuspended in 10 mL of buffer A (10% glycerol, 2.5 mM 
MgCl2, 50 mM Tris, pH 8.0, 300 mM NaCl, 1 mM ATP, 0.05% β-mercaptoethanol 
(BME))  per gram of frozen pellet and 5 mg DNAase, 1 mg RNAase A, 20 µl RNAase 
T1 (100,00 µ/mL) and 1 tablet EDTA free protease inhibitor tablet (Roche).  Then 0.3X 
Bugbuster
TM
 was added along with 20 mg lysozyme.  The cell suspension was kept on ice 
and stirred for thirty minutes to allow lysis.  The lysate was centrifuged at 16000 rpm for 
thirty minutes.  The supernatant containing the soluble protein was passed over a 5 mL 
GE Healthcare His Trap
TM
 column.  Buffer B (10% glycerol, 2.5 mM MgCl2, 50 mM 
Tris, pH 8.0, 300 mM NaCl, 1 mM ATP, 1 M imidazole, 0.05% BME) was the elution 
buffer.  The column was first washed with 5% Buffer B and then eluted with 10% Buffer 
B.  The results of the purification are shown in Figure 2.6. 
The fractions of the 10% Buffer B elution were pooled together and the solution 
containing C-Rio2p was then diluted so that the final concentrations of solution 
components were 200 mM NaCl, 50 mM HEPES, pH 7.0, 10% glycerol, 2.5 mM MgCl2, 




column.  The loading buffer, Buffer C, for the cation exchange 
column was 10% glycerol, 200 mM NaCl, 2.5 mM MgCl2, 50 mM HEPES, pH 7.0, 1 
mM ATP, 0.01% BME. Buffer D, the high salt buffer,  was 10% glycerol, 2.5 mM 
MgCl2, 1 M NaCl, 50 mM HEPES, pH 7.0, 1 mM ATP.  A gradient of the two buffer was 
run from 200 mM NaCl to 1 M NaCl over 100 mL.  The results of the purification are 
shown in Figure 2.7. 
C-Rio2p eluted around 524 mM NaCl.  The two most pure and concentrated 
fractions eluting between 504 mM NaCl and 544 mM NaCl were pooled together and 
dialyzed against 20 mM Tris, pH 8.0, 300 mM NaCl, 2.5 mM MgCl2, 10% glycerol, 1 
mM ATP.  Rio2p was then purified on a Superdex 200 Prep Grade gel filtration column 
equilibrated in dialysis buffer.  The results of the purification are shown in Figure 2.8.  
Fractions 19, 20, 21 were concentrated to 20 mg/ml as determined by the Bradford 
Assay.   
2.3.3:  Crystallization of Rio2p 
Crystal trays were set up with 10 mg/mL and 20 mg/mL C-Rio2p and 20 mM 
ATP substrate.  The screens tested were Qiagen’s PEG Suite, Hampton’s Index Screen, 
Emerald Biosystems Wizard I, II, and III screens, and Qiagen’s Cryos Suite.  Seven days 
later crystals formed in the PEG Suite, condition number 68, 2:1 precipitant to protein.  
The formulation was 0.2 M magnesium formate, 20% PEG 3350.  The hanging drop 
method was used to optimize crystal formation.  In this method, the protein and 
precipitant solution were mixed in the ratio from the screen in a 4-µl drop.  The drop was 
put on a slide that was then affixed over a well containing 1 mL of the precipitant 
solution.  By vapor diffusion, some of the water gradually left the drop to join the 
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precipitant solution until equilibrium was achieved, thereby slowly concentrating the 
protein in the drop.  The concentration of magnesium formate and the PEG 
concentrations were varied along 24 different wells in order to optimize crystal 
formation.   
2.4:  Results 
2.4.1:  Difficulties Encountered with Purification of Rio2p 
 
In order for optimal crystallization of proteins, several criteria have to be met.  
Rio2p has to be purified to greater than 95% purity.  Rio2p has to be fairly soluble.  At 
least 10mg of protein is needed to screen the protein through all the desired different test 
crystallization conditions.  The His tag used in Rio2p purification can also be an 
impediment to crystallization and should be removed.  
It was difficult to purify Rio2p to 95% purity because Rio2p is easily degraded by 
proteases.  The SDS-PAGE gel for the initial affinity purification of Rio2p using the His 
Trap
TM
 column showed numerous low molecular weight bands that appeared in a ladder.  
The reason that most of the contaminating bands were attributed to degradation is that 
most of these contaminating bands disappeared after addition of protease inhibitor tablets 
to the lysate.  By adding three protease inhibitor tablets per 50 mL of lysate solution, the 
number of degradation products showing up on the SDS-PAGE gel after His Trap
TM
 
slowly decreased as seen in Figure 2.6 compared to Figure 2.9.  In order to purify Rio2p 
to 95% purity for crystallization screening, it had to be separated from its numerous 
degradation products.  
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Rio2p was not a very soluble or abundantly isolated protein.  First attempts at 
purification resulted in 5mg of protein isolated per 2 L of culture.  The solubility of 
Rio2p was initially less than 5 mg/mL. 
2.4.2:  Purification of the  N-terminal His Tag Construct and a C-terminal 
His Tag Construct 
 
Of the two constructs C-Rio2p and N-Rio2p, success came with the C-Rio2p 
construct.  N-Rio2p was purified first on a His Trap
TM
 column, followed by a Q
TM
 
column, and finally by gel filtration.  N-Rio2p could not be purified of all its degradation 
products but was co-purified with a slightly lower molecular weight degradation product 
in gel filtration (Figure 2.10). 
C-Rio2p could be made 95% pure by a purification method that involved use of 
the His Trap
TM
 column as the first step of purification followed by a cation exchange 
column.  Although the pI of Rio2p is 5.13, it still binds to the cation exchange column—
possibly because the N-terminal winged helix domain has an electrostatically positive 
surface potential despite the overall negative charge of the protein.  Rio2p bound tightly 
to the S
TM
 column and eluted at 500 mM salt, in support of this hypothesis.  The 
purification could occur because binding of C-Rio2p to the cation exchange column was 
via the N-terminal winged helix domain and the degradation products containing only C-
terminal fragments would not bind.  The first step of purification of C-Rio2p on the His 
Trap
TM
 column, via the C-terminal His tag, eliminated the degradation products 
containing the N-terminal domain.    
The final polishing step to purify C-Rio2p involved passing it over a gel filtration 
column.  Traces of small molecular weight degradation products or contaminating protein 
were then removed.  Also traces of C-Rio2p that had unfolded during purification could 
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be removed from folded protein.  Unfolded protein would have a larger Stokes’ radius 
and elute in a smaller volume on the gel filtration column.  Following this method, I was 
able to efficiently purify C-Rio2p (Figure 2.8).  
2.4.3:  Use of Chemical Lysis and Induction Overnight at 20°C to Combat 
Degradation 
 
As discussed previously, it appeared as if Rio2p was being cleaved by proteases 
after lysis.  To purify this kinase, many changes were made to stop degradation of Rio2p.  
The first of these changes was that initially the cultures of Rio2p were grown in 2 L 
culture volumes in 4 L flasks.  The flasks were shaken at 220 rpm.  We found that this 
method of growing cultures was inefficient at aerating the cultures, which led to an 
increase in degradation products.  Thereafter, all cultures were grown in 1 L of media in a 
4 L flask with shaking at 250 rpm.   
 As another way to combat the problem of degradation, the method of lysis was 
changed from a French Press to chemical lysis in an ice bath at 4°C with BugBuster
TM
.  
The problem with a French Press is that it heats the lysate during its use.  This leads to 
decreased protein stability, especially if the protein heats past its melting temperature.  
Use of the press also leads to an increase in proteolytic activity as it nears the temperature 
at which proteases are optimally active, i.e. 37°C.   
Another change made to combat the problem of degradation, was to change the 
induction from 30°C for four hours to 20°C overnight. Since Rio2p is a yeast protein, and 
the optimal temperature for growing yeast is at 30°C, Rio2p expression can be induced at 
30°C.  However, yeast proteins with low melting temperatures, such as Rio2p, are more 
stable at lower temperatures.  Inducing at 20°C overnight helps maintain low melting 
point proteins in a more folded state.   It is possible that lowering the temperature to 20° 
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could slow translation and help with proper folding, which could lead to a lower incident 
of protein degradation.  
2.4.4:  Approach to Increase the Solubility of Rio2p by Adding ATP or ADP 
and MgCl2  
 
ATP and MgCl2 or ADP and MgCl were added to all buffers to increase the 
solubility of Rio2p.  Since Rio2p is a serine kinase and archaeal Rio2p has been shown to 
autophosphorylate, ATP is a substrate of Rio2p.  Including ATP or an analogue of ATP, 
such as AMP or ADP, in the solution changes the conformation of Rio2p into a more 
folded and stable structure that is more soluble.  The increased stability of Rio2p with 
ATP or ADP was demonstrated by the fact that the melting temperature of C-Rio2p 
increased in the presence of ATP from 43°C (bound to AMP) to 47°C and increased even 
more in the presence of ADP to 51°C (Sagar,V. (2011). Personnel research.).  C-Rio2p 
was purified two ways:  by including 1 mM ATP in all buffer solutions; alternatively by 
including 1 mM ADP in all buffer solutions.   
 Mg
2+
 helps to stabilize the ATP and ADP bound structure in the active site.  Thus 
2.5 mM MgCl2 was included in the lysis solution and all buffer solutions along with ATP 
or ADP. 
The results of adding ATP and MgCl2 or ADP and MgCl2 were the same.  The 
solubility of Rio2p was increased and the net yield of protein increased from 5 mg per 2 
L culture to 20 mg/ 2 L culture.  Addition of ATP or ADP and MgCl2 combined with the 
change in the construct used helped increase the maximum level at which Rio2p can be 
concentrated from 5 mg/mL (N-Rio2p w/o ATP and MgCl2 or ADP and MgCl) to 40 
mg/mL (C-Rio2p w/ ATP and MgCl2 or ADP and MgCl), which allowed for 
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crystallization screening of the protein.  The SDS-PAGE gel in Figure 2.5 demonstrates 
that C-Rio2p has limited solubility in the supernatant in the absence of ATP or ADP. 
2.4.5:  Addition of RNases to Lysate Prevent Rio2 from Nonspecifically 
Binding to RNA 
 
Rio2 proteins have been shown to nonspecifically bind RNA.  The 
chromatograms of Rio2p, ctRio2 and afRio2 on a Q
TM
 column shows a large peak eluting 
at high salt concentrations.  This peak does not show up on the protein gel and has a high 
260/280 absorbance, suggesting it is RNA or DNA contamination that co-eluted with 
Rio2 from the first step of purification, the His Trap
TM
.  With RNA nonspecifically 
bound to Rio2p, the protein sample is not homogenous, and is less likely to crystallize.  
Thus RNases A and RNase T1 were included in the lysate to minimize binding of Rio2p 
to RNA.  At the finish of purification, the A60/A280 ratio was 0.8 for fractions of Rio2p, 
characteristic of a protein unbound to RNA or DNA.  
2.4.6:  Results of Crystal Screens of C-Rio2p 
 
The crystals from the sitting drop screen were reproducible in hanging drop after 
a period of three to four weeks, but did not grow larger in size than those found in the 
initial screen,  remaining microcrystals (Figure 2.11).   
Crystal screens were set up with 20 mM ADP instead of 20 mM ATP, since ADP 
(51°C) stabilizes C-Rio2p more than does ATP (47°C), as witnessed by the melting 
temperature.  C-Rio2p was also screened for crystallization without glycerol.  Including 
glycerol in solution increased the solubility of C-Rio2p but adversely increased the 
precipitant concentration needed for crystallization.  Since the crystallization screens 
were set at one precipitant concentration, getting initial crystal hits with glycerol might be 
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a problem.  In many of the wells with both ATP and ADP, with and without glycerol, 
quasi crystals formed that indicated the protein was becoming supersaturated in pocketed 
areas but not nucleating to form crystals.   
2.5:  Summary  
 
 During lysis, Rio2p degrades to smaller fragments which are difficult to remove 
during purification.  Two constructs were made with a N and C terminal His tag to 
determine which produced the most purifiable protein product.  C-Rio2p could be 




 column to remove C-terminal (His Trap
TM
 
column) and N-terminal (S
TM
 column) degradation products.  Though the overall charge 
of the protein is basic it could still bind the S
TM
 column via the positively charged N-
terminal wing helix domain. 
 ATP and Mg
2+ 
was added to the solubilization buffers and increased the 
solubility of Rio2p from 5 mg/mL to 20 mg/mL.  ATP and Mg
2+
 stabililized Rio2p in a 
more folded form as witnessed by the increase in melting temperature of Rio2p in the 
presence of these additives.   
 Rio2p binds to RNA nonspecifically and to remove RNA from the protein 
solution, RNases were included in the lysate.  RNA contamination of Rio2p would 
impede it’s crystallization.  With these modifications, I could successfully purify a large 
quantity of Rio2p.   
 Rio2p did not yield diffraction quality crystals.  The key to this problem might be 
found in the initial observations that Rio2p degrades easily.   Rio2p might contain large 
unstructured regions that prevent the protein from forming a stable and rigid crystal 
lattice.  Alignment of the sequence of Rio2 from A. fulgidus bacteria and Rio2p reveals 
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that they align well with small insertions in Rio2p (Figure 2.1).  However, Rio2p contains 
an extended C-terminus.  Since the N-terminus forms a fairly well structured winged 
helix domain, and the RIO domain is also fairly well structured, degradation from this 
extended C-terminus might lead to the degradation of Rio2p seen on the SDS-PAGE gel 
after His Trap
TM
.  This supposedly floppy C-terminal region might be the reason why a 
C-terminal His tag without any linker still binds to the His Trap
TM
 as the C-terminal 
sequence provides the flexible linker to the His tag.  Redesigning the construct to include 
a truncated C-terminus might lead to fewer degradation products.  It may also eliminate 
the unstructured regions of Rio2p and lead to successful crystallization of Rio2p.  The 
problem is knowing where to truncate Rio2p.  Sequence alignment with archaeal Rio2p 
and secondary structure prediction might provide a clue as to where to terminate the 
sequence of Rio2p, but would not ensure that the protein will fold properly.  Several 
constructs might have to be tried before a solution to the problem of crystallization is 
found.  My approach to this problem was to move on from Rio2p and attempt to purify 
(and crystallize) another eukaryotic version of Rio2—human Rio2, which will be 
discussed in Chapter 3.   
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                     10        20        30        40        50        60 
                      |         |         |         |         |         | 
AFRio2       MNIAELYG-KMGKHSWRIMDAIFKNLWDYEYVPLQLISSHARIGEEKARN-ILKYLSDLR 
Rio2p        MKLDTSHMRYLTTDDFRVLQAVEQGSRSHEVVPTPLIHQISGMRSQSGTNRAISDLAKLS 
             *::   :   : ...:*:::*: :.  .:* **  ** . : : .:.. *  :. *:.*  
                     70        80        90       100       110       120 
                      |         |         |         |         |         | 
AFRio2       VVQNRQ-KDYEGSTFTFIGLSLYSLHRLVRSGKVDAIGKLMGEGKESAVFNCYSEKFGEC 
Rio2p        LISKMRNVKYDGYRLTYNGIDYLALKTMLNRDTVYSVGNTIGVGKESDIYKVSDKNGNPR 
             ::.: :  .*:*  :*: *:.  :*: ::. ..* ::*: :* **** :::  .:: .   
                    130       140       150       160       170       180 
                      |         |         |         |         |         | 
AFRio2       VVKFHKVGHTSFKKVKEKRDYGD--------LHFSVLAIRSARNEFRALQKLQGLAVPKV 
Rio2p        VMKIHRLGRTSFHSVRNNRDYLKKSNQGANWMHLSRLAAN-KEYQFMSMLYSKGFKVPEP 
             *:*:*::*:***:.*:::*** .        :*:* ** .  . :* ::   :*: **:  
                    190       200       210       220       230       240 
                      |         |         |         |         |         | 
AFRio2       YAWEGNAVLMELIDAKELYRVR-VENPDEVLDMILEEVAKFYHRGIVHGDLSQYNVLVSE 
Rio2p        FDNSRHIVVMELIEGYPMRRLRKHKNIPKLYSDLMCFIVDLANSGLIHCDFNEFNIMIKD 
             :  . : *:****:.  : *:*  :*  :: . ::  :..: : *::* *:.::*:::.: 
                    250       260       270       280       290       300 
                      |         |         |         |         |         | 
AFRio2       E-------GIWIIDFPQSVEVGEEGWREILERDVRNIITYFSRTYRTEKDINS------- 
Rio2p        KLEDENDCGFVVIDFPQCISIQHQDADYYFQRDVDCIRRFFKKKLKYEPKPDSSMLDTEG 
             :       *: :*****.:.: .:.    ::***  *  :*.:. : * . :*        
                    310       320       330       340       350       360 
                      |         |         |         |         |         | 
AFRio2       --------------------AIDRILQE-------------------------------- 
Rio2p        FGDGYKYAYPDFKRDVKRTDNLDELVQASGFSKKHPGDRGLETAVESMRNAVYNSDDDMS 
                                  :*.::*                                  
                    370       380       390       400       410       420 
                      |         |         |         |         |         | 
AFRio2       ------------------------------------------------------------ 
Rio2p        NDEAEEENGEGDYSEEDEYYDSELDNESSEDDSEDAQEEENERIIEALSSGVENLKMDKL 
                                                                          
              
              
AFRio2       ------ 
Rio2p        GNYILE 
                      
Figure 2.1:  Alignment between AfRio2 and Rio2p.  
 Alignment was performed with the program CLUSTALW using sequences from A. fuligidus  (AFRio2) 
and Rio2p (from yeast).  Identical, highly similar, and weakly similar residues are indicated by red, green, 
and blue letters respectively.  The wing helix domain of afRio2 is highlighted in yellow, the N-terminal 
lobe in green and the C-terminal lobe in blue.  The C-terminal extension of Rio2p is in the boxed region 






N’ Rio2p 6x His Tag C’ 
 
Figure 2.2: Two Constructs Designed for Rio2p Purification   
A.  N-Rio2p construct was designed with an N-terminal 6x His tag followed by a TEV cleavage site. 
B.  C-Rio2p construct was designed with a  C-terminal 6x His tag. 
  





RBS Site Coding Sequence Rio2p 
B. 
CTACTA GTGATGATGGTGGTGATG CTCTAGTATATAGTTACCTAGTTTATCCCAT 






Attb1 Site Rbs Site 
D. 
GGGGACCATTTGTACAAGAAAGCTGGTC CTACTA GTGATGATGGTGGTGATG 
Attb2 Site Stop Codons 6x His Tag 
 
Figure 2.3:  PCR of C-Rio2p 
In PCR1, Rio2p was amplified from the  pDEST527 plasmid containing an insert for the Rio2p gene.  A. 
The forward primer for PCR1 was used to add an RBS site to the 5’ end of the Rio2p gene.  B. The reverse 
primer for PCR1 was used to add a 6x His tag and two stop codons to the 3’ end of the Rio2p gene.  C. and 
D The forward and reverse primers for PCR2.  C. was used to add an attb1 site to the 5’ end of PCR1 



























Figure 2.4:  PCR Products 
Both PCR1 and PCR2  products were run on a 1% agarose gel stained with ethidium bromide.  In PCR1, 
Rio2p was amplified from the pDEST527 plasmid containing an insert for the Rio2p gene.  Using PCR 
primers, A RBS site was added to the 5’ end of the Rio2p gene and a 6x His tag and two stop codons were 
added to the 3’ end of the Rio2p gene.  In, PCR2, the gene product from PCR1 was amplified.  An attb1 
site was added to the 5’ end of PCR1 product and an attb2 site was added to the 3’ end of PCR1 product. 














































Figure 2.5:  Induction of C-Rio2p 
Rossetta
TM
 cells were transformed with pDEST 14-C-Rio2p.  Four individual colonies were grown in small 
cultures and induced overnight at 18°C with 1mM IPTG.  An SDS-PAGE gel was run of samples of the 
four cultures before and after induction lysed with 5x SDS loading dye and stained with Coomassie Blue.  
Samples of the four cell cultures were also lysed with 0.3x Bugbuster ,centrifuged, and the four 



























































































Figure 2.6:  C-Rio2p Purification Step 1  
Supernatant with overexpressed C-Rio2p was passed over a His Trap
TM
 column.  The column was washed 
with 50 mM imidazole.  C-Rio2p was eluted from the column in a step gradient at 100 mM imidazole and 
300 mM imidazole steps. The SDS-PAGE gel is stained with Coomassie Blue.  Rio2p is expected to run at 










Figure 2.7: C-Rio2p Purification Step 2 
After His Trap
TM
, C-Rio2p was run on a cation exchange column S
TM
 column.  The gel shows the pooled 
C-Rio2p fractions from the His Trap
TM
 column.  The fractions were diluted to 200 mM NaCl ( labeled on 
the gel as “diluted fractions”) and loaded onto the S
TM
 column.  C-Rio2p was eluted over a gradient of 200 
mM to 1 M NaCl over 100 mL solvent.  The SDS-PAGE gel, stained with Coomassie Blue, shows the 
flow-through from the S
TM
 column as well as  individual fractions labeled with the approximate salt 




















































Figure 2.8:  C-Rio2p Purification Step 3 
C-Rio2p previously purified by His Trap
TM
 column and  by S
TM
 column was loaded on a Superdex 200 
Prep Grade gel filtration column.   A.  The chromatogram of C-Rio2p shows the elution profile from the 
size exclusion column. B. The SDS-PAGE gel (stained with Coomassie Blue) is labeled with the fraction 


































































































100.0%  Buffer B













Figure 2.9:  Rio2p Degradation Observed with N-Rio2p 
This gel is a SDS-PAGE gel stained with Coomassie.  Rosetta
TM 
cells containing the plasmid for N-Rio2p 
were grown and  lysed with 0.3x Bugbuster in the presence of three protease inhibitor tablets.  The 
supernatant was passed over a His Trap
TM
 column and N-Rio2p was eluted from the column over 100 mM-
270 mM imidazole.  The lysate,  supernatant, flow-through, and fractions from the elution were run on a 
gel.  The slightly lower molecular weight protein contamination that co-elutes with  N-Rio2p on the His 
Trap
TM








Figure 2.10:  N-Rio2p Co-Purifies with Degradation Product 




 column, N-Rio2p was loaded on a gel filtration column.  The 
lanes are labeled with the elution volumes from the column.  A close molecular weight degradation product 









Figure 2.11:  Crystallization of C-Rio2p 
Sitting drop screens of C-Rio2p were performed. Microcrystals of C-Rio2p formed in 0.2 M magnesium 


















Protein Construct Crystal Purification Results 





• Crystals were not 
diffraction quality. 
• PI=5.6 but purify 
by cation exchange 
column. 
• Add RNAases to 
lysate. 
• Add ATP to buffer 
to solubilize. 





x Deletion of 
Wing Helix 
Domain 
• Poor Solubility. 




• ATP, ADP, AMP, 
NP40 solubilized 









• Diffraction quality 
crystals. 
• Overload Ni 
column to remove 
contaminating 
proteins. 
•  Anion exchange 
column to remove 
bound RNA. 
 
Table 2.1:  Eukaryotic Proteins Purified and Attempts Made to Crystallize 
The table summarizes the results of Chapters 2-4.  The first column delineates the protein purified.  The 
second column delineates the constructs made with bold letters indicating the construct that gave purifiable 
protein.  The third column delineates problems or successes made with the protein. The fourth column 
delineates the techniques used to overcome problems encountered during purification. 
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Chapter 3:  Purification of Human Rio2 
3.1:  Introduction  
 
Human Rio2 (hRio2) may contain structural differences from the archaeal version 
that may be critical to its kinase function.  Most importantly hRio2 contains an extended 
C-terminus compared to AFRio2 (Figure 3.1).  To elucidate the hRio2 function, I purified 
the protein using E. coli expression.  
Initial studies showed that in E. coli hRio2 had a low level of expression, low 
solubility, and the recombinant protein co-purified with many degradation products.  To 
overcome these problems I made three different versions of hRio2.  In addition, I added 
different additives to increase the prospect of a soluble, purifiable protein product. 
3.2:  Design 
 
Three recombinant constructs were designed for hRio2.  The N-hRio2 construct 
was made by subcloning of the human Rio2 gene with an N terminal TEV cleavage site 
into Gateway
TM 
vector pDEST 527 that codes for a N-terminal 6x His tag.  A schematic 
of the construct is shown in Figure 3.2A.  The C-hRio2 construct was made by 
subcloning of the human Rio2 gene engineered with a C-terminal His tag into Gateway
TM   
vector pDEST 14.  A schematic of the construct is shown in Figure 3.2B.  In the third 
Δ71-C-hRio2 construct, the first 71 amino acids were deleted from the N-terminus by site 
directed mutagenesis and a 6x His tag was engineered at the C-terminus.  Δ71-C-hRio2 
was subcloned into Gateway
TM
 vector pDEST 14.  A schematic of the construct is shown 
in Figure 3.2C.  
These three constructs were designed to determine which construct would have 
the best induction, solubility, and purification.  For yeast Rio2, it was found that the C-
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terminal 6x His tag was best in all domains (Chapter 2).  Constructs with both C-terminal 
and N-terminal 6x His tags were investigated for hRio2 to determine, in this case, which 
was better in terms of induction, solubility, and purification.  Another construct, Δ71-C-
hRio2 with truncation of the winged helix domain, was also investigated to determine if it 
would help with the low solubility of hRio2.  Since it was found that removing the N-
terminus of Rio1and Rio3 made the proteins more soluble (Kiburu, I. and Thomas, S. 
(2011). private communication, unpublished raw data.), it was hypothesized that the same 
would occur by removing the winged helix domain from hRio2.  Moreover, the construct 
of Rio2p minus the winged helix domain was soluble in yeast cells (Chapter 6). 
3.3:  Methods 
 
 3.3.1:  General Methods 
 All three contructs were transformed into Rosetta DE3 (pLysS)
TM
  cells.  They 
were grown in 2L cultures of LB and induced with 1 mM IPTG.  Cells were chemically 
lysed with Bugbuster and then passed over a His Trap
TM
 column.  If protein was 
purifiable, the protein was then passed over a S
TM
 column. 
3.3.2:  Subcloning of C-hRio2 
 
HRio2 with the C-terminal 6x His tag (C-hRio2) was the construct that produced 
the most purifiable hRio2.  The PCR for formation of this construct follows.  In order to 
express this protein in E. coli the full length protein was subcloned into an inducible 
bacterial expression vector.  As described in previous chapters, The Gateway
TM
 system 
was used to clone C-hRio2 into pDEST 14. 
C-hRio2 was amplified from the pDEST 527 plasmid containing an insert for the 
hRio2 gene obtained from Dr. Nicole LaRonde LeBlanc from her work at NCI.  PCR was 
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performed in two steps as described in Chapter Two.  The forward and reverse primers 
for the two PCR reactions are diagramed in Figure 3.3.   Thereafter an agarose gel was 
run with the PCR products obtained from the screen of two positive clones (Figure 3.4).   
3.3.4:  Expression and Purification of hRio2  
 
The C-hRio2 construct produced the most purifiable hRio2 (Figure 3.2B).  The 
procedure used for hRio2 expression and purification is as follows.  C-hRio2 was cloned 
into a pDEST14 vector.  The vector was transformed into E. coli Rosetta (pLysS)
TM
 cells.  
An 80 mL starter culture of Rosetta
TM
 cells with 100 μg/mL ampicillin and 32 μg/mL 
chloroamphenicol was grown overnight at 37°C.  Next day, the 80 mL starter culture was 
used to inoculate 4 L of LB media in four 4 L flasks with ampicillin and 
chloroamphenicol.  When the O.D. 600 reached 0.6, the culture was transferred to an 
18°C shaking incubator to cool the flasks.  When the O.D. 600 reached 0.8, the culture 
was induced with 1 mM IPTG and transferred to an 18°C incubator overnight.  The 
O.D.600 had reached 2.0 by the next morning and the cells were spun down and 
transferred to a conical vial.  The vial held approximately 3 g of cell pellet per L.  The 
vial was frozen and maintained in a –80°C freezer. 
The frozen pellet was resuspended in 10 mL of Buffer A (0.05% BME, 500 mM 
NaCl, 50 mM Tris, pH 8.0, 10% glycerol, 2.5 mM MgCl2, 1 mM ATP) per gram of frozen  
pellet. 0.5 mM PMSF, 2 mM Benzamidine, 1 EDTA free protease inhibitor tablet,  5 mg 
DNAse/L cell culture, 1 mg RNase A/L cell culture, and 20 μL RNase T1 (100,00U/mL) 
was added to the solution.  The cell pellet was dissolved by vigorous vortexing in this 
buffer.  To the dissolved cell pellet was added 0.3x Bugbuster
TM
 and 0.5 mg/ml 
lysozyme.  Lysis was performed on ice for an hour.  Lysed cells were centrifuged at 
42 
16,000 rpm for 30 minutes.  The pellet was discarded.  The supernatant containing the 
soluble protein was filtered and loaded onto a GE Healthcare His Trap
TM
 5 mL column.  
Elution Buffer, Buffer B, was 1M imidazole, 0.05% BME, 500 mM NaCl, 50 mM Tris, 
pH 8.0, 10% glycerol, 2.5 mM MgCl2 and 1 mM ATP.  The His Trap column was 
washed with 5% Buffer B and then 10% Buffer B and 5 mL fractions were collected.  A 
gradient was run from 10% Buffer B to100% Buffer B in 100 mL and 5mL fractions 
were collected.   
The fractions with hRio2 protein were pooled and the solution was diluted so that 
the final concentration of solution components was 200 mM NaCl, 50 mM HEPES, pH 
7.0, 2.5 mM MgCl2, 0.05% BME, 1 mM ATP and 10% glycerol.  Buffer C, the loading 
buffer for the cation exchange column, was 10% glycerol, 2.5 mM MgCl2, 50 mM 
HEPES pH 8.0, 200 mM NaCl, 0.05% BME, 1 mM ATP and Buffer D, the high salt 
buffer was 1M NaCl, 10% glycerol, 2.5 mM MgCl2, 50 mM HEPES pH 8.0, 0.05% 
BME, 1 mM ATP .  Protein was then loaded onto a S
TM
 column and a gradient (of Buffer 
C and D) from 200 mM to 1 M salt was run over 100 mL.  5 mL fractions were collected. 
3.4:  Results 
3.4.1:  Purification of N-hRio2 
 
Induction and solubility of N-hRio2 were found to be adequate in some of the 
conditions tested.  Induction of Rosetta
TM
 cells containing the pDEST 527-N-hRio2 was 
attempted both at 37°C for four hours and overnight at 18°C with 1 mM IPTG.  N-hRio2 
had the best induction at 37°C, as seen in Figure 3.5.  Overnight induction at 18°C with 
1mM IPTG was found to be too low to observe, as seen in Figure 3.6.  N-hRio2 was 
solubilized with both 250 mM NaCl and 500 mM NaCl.  The best solubility of N-hRio2 
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was in 500 mM NaCl.  At this concentration of salt, N-hRio2 bound tightly to the His 
Trap
TM
 column and eluted at 125 mM imidazole over several fractions.  At 250 mM 
NaCl, N-hRio2 bound to the His Trap
TM
 column weakly and eluted in the 40 mM wash in 
only one fraction.   
While induction and solubility of N-hRio2 were sufficient, the amount of 
degradation products that co-purified with N-hRio2 at 125 mM imidazole was extensive, 
as can be seen from the SDS-PAGE gel of the His Trap
TM
 elution in Figure 3.7.  For this 
reason further attempts at purification of N-hRio2 were abandoned. 




 cells harboring the pDEST 14-Δ71-C-hRio2 plasmid were induced at 
18°C overnight with 1 mM IPTG.  Though the yeast construct was soluble without the 
winged helix domain (Chapter 6), the human construct was not.  Little to no protein 
appeared in the supernatant after lysis of the E. coli cells.  The supernatant containing 1 
mM ATP was purified on the His Trap
TM
 column to see if a small amount of protein was 
solubilized.  No protein eluted in the gradient and no fractions were available from the 
elution to run on the SDS-PAGE gel (Figure 3.8).  The Δ71-C- hRio2 construct could not 
be used to increase the solubility of hRio2. 
3.4.3:  Purification of C-hRio2. 
 
 The induction level of C-hRio2 was adequate at 18°C overnight with 1 mM IPTG.  
However, as discussed later, the solubility was low.  I used the purification method of C-
Rio2p (Chapter 2) to purify C-hRio2.  C-hRio2 was passed over a His Trap
TM
 column to 
remove N-terminal degradation products and thereafter passed over a S
TM
 column to 
remove C-terminal degradation products.  Though the pI of C-hRio2 was 5.66, it was 
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found to still bind to the cation exchange column despite the overall negative charge of 
the molecule, possibly because the N-terminal winged helix domain has an 
electrostatically positive surface potential.  C-hRio2 did bind tightly to the S
TM
 column 
and eluted at 530 mM salt (Figure 3.10).  I purified C-hRio2 using the above two-step 
method.  For this reason, N-hRio2 and Δ71-C-hRio2 constructs were not pursued further. 
 The problem with the C-hRio2 construct was that while C-hRio2 was induced it 
had poor solubility.  Though the protein could be isolated from the His Trap
TM
 in 
relatively pure form, the C-hRio2 precipitated 24-hours later.  In fact, the C-hRio2 could 
not remain soluble for more than one day unless C-hRio2 was diluted to 0.3 mg/ mL and 
stored at that concentration.  Furthermore, C-hRio2 once diluted, could not again be 
concentrated because the protein bound to the membrane filter of the ultraconcentrator.   
3.4.4:  Additives Tested for Their Ability to Solubilize C-hRio2 
 
Several additives were added to the buffers and tested for enhanced solubility of 
C-hRio2.  The additives tested were 0.1% NP40 with 10% glycerol, 1 mM AMP, 1 mM 
ATP, and 1 mM ADP.  If hRio2 contained hydrophobic regions, adding detergent and 
glycerol in the lysate would solubilize these domains.  0.1% NP40 was the detergent used 
to solubilize Rio2p and the ribosome during TAP Tag pull downs (Chapter 6).  Therefore, 
0.1% NP40 was chosen to solubilize C-hRio2. 
AMP should stabilize C-hRio2 in a manner similar to that in which ADP and ATP 
stabilized Rio2p.  Though AMP is neither a substrate nor a product of 
autophoshorylation, it maintains the adenosine moiety of both compounds and contains a 
phosphate group.  AMP was chosen in addition to ADP and ATP because it is a more 
stable molecule than either ADP or ATP and can remain in solution longer without 
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deteriorating.  ATP can deteriorate to ADP; similarly ADP can deteriorate to AMP.  Thus 
Rio2 protein in solutions of ATP and ADP will, over time, become heterogeneous as 
different portions of the protein will bind to ATP, ADP and AMP.  By using AMP this 
heterogeneity is avoided.    
ATP was tested as an additive in the buffer solutions, because it was expected to 
stabilize C-hRio2 to a greater degree than AMP.  The melting temperature of Rio2p 
bound to ATP is greater (47°C) than the melting temperature of Rio2p bound to AMP 
(43°C) (Sagar, V. (2011)).  
ADP was tested as an additive in the buffer solutions, because it was expected to 
stabilize C-hRio2 to a greater degree than ATP.  The melting temperature of Rio2p bound 
to ADP (51°C) is greater than the melting temperature of Rio2p bound to ATP (47°C) 
(Sagar, V. (2011)).  ADP is also a more stable molecule than ATP. 
3.4.4.1:  Results of Adding NP40 to Buffer Solutions. 
 
The additive 0.1% NP40 along with 10% glycerol was used to try to solubilize C-
hRio2.  As seen from the SDS-PAGE gel in Figure 3.9, induction of C-hRio2 showed a 
thick band.   A slightly smaller band was seen in the lane with the supernatant indicating 
the protein was not fully soluble with this additive.  0.1% NP40 slightly enhanced the 
solubility of C-hRio2.  The elution of C-hRio2 from the His Trap
TM
 revealed only a small 
to moderate amount of protein eluting from the column and the protein bands on the 
SDS-PAGE gel were narrow.  In Figure 3.10, evidence can be seen of the small amount 
of soluble protein obtained after lysis through the SDS-PAGE gel of the elution of C-
hRio2 from the S
TM
 column.  The protein band width shown on this gel is very thin.   
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Another problem with purifying the protein with 0.1% NP40, was that with NP40 
C-hRio2 bound poorly to the column and results of subsequent purifications of C-hRio2 
were found to be variable as to whether or not any protein bound to the His Trap
TM
 
column.  Usually such ambiguous results might be indicative of RNA contamination of 
the protein that interfered with protein binding to the His Trap
TM
 column.  
3.4.4.2:  Results of Adding AMP as an Additive to Buffer Solutions. 
 
AMP was added to the buffer solutions to try to solubilize C-hRio2.  However, 
the addition of AMP to the buffers had a more negative effect on the solubility of C-





column purification.  The size and appearance of the protein bands on the SDS-PAGE 
gels in Figures 3.11 and 3.12 are small and faint.  The soluble concentration of protein in 
the supernatant obtained after adding AMP to the buffers was low, leading to dilute 





3.4.4.3:  ATP as an Additive to Buffer Solutions. 
 
ATP was added to the buffer solutions in order to solubilize C-hRio2.  The 
solubility of C-hRio2 increased with ATP in the buffers more than with NP40 or AMP.  
After passing the protein over the His Trap
TM
, most of the protein had precipitated by the 
next day when the SDS-PAGE gel was loaded, so the true extent of the effect of ATP on 
the solubility of C-hRio2 cannot be seen from the gel.  The size and appearance of the 
protein bands on the SDS-PAGE gel are still moderate (Figure 3.13).  The fact that C-
hRio2 precipitated by the next day, shows that the protein is not stable even in the 
presence of 1 mM ATP. 
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3.4.4.4:  ADP as an Additive to Buffer Solutions. 
 
ADP was added to the buffer solutions in order to solubilize C-hRio2.  The 
solubility of C-hRio2 with ADP in the buffers could not be determined due to purification 
issues.  During elution of C-hRio2 from the His Trap
TM
 column, with ADP present in the 
buffers the pressure in the His Trap
TM
 column became too high.  This could have 
happened because ADP stabilized a conformation of C-hRio2 that was prone to 
precipitation.  To counteract this problem, a batch process was used for elution.  The 
protein was loaded on the His Trap
TM
 column, then the resin was removed from the 
column, and the elution buffer was mixed with the resin.  The resin was allowed to settle 
and the elution buffer was removed from the top of the column.  The C-hRio2, then in the 
elution buffer, was diluted to 0.3 mg/mL to stabilize the protein before loading on a SDS-
PAGE gel. 
The next day, C-hRio2 was loaded onto an S
TM
 column (Fig 3.15).  In this case 
also during elution from the S
TM
 column, the pressure became too high.  Only two 
fractions eluted from the column during this time.  Those two fractions were run on an 
SDS-PAGE gel and the fraction at 300 mM NaCl contained pure protein.  However, only 
one protein fraction could be rescued from the column.  The remaining C-hRio2 probably 
precipitated and was lost. Thus with ADP present in the buffers, the protein could not be 
purified in large amounts.  Rather the presence of ADP in the buffers made C-hRio2 
more prone to precipitation during purification.  
3.5: Summary 
 
Several different constructs were designed to determine which recombinant 
construct results in the most purifiable protein.  Summary information on the three 
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constructs purified is available in Table 3.1 at the end of this chapter.  Δ71-C-hRio2 was 
not soluble in the supernatant and could not be purified. Whereas N-hRio2 gave several 
degradation bands after His Trap
TM
, C-hRio2 could be purified to greater than 95% purity 




 column.  The main issue with C-hRio2 was its low 
solubility in buffer solution.  While the use of solubilizing agents such as NP40, ADP, 
and AMP resulted in lower solubility of C-hRio2 in the supernatant, the addition of ATP 
to buffers allowed a yield of large amounts of highly soluble C-hRio2.  However, C-
hRio2 could only be stored overnight without precipitating at a low concentration of 0.3 
mg/mL.  This is not sufficient for crystallization screening.  A new construct for hRio2 
needs to be developed to increase its stability. 
Since the N-terminus is critical for even minimal solubility of human Rio2, it 
must remain intact.  Rather the C-terminus could be truncated.  Figure 3.1, shows 
alignment between hRio2 and A. fulgidus Rio2.  The two proteins align with few gaps, 
but hRio2 contains an extended C-terminus.  This C-terminus might be the reason that 
hRio2 is minimally soluble and stable at 0.3 mg/mL while A. fulgidus Rio2 is stable at 5 
mg/ml.  Instead of developing a new construct of hRio2, my approach to crystallizing 
Rio2 was to purify and crystallize a new protein from a different eukaryotic organism.  
That organism was Chaetomium thermophilum and results from this purification and 
crystallization were successful as discussed in the Chapter 4. 
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                    10        20        30        40        50        60 
                      |         |         |         |         |         | 
hRio2        MGKVNVAKLR-YMSRDDFRVLTAVEMGMKNHEIVPGSLIASIASLKHGGCNKVLRELVKH 
AFRio2       ---MNIAELYGKMGKHSWRIMDAIFKNLWDYEYVPLQLISSHARIGEEKARNILKYLSDL 
                :*:*:*   *.:..:*:: *:  .: ::* ** .**:* * : .  ..::*: * .  
                     70        80        90       100       110       120 
                      |         |         |         |         |         | 
hRio2        KLIAWERTKTVQGYRLTNAGYDYLALKTLSSRQVVESVGNQMGVGKESDIYIVANEEGQQ 
AFRio2       RVVQ-NRQKDYEGSTFTFIGLSLYSLHRLVRSGKVDAIGKLMGEGKESAVFNCYSEKFGE 
             :::  :* *  :*  :*  * .  :*: *     *:::*: ** **** ::   .*:  : 
                    130       140       150       160       170       180 
                      |         |         |         |         |         | 
hRio2        FALKLHRLGRTSFRNLKNKRDYHKHRHNVSWLYLSRLSAMKEFAYMKALYERKFPVPKPI 
AFRio2       CVVKFHKVGHTSFKKVKEKRDYG----DLHFSVLAIRSARNEFRALQKLQG--LAVPKVY 
              .:*:*::*:***:::*:****     :: :  *:  ** :**  :: *    :.***   
                    190       200       210       220       230       240 
                      |         |         |         |         |         | 
hRio2        DYNRHAVVMELINGYPLCQIHHVEDPASVYDEAMELIVKLANHGLIHGDFNEFNLILDES 
AFRio2       AWEGNAVLMELIDAKELYRVR-VENPDEVLDMILEEVAKFYHRGIVHGDLSQYNVLVSE- 
              :: :**:****:.  * ::: **:* .* *  :* :.*: ::*::***:.::*:::.*  
                    250       260       270       280       290       300 
                      |         |         |         |         |         | 
hRio2        DHITMIDFPQMVSTSHPNAEWYFDRDVKCIKDFFMKRFSYESELFPTFKDIRREDTLDVE 
AFRio2       EGIWIIDFPQSVEVGEEGWREILERDVRNIITYFSRTYRTEKDINSAIDRILQE------ 
             : * :***** *.... . .  ::***: *  :* : :  *.:: .::. * :*       
                    310       320       330       340       350       360 
                      |         |         |         |         |         | 
hRio2        VSASGYTKEMQADDELLHPLGPDDKNIETKEGSEFSFSDGEVAEKAEVYGSENESERNCL 
AFRio2       ------------------------------------------------------------ 
                                                                          
                    370       380       390       400       410       420 
                      |         |         |         |         |         | 
hRio2        EESEGCYCRSSGDPEQIKEDSLSEESADARSFEMTEFNQALEEIKGQVVENNSVTEFSEE 
AFRio2       ------------------------------------------------------------ 
                                                                          
                    430       440       450       460       470       480 
                      |         |         |         |         |         | 
hRio2        KNRTENYNRQDGQRVQGGVPAGSDEYEDECPHLIALSSLNREFRPFRDEENVGAMNQYRT 
AFRio2       ------------------------------------------------------------ 
                                                                          
                    490       500       510       520       530       540 
                      |         |         |         |         |         | 
hRio2        RTLSITSSGSAVSCSTIPPELVKQKVKRQLTKQQKSAVRRRLQKGEANIFTKQRRENMQN 
AFRio2       ------------------------------------------------------------ 
                                                                          
                    550 
                      | 
hRio2        IKSSLEAASFWGE 








Figure 3.1:  Alignment between AFRio2 and hRio2  
 Alignment was performed with the program CLUSTALW using sequences from A. fuligidus  (AFRio2) 
and hRio2 (from yeast).  Identical, highly similar, and weakly similar residues are indicated by red, green, 
and blue letters respectively.  The wing helix domain of AFRio2 is highlighted in yellow, the N-terminal 
lobe in green and the C-terminal lobe in blue.  The C-terminal extension of hRio2 is in the boxed region 









Figure 3.2:  Schematic of Three hRio2 Constructs  
A. Schematic of  N-hRio2 with a 6x N-terminal His tag followed by a TEV cleavage site. 
B. Schematic of  C-Rio2 with a 6x C-terminal His tag. 
C. Schematic of  Δ71-C-hRio2 with deletion of the first  N-terminal 71 residues of hRio2 and 
engineered with a C-terminal 6x His tag. 
  
N’ 6x His Tag TEV Site Human Rio2 C’ 
N’ Human Rio2  6x His Tag C’ 
N’ (72-552) Human Rio2 
 









TTATTA GTGGTGGTGGTGGTGGTG TTCTCCCCAAAAGCTAGCTGCTTCC 








Attb1 Site RBS Site 
 
D. 
GGGGACCATTTGTACAAGAAAGCTGGG TTATTA GTGGTGGTGGTGGTGGTG TTCTC 
Attb2 Site Stop 
Codons 




Figure 3.3:  PCR of C-hRio2 
In PCR1, Rio2p was amplified from the  pDEST527 plasmid containing an insert for the hRio2  gene.  A. 
The forward primer for PCR1 was used to add an RBS site to the 5’ end of the hRio2 gene.  B. The reverse 
primer for PCR1 was used to add a 6x His tag and two stop codons to the 3’ end of the hRio2 gene.  C. and 
D The forward and reverse primers for PCR2.  C. was used to add an attb1 site to the 5’ end of PCR1 

























Figure 3.4:  Subcloning of C-hRio2 
pDEST 14-C-hRio2 plasmid was transformed into DH5α E. coli cells.  The plasmids were isolated from 
DH5α cells and screened by PCR for the insert using the forward and reverse primers of PCR1 (Figure 3.2 
A and B).  The agarose gel, stained with ethidium bromide, shows the PCR product of two positive clones.  

















Rosetta cells expressing the plasmid for N-hRio2 were induced at 37°C for four hours with 1mM IPTG.  A 
band for overexpressed N-hRio2 in the lysate after induction is indicated by an arrow.  N-hRio2 was 
purified by His Trap
TM
 Column.  Fractions from the flow-through, 40mM imidazole wash, and elution were 





Figure 3.6:  Induction of Rossetta Cells at 18°C 
Rosetta cells expressing pDEST 527-N-hRio2 plasmid were induced at 18°C overnight with 1 mM IPTG.  
Two clones labeled 1 and 2 were tested for expression and solubility.  Cells were lysed using 5x SDS 
loading dye before and after induction and samples were run on SDS-PAGE gel stained with Coomassie 
Blue.  Cells were also lysed with 0.3x Bugbuster, and the supernatant was run on SDS-PAGE gel 
(“soluble”).  The expected molecular weight of N-hRio2 is 66kDa. This SDS-PAGE gel also shows the 40 
mM imidazole wash from Figure 3.5 purification of N-hRio2 on His Trap.  This 40 mM imidazole fraction 






Figure 3.7:  N-hRio2 Purified with 500 mM NaCl on His Trap
TM
 
N-hRio2 was solubilized with 500 mM NaCl in the lysis solution and then the supernatant was  run on His 
Trap
TM
.  The SDS-PAGE gel, stained with Coomassie Blue, is labeled with the imidazole concentration at 
which the fraction eluted. Protein eluted both in the 20 mM wash and at 125 mM imidazole elution.  N-
























Figure 3.8:  Δ71-C-hRio2 Purification 
Rosetta cells containing the pDEST 14 plasmid for expression of  Δ71-C-hRio2 were induced with 1 mM 
IPTG overnight at 18°C.  The lysate and supernatant were run on the SDS-PAGE gel, stained with 
Coomassie Blue.  The supernatant was loaded on a His Trap
TM
 column.  No protein eluted from the His 
Trap
TM


































Figure 3.9:  C-hRio2 Purified on His Trap
TM
 with NP40 in the Buffers 
The SDS-PAGE gel is stained with Coomassie Blue.  Rosetta cells contained pDEST14 plasmid for 
expression of C-hRio2.  Lysis of 2 L cultures of Rossetta cells was performed with and without  0.1% 
NP40 and 10% glycerol. The supernatant containing 0.1% NP40 was then loaded onto a His Trap
TM
 
column.  The His Trap
TM
 column was washed with 50 mM imidazole and C-Rio2p was eluted with 100 
mM imidazole.  The SDS-PAGE gel, stained with Coomassie Blue, is labeled with the concentration of 








Figure 3.10:  C-hRio2 Purified on S
TM
 Column 
C-hRio2 was purified first on the His Trap
TM
 column. All buffers contained 0.1% NP40 and 10% glyerol.  
The fractions from the His Trap
TM 
column containing C-hRio2 were pooled together (“pooled fractions”), 
diluted to 200 mM NaCl (“diluted fractions”) and run on a S
TM
 column.  While C-Rio2p was bound to the 
S
TM
 column, the 0.1% NP40 was washed from the protein.   C-hRio2 was then eluted. The SDS-PAGE gel, 












Figure 3.11:  C-hRio2 Purified on His Trap
TM
 w 1 mM AMP in Buffers 
1mM AMP was added to all buffers during the purification of C-hRio2.  Lysate containing overexpressed 
C-hRio2 was passed over a His Trap
TM
 column.  C-hRio2 elutes in dilute fractions in the gradient between 











Figure 3.12:  C-hRio2 Purified on S
TM
 Column with 1 mM AMP in Buffers 
After purification on His Trap
TM
 column, C-hRio2 was loaded on a S
TM
 column and eluted over a gradient 
of 200 mM NaCl to 100 mM NaCl over 100 mL.  1 mM AMP was maintained in all buffers.  The SDS-
PAGE gel, stained with Coomassie Blue, is labeled with the salt concentrations the different fractions of C-







Figure 3.13:  C-hRio2 Purified with on His Trap
TM 
with 1 mM ATP in Buffers 
Lysate containing overexpressed C-hRio2 was loaded onto a His Trap
TM
 column.  1 mM ATP was included 
in all buffers.  The column was washed with 50 mM imidazole and 100 mM imidazole.  C-hRio2 was 
eluted at 130-260 mM imidazole.  The SDS-PAGE gel, stained with Coomassie Blue, is labeled with the 
imidazole concentration at which each fraction eluted from the His Trap
TM
 column.  C-hRio2 is expected to 























Figure 3.14:  C-hRio2 Purified with 1 mM ATP on His Trap
TM
 Precipitates 
Overnight Supernatant containing overexpressed C-hRio2 was purified on His TrapTM.  1mM ATP was 
present in all the buffers. The next day, the protein in the fractions from the His Trap
TM
 had precipitated.  
The precipitate was run on the SDS-PAGE gel stained with Coomassie Blue. The protein was then filtered 



























 Column with 1 mM ADP in 
Buffers 
Supernatant containing overexpressed C-hRio2 was loaded onto a His Trap
TM 
column.  The resin was 
removed from the column, and mixed with 500 mM imidazole elution buffer.  The resin was allowed to 
settle and the elution buffer was removed from the top of the resin (“elution His Trap
TM
). C-hRio2 was 
diluted to 0.3 mg/mL and then loaded onto a S
TM
 column.  The pressure on the column rose and only one 
fraction of C-hRio2 eluting at 300 mM NaCl was able to be obtained from the column.  The SDS-PAGE 









Pure? MW PI 
N-hRio2 1-552 Yes 37°C No 66,283 5.66 
C-hRio2 1-552 Yes 18°C Yes 63,283 5.66 
Δ71-C-
hRio2 
72-552 No 18°C N/A 55,297 5.18 
 




Chapter 4:  Purification and Crystallization of Rio2 from Chaetomium 
thermophilum 
4.1:  Introduction 
 
Chapters 2 and 3 described the purification of Rio2p and hRio2 and the efforts to 
obtain the structure of a eukaryotic Rio2.  In the case of Rio2p the crystals were small, 
and in the case of hRio2 poor solubility prevented crystal screening.  In this chapter, I 
discuss the purification and crystallization of Rio2 from a thermophilic fungus, 
Chaetomium thermophilum (ctRio2).  The construct shown in Figure 4.1, was obtained 
from the laboratory of Dr. Ed Hurt in the Biochemistry Center, Heidelberg University, 
Germany.   CtRio2, like Rio2p and hRio2, has an extended C-terminus (Figure 4.2).   
There were issues in the purification and crystallization of ctRio2: it co-purified 
with a close molecular weight degradation product; it nonspecifically bound to RNA in 
the lysate; and crystals of ctRio2 were small and did not diffract well.  These problems 
were corrected by overloading the His Trap
TM
 column, which caused ctRio2 to elute 
differently from the close molecular weight contaminant, using a Q
TM
 column to separate 
RNA from ctRio2, and seeding with microcrystals to produce larger, better diffracting 
crystals. 
4.2:  Methods 
4.2.1:  Purification of CtRio2  
 
The optimized procedure for purification of ctRio2 (Figure 4.1) is outlined below.  
The p7-ctRio2 vector (from the Hurt lab), transformed into E. coli Rosetta
TM
 DE3 
(pLysS) cells, was used to inoculate an overnight 100 mL culture containing both 100 
μg/ml ampicillin and 34 μg/ml chloroamphenicol at 37ºC.   The overnight culture was 
diluted 1/100 into four 4 L baffle flasks containing 1 L of LB with ampicillin and 
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chloroamphenicol.  The four flasks were then incubated at 37°C with shaking at 250 rpm.  
At O.D.600 of 0.5, the flasks were moved to an 18°C shaking incubator to cool the 
cultures to 18°C.  At 0.6-0.8 O.D.600 the culture was induced with 1 mM IPTG and 
incubated overnight.   
The cells were centrifuged at 5,000 rpm for thirty minutes.  The pellet was about 
4-5 grams per L of cell culture.  The cell pellets were frozen at -80°C.  The frozen pellet 
was resuspended in 10 mL of Buffer A (200 mM NaCl , 10% glycerol, 50 mM Tris, pH 
8.0, 2.5 mM MgCl2, 0.05% BME) per gram of cell pellet.  5 mg of DNAse, 1 mg of 
RNase A, and 20 µl of RNase T1 (100,000 U/mL) per liter of cell pellet were added to 
the solution.  One Complete, EDTA free, protease inhibitor cocktail tablet (Roche) was 
added to the cell suspension.  0.3X Bugbuster
TM
  and 0.5 mg of lysozyme/mL cell 
suspension were added to lyse the cells.  The cells were stirred at 4°C for thirty minutes.  
The lysate was centrifuged at 16,000 rpm for one hour to pellet the cell debris.  The 
supernatant containing the soluble protein was filtered through a 0.25 micron filter.  
The supernatant was passed over a GE Healthcare 5mL His Trap
TM
 column that 
was pre-equilibrated with Buffer A.  Buffer B (200 mM NaCl, 10% glycerol, 50 mM 
Tris, pH 8.0, 2.5 mM MgCl2, 1 M imidazole, 0.05% BME) was used to elute the protein.  
3% Buffer B was used to elute CtRio2 from the column and 5 mL fractions were 
collected.  The column was washed with 10% Buffer B and then 100% Buffer B.   
A SDS-PAGE gel was run of the fractions collected during the 3% Buffer B 
elution.  The concentrated and pure fractions were pooled together for TEV cleavage.  
The protein concentration of the combined fractions was determined by A 280.  A 280 of 
one was assumed to be a 1 mg/mL concentration of ctRio2.  CtRio2 was concentrated to 
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5 mg/mL on a Millipore Centrifugal Filter Unit at 4°C.  Three mg of TEV protease was 
added to the ctRio2, which was then  dialyzed overnight in Buffer A at 4°C.   
The next day, the His Trap
TM
 column was equilibrated with Buffer A.  CtRio2 
was passed over the column and the flow-through was collected and assumed to be 
cleaved protein.  The column was also eluted with 10% Buffer B to retrieve the 
uncleaved protein.  The column was washed with 100% Buffer B. 
The solution containing ctRio2 was diluted, the final concentrations of solution 
components were 200 mM NaCl, 50 mM Tris pH 8.0, 2.5 mM MgCl2, 10% glycerol, 
0.05% BME.  Two GE Healthcare Q
TM
 columns were connected and were pre-
equilibrated with the loading buffer, Buffer C, (200 mM NaCl, 50 mM Tris pH 8.0, 2.5 
mM MgCl2, 10% glycerol, 0.05% BME).  Buffer D, the high salt buffer, was 1 M NaCl, 
50 mM Tris pH 8.0, 2.5 mM MgCl2, 10% glycerol, 0.05% BME.  The ctRio2 was loaded 
onto the Q
TM
 column.  A gradient of the two buffers was run from 150 mM NaCl to 1 M 
NaCl over 100 mL.  CtRio2 eluted at 300 mM NaCl.  The purest and highest 
concentration fractions were combined and dialyzed against 1 L of Buffer E (10 mM Tris 
pH 8.0, 150 mM NaCl, 2.5 mM MgCl2, and 0.5% BME).  The ctRio2 was concentrated 
to 10 mg/mL as determined by A280. 
Selenomethionine substituted protein was grown using M9 SeMET High-Yield 
Growth Media Kit (Shanghai Medicilon Inc.) following the instructions provided.    
Selenomethionine substituted ctRio2 was purified same as described above.  
4.2.2:  Crystallization of CtRio2 
Crystal screens used were Qiagen’s PEG Suite, Hampton’s Index Screen, Emerald 
Biosystems Wizard I, II, and III Screens, Hampton Research’s Natrix Screen and 
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Qiagen’s Cryos Suite.  In these screens sitting drops were set up in 0.6 µl drops of well-
to-protein ratios of 1:2, 1:1, and 2:1.  A total of 384 conditions were tested in three 
different protein-to-well solution ratios.  The screens were incubated at 20°C. 
4.3:  Results 
 4.3.1:  Overloading the His Trap
TM
 Column Can Eliminate Degradation 
Products 
 
The construct obtained from Dr. Hurt contained an N-terminal 6x His tag and a 
TEV cleavage site to remove the His tag from the final product (Figure 4.1).  After 
transformation in Rosetta
TM
 cells, a robust expression of recombinant ctRio2 was 
obtained.  Two purification strategies were used to purify ctRio2 and eliminate 
degradation products, and one of these methods was shown to have superior performance 
over the other.   
In the first method, two His Trap
TM
 columns were used in tandem to avoid 
exceeding the binding capacity of the columns. While ctRio2 bound well to the column 
and eluted at 100 mM imidazole concentration, it copurified with many contaminants or 
degradation products (Figure 4.3).  The His tag was cleaved with TEV protease and then 
ctRio2 was passed over the His Trap
TM
 column a second time to remove protein 
contaminants not cleaved by TEV.  However, the first method (two columns) could not 
remove all contaminants because ctRio2 copurified with a degradation product slightly 
smaller than the full-length ctRio2 (Figure 4.4).  
 In the second method, one His Trap
TM
 column was used in order to overload the 
column and it was found to successfully purify ctRio2.  Overloading the column changed 
the elution profile of ctRio2 so that it eluted much earlier (at 30 mM imidazole) and in 
more pure and concentrated fractions (Figure 4.5).  Also the low molecular weight 
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degradation product that persisted with ctRio2 in method one continued to elute at 100 
mM imidazole and was separated from full length ctRio2 which eluted at 30 mM 
imidazole.  After TEV cleavage, ctRio2 was passed over the single His Trap
TM
 column.  
The ctRio2 eluted in the flow-through while the contaminants remained on the column 
(Figure 4.6).   
In conclusion, protein overloading allowed the elimination of protein 
contaminants including the degradation product.  Since ctRio2 has higher affinity for the 
nickel column and binding sites on the nickel column are limited, ctRio2 will compete 
with protein contaminants for binding to the column.  The result is that major protein 
contaminants will not bind to the column.  In addition, since the ratio of ctRio2 to nickel 
atoms increased in method two, the binding affinity for ctRio2 decreased.  As a result, the 
elution profile of ctRio2 changed in method two such that ctRio2 eluted earlier (at 30 
mM imidazole) and was separated from the tighter binding close molecular weight 
degradation product that eluted at 100 mM imidazole. 
4.3.2:  Improving TEV Cleavage Increased Yield of CtRio2 
 
TEV cleavage was improved in the purification procedure.  Initially 1mg of TEV 
was used to cleave the large quantity of ctRio2 eluting from the His Trap
TM
.  The 
concentration of ctRio2 was 1 mg/ml during cleavage and cleavage was performed 
overnight at 4°C.   Under these conditions, the TEV cleavage was not complete, as half 
the ctRio2 remained uncleaved and did not elute in the flow-through.  The conclusion 
was that, the His tag was difficult to cleave from the N-terminus.  The concentration of 
ctRio2 was then increased to 5 mg/ml and TEV protease was increased to 3 mg.  With 
these changes, most of ctRio2 was found to be cleaved and eluted in the flow-through.  
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4.3.3:  CtRio2 Binds to RNA Nonspecifically 
 
An observation that helped to purify ctRio2 is that ctRio2 binds to RNA despite 
RNases being present in the lysate.  The last step of purification of ctRio2 involved 
passing the protein over an anion exchange Q
TM
 column (Figure 4.7).  In the 
chromatogram of the elution of the protein from the Q
TM
 column two peaks appear, one 
for ctRio2 at a lower concentration of 300 mM salt, and one for RNA at a higher 
concentration of 500 mM salt (Figure 4.7A).  The second peak is most likely RNA 
because it has a high affinity for the Q
TM
 column—its A260/A280 absorbance ratio is 
over 2 and it shows no protein bands on the gel. 
The Q
TM
 column is an important step for purification.  If RNA continues to 
remain bound to ctRio2, it would prevent ctRio2 from forming crystals.  The RNA is 
bound nonspecifically and consists of a variety of different RNAs.  Any heterogeneity in 
the protein sample precludes the protein from crystallization. 
4.3.4:  Crystal Screens 
 
In order to maximize the number of hits ctRio2 was screened at 10 mg/mL and at 
20 mg/mL concentrations.  CtRio2 was also screened with and without 20 mM ADP.  
The crystals began to appear after one month and they did not grow large enough for 
diffraction.  However, the number of positive hits was large in both the PEG Screen and 
the Index Screen (Figures 4.8 and 4.9).  Many factors could account for the delayed 
crystallization.  Nucleation of the crystal is usually the rate limiting step, after which the 
crystal usually grows quite rapidly.  The protein might undergo degradation to a more 
stable fragment before it crystallizes.  
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I attempted to reproduce positive hits by the hanging drop method.  In the hanging 
drop method, the protein was mixed with the well solution in the ratios from the crystal 
screen in a 4 µl drop on a cover-slip.  That coverslip was then affixed over a well 
containing 1 mL of the precipitant solution.  Vapor from the drop on the coverslip 
diffused into the well solution where the concentration of the precipitant was greater.  
This allowed the protein on the cover-slip to become slowly concentrated, resulting in 
crystal formation.   
Optimization screens were performed in 6 by 4, 24-well format. The 
concentration of precipitant was varied across the six wells and ranged from smaller to 
larger concentrations of precipitant than the screen solution.  The pH was varied along 
each of the rows so that four different pHs were tested.    
After months of incubation time, the hanging drop was ineffectual at reproducing 
the crystals formed with or without ADP and led me to try microseeding.  Crystals were 
broken into tiny seeds and added to a new 4 µl protein/precipitant droplet.   The 
microcrystals obtained in the Index Screen solution number 45 (0.1 M Tris pH 8.5, 25% 
PEG 3350) were used for the seed solution. 
The 24-well hanging drop screen solutions were set up as before, as were the 4 µl 
protein/precipitant droplets.  The protein droplets were allowed to incubate with the well 
solution for two days.  Then 2 µl of the protein droplet was mixed with the microcrystals 
obtained from the sitting drop screen.  The microcrystals in this solution were pipetted up 
and down to break the microcrystals into smaller seed crystals.   0.2 µl of that seed 
solution was used to seed 8 of the wells from the hanging drop optimization screen.  The 
screen was then incubated at 20°C. 
73 
After one month with seeding, larger crystals appeared in the wells (Figure 4.10).  
The precipitant concentration in these wells was less than that from the original crystal 
screen.  Diffraction data were collected with a few of the crystals at the University of MD 
source x-ray beam.  The crystals were soaked in different amounts of glycerol and 
ethylene glycol to freeze them.  25% ethylene glycol was added to prevent the formation 
of ice rings in the diffraction pattern.  The crystals diffracted to 3.6 Å.  For better 
resolution data, the crystals were frozen and shipped to the synchrotron at Argonne, 
Illinois.   Data were collected at the NE-CAT beamline on several crystals that diffracted 
at an average of 2.5 Å.   
Later crystals were grown with 2 mM ATP.  10 mg/mL ctRio2 was incubated 
with 2 mM ATP (30x dilution) and 2.5 mM MgCl2 (included in ctRio2 buffer solution) 
for one hour.  The crystals were grown in a sitting drop screen.  0.4 µL of protein solution 
were mixed with 0.2 µL of precipitant solution (0.2 M Magnesium chloride hexahydrate, 
0.1 M Bis-Tris, pH 5.5, 25% (w/v) PEG 3350) and placed in a sitting drop next to a well 
containing 200 µL of precipitant solution.  Crystals grew large enough for X-ray 
diffraction studies after 4-5 days at 20°C.  Data were collected at the NE-CAT beamline 
on several crystals that diffracted at an average of 2.2 Å.   
4.4:  Summary 
 





columns.  Success was achieved by overloading the His Trap
TM
 column to remove major 
protein contaminants and degradation products.  TEV cleavage was optimized to cleave 
most of the ctRio2 in solution.  Passing of ctRio2 over the His Trap
TM
 a second time after 




column to remove non-specifically bound RNA that could impede its crystallization.  
Following this modified procedure, crystals of ctRio2 were obtained with ADP and with 
ATP that diffracted at 2.5Å and 2.2Å respectively at the synchrotron, and finally a 






Figure 4.1:  Schematic of CtRio2 Construct 
CtRio2 construct was designed with an N-terminal 6x His tag followed by a TEV cleavage site. 
  
N’ 6x His Tag TEV Site ctRio2 C’ 
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                    10        20        30        40        50        60 
                      |         |         |         |         |         | 
AFrio2       MNIAELYG-KMGKHSWRIMDAIFKNLWDYEYVPLQLISSHARIGEEK---ARNILKYLSD 
ctrio2       MKLDTRAMRHLTAEDWRVLTAVEMGSKNHEIVPTPLIEKIARLRGGSSGVHKSIATLAKA 
             *::      ::  ..**:: *:  .  ::* **  **.. **:   .    :.* .  .  
                     70        80        90       100  P-loop         120 
                      |         |         |         |  xxxxxx |         | 
AFrio2       LRVVQNRQKDYEGSTFTFIGLSLYSLHRLVRSGKVDAIGKLMGEGKESAVFNCYSEKFGE 
ctrio2       GLIARMKEAKYDGYRLTYGGLDYLALHTHAARKDVYSVGSRIGVGKESDIMIVADEKGKQ 
               :.: :: .*:*  :*: **.  :**  .   .* ::*. :* **** ::   .**  : 
                    130       140       150       160       170       180 
                      |         |         |         |         |         | 
AFrio2       CVVKFHKVGHTSFKKVKEKRDYG----DLHFSVLAIRSARNEFRALQKL--QGLAVPKVY 
ctrio2       KVLKIHRLGRISFRTVKANRDYLRNRSTGSWMYLSRLAAIKEFAFMKALYEEGFPVPEPI 
              *:*:*::*: **:.** :***        :  *:  :* :**  :: *  :*:.**:   
                    190       200       210       220       Catalytic 240 
                      |         |         |         |        xxxxxx     | 
AFrio2       AWEGNAVLMELIDAKELYRVR-VENPDEVLDMILEEVAKFYHRGIVHGDLSQYNVLVSEE 
ctrio2       AQSRHTIVMSLVDALPMRQVSSVPDPASLYADLIALILRLAKHGLIHGDFNEFNILIREE 
             * . ::::*.*:**  : :*  * :* .:   ::  : :: ::*::***:.::*:*: ** 
                    250     Metal       270       280       290       300  
                      |     xxxxx         |         |         |         | 
AFrio2       G-----------IWIIDFPQSVEVGEEGWREILERDVRNIITYFSR-------------- 
ctrio2       KDAEDPSSITLTPIIIDFPQMVSMDHPNAEMYFDRDVQCIKRFFERRFHFVSTTPGPFYK 
                           ****** *.:.. . .  ::***: *  :*.*               
                    310       320       330       340       350       360 
                      |         |         |         |         |         | 
AFrio2       -----------------------TYRTEKDINSAIDRILQE------------------- 
ctrio2       DAKKTVGKDGAKRLDAALEASGFTKKMAKDLEAAIREQQESRNDEEDSDDYEEDSDKEKA 
                                    * :  **:::** .  :.                    
                    370       380       390 
                      |         |         | 
AFrio2       ------------------------------------ 





Figure 4.2:  Alignment between AfRio2 and CtRio2  
Alignment was performed with the program CLUSTALW using sequences from A. fuligidus  (AFRio2) and 
ctRio2.  Identical, highly similar, and weakly similar residues are indicated by red, green, and blue letters 
respectively.  The wing helix domain of AfRio2 is highlighted in yellow, the N-terminal lobe in green and 










Figure 4.3:  Purification of CtRio2 on His Trap
TM
 Column – Method One 
Supernatant containing overexpressed ctRio2 was passed over two connected His Trap
TM
 columns. The 
SDS-PAGE gels, stained with Coomassie Blue, are labeled with the imidazole concentration at which the 
fraction eluted. A.  CtRio2 begins to elute from the His Trap
TM
 columns at 80 mM imidazole. B. A close 






















Figure 4.4:  TEV Cleavage of CtRio2 – Method One  
CtRio2 was cleaved with TEV protease and then passed over two connected His Trap
TM
 columns a second 
time. The SDS-PAGE gel, stained with Coomassie Blue, is labeled with the imidazole concentration at 
which the fraction eluted.  CtRio2 elutes at 20 mM imidazole and co-purifies with a degradation product of 








Figure 4.5:  Purification of CtRio2 on His Trap
TM
 Column – Method Two 
Supernatant containing overexpressed ctRio2 was passed over one His Trap
TM
 column. The SDS-PAGE 
gels, stained with Coomassie Blue, are labeled with the imidazole concentration and fraction number  at 
which the fraction eluted. A.  CtRio2 begins to elute from the His Trap
TM
 column at 30 mM imidazole. B. 






Figure 4.6:  TEV Cleavage of CtRio2 – Method Two  
CtRio2 was cleaved with TEV protease and then passed over a His Trap
TM
 column a second time. The 
SDS- 
PAGE gel, stained with Coomassie Blue, is loaded with a sample of ctRio2 before TEV cleavage (“Before 
TEV”) and a sample of ctRio2 after TEV cleavage (“After TEV”) before loading on the column.  The flow-
through from the His Trap
TM
 column contains the cleaved ctRio2 and the fractions at 100 mM imidazole 








Figure 4.7:  CtRio2 Purified on Q
TM
 Column. 
CtRio2 was passed over a Q
TM
 column and then eluted over a 150 mM to 1 M NaCl gradient.  A. The 
chromatogram of elution from the Q
TM
 column.  Peak one is ctRio2.  B. The SDS-PAGE gel, stained with 






























































Figure 4.8:  Apo CtRio2 Crystals  
The crystals are formed with apo ctRio2 at a concentration of 10 mg/mL.  Crystals are obtained from  
A.  PEG Screen condition number 38 (0.1 M Sodium HEPES pH 7.5, 25 %(w/v) PEG 4000).  B. PEG 
Screen condition number 35(0.1 M MES pH 6.5, 20 %(w/v) PEG 10000).  C. Index Screen condition 









Figure 4.9:  CtRio2 Crystals Grown with ADP 
These crystals were produced with 20mM ADP and 20 mg/mL ctRio2.  A. PEG Screen condition number 
35, 2:1 protein to well solution (0.1 M MES pH 6.5, 20 %(w/v) PEG 10000). B.  PEG Screen condition 










Figure 4.10:  CtRio2 Crystals Formed in Hanging Drop 
The crystals were produced with 20 mM ADP and 10 mg/mL protein in hanging drop by microseeding 
from crystallization screen.  A.Condition was 2:1 protein to well solution in 0.1 M Tris, pH 8.5, 16% PEG 








Chapter 5:  Structure of the Eukaryotic Rio2 Kinase from CtRio2 
5:1:  Introduction 
 
In this last chapter, I discuss acquiring x-ray diffraction data and analysis of the 
structural features of ctRio2.  This is the first structure of a eukaryotic Rio2 kinase, which 
is significantly extended compared to the archaeal version for which we currently have 
structural information.  Therefore, I performed structural analysis to determine the 
similarities and differences between ctRio2 and afRio2, and decipher the additional 
functionality provided by the extended sequences in eukaryotic Rio2.   
5.2:  Procedures 
5.2.1:  Obtaining the Crystal Structures of CtRio2 
 
Both apo ctRio2 crystals and ctRio2 with ATP crystals were flash frozen in 
mother liquor containing 25% ethylene glycol.  Diffraction data were collected at 100K 
with a MAR300 CCD detector at the NE-CAT beamline, 22-ID located at the Advanced 
Photon Source, Argonne National Laboratory (Argonne, IL, USA).  The data were 
integrated and merged using HKL2000 (46).  Tables 5.1 and 5.2 contain the relevant 
statistics of these two data sets.   
The structure of apo ctRio2 was solved by molecular replacement using the 
known structure of afRio2 with ADP and Mn
2+
 bound.  An all alanine model of afRio2 
was used for molecular replacement.  The program used for molecular replacement was 
AutoMR from the Phaser crystallography software suite (47).  Refinement was done with 
phenix.refine in Phaser (48-50).  Rfree was monitored by using 8% of the reflections as a 
test set.  The crystallographic refinement statistics are shown in Table 5.1.  The figures 
that depict the structures of ctRio2 were created using PYMOL (51) .   
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The structure of ctRio2 with ATP was solved by molecular replacement using the 
partially refined structure of apo structure of Rio2 as a search model, also using AutoMR 
within Phaser (47).  Autobuild (also within Phaser) was used to perform automatic model 
building using a map produced using the phases obtained from molecular replacement.  
The ligand was placed in the model and the structures were finalized by multiple rounds 
of rebuilding using COOT and refinement with phenix.refine (48-50).  Rfree was 
monitored by using 5% of the reflections as a test set.  The refinement statistics are 
shown in Table 5.2. 
5.2.2:  Testing the Kinase Activity of CtRio2 
A solution was prepared of 5 mM ATP with 10 mM MgCl2 and 50 mM Tris pH 
8.0.  1 in 10 serial dilutions of this stock solution were made to give 0.5 mM ATP, 0.05 
mM ATP, and 0.005 M ATP.  1 μl or 5 μl of 10 mg/ml ctRio2 was mixed with 10 μl 2x 
Buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 1 mM MgCl2).  The total volume was 
brought to 17 μl with water.  1 μl of a 1/10 dilution of the γ-P
32
-ATP (10 μCi per μl) was 
added to 2 μl of the varying concentrations of ATP.  Then the 3 μl of each ATP solution 
was added to each reaction to give final ATP concentrations of 0.5 mM ATP, 0.05 mM 
ATP, 0.005 mM ATP, and 0.0005 mM ATP.  The reaction was incubated at 37°C for 1 
hour and then quenched with 8 μl of 5x loading dye.  The samples were boiled for five 
minutes and then loaded on a SDS-PAGE gel.  The gels were dried and then exposed 
overnight on a phosphor imaging plate.   
5.3:  Results 
5.3.1:  Overview of the Structure of CtRio2 
 
88 
Crystals of the apo structure and the ATP complex were isomorphous and 
belonged to the space group H3, with one molecule per asymmetric unit.  Diffraction of 
the ATP complex and apo structure, extending to resolutions 2.2 Å and 2.5 Å 
respectively, was measured on a synchrotron source (NE-CAT, Argonne National 
Laboratories Advanced Photon Source).   
Apo ctRio2 was crystallized in the presence of 20 mM ADP and 2.5 mM MgCl2.  
However, no ADP was observed in the active site of the enzyme.  CtRio2 was also 
crystallized with 2 mM ATP and 2.5 mM MgCl2.  Details of the crystallization methods 
were described in Chapter 4. 
 The core domain of ctRio2 mimicked the structure of afRio2 except for an 
extended C-terminal domain.  Although some of the C-terminus was observed, electron 
density was not observed for most of it.  There is no electron density for fifty-five of the 
extended C-terminal eighty-nine residues.  It might be that the C-terminal domain is 
degraded or that it is highly flexible.  Another hypothesis could be, since the apo 
structure was solved by molecular replacement with afRio2, it lacks phase information of 
the extended C-termini not seen in the afRio2 structure.  As such the weak electron 
density of a more flexible C-terminus might not show up in the difference Fourier map.  
Phase information for these fifty-five residues might have to be obtained by heavy metal 
soaks of the native crystals or by obtaining selenomethionine substituted crystals.  The 
problem with obtaining this information was that large native crystals needed for heavy 
metal soaks were not reproduced even by seeding.  Also it was found that 
selenomethionine-substituted protein does not crystallize as efficiently as native protein 
and it has many fewer hits on the crystal screens.  During crystal optimization in the 
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hanging drop format, the selenomethionine-substituted protein produced only small 
crystals with seeding.  The protein that was visible in the crystal structure is analyzed 
below. 
The N-terminus of ctRio2 contains a winged helix domain.  It is comprised of 
four α helices followed by a β-strand wing β-strand motif, and another α helix (Figure 
5.1).  The RIO domain in ctRio2 (as in afRio2) consists of an N-terminal lobe and a C-
terminal lobe with a flexible hinge region between them (Figures 5.2).  ATP binds in the 
large cleft between the two lobes.  The N-terminal lobe consists of a five-stranded 
antiparallel β sheet and a long α helix.  The C-terminal lobe of the RIO domain consists 
of two antiparallel β strands and two α helices.  The third α helix seen in afRio2 is 
missing in the ctRio2 structure.  However, instead there is another C-terminal α helix that 
is not seen in the afRio2 structure partially obstructing the opening to the active site.  
This α helix, labeled αJ, is situated in the cleft between the C and N terminal lobes of the 
RIO kinase domain (Figures 5.2). 
The active site of ctRio2 contains three loops—the P-loop, the “DFG” loop, and 
the catalytic loop.  The P-loop is involved in binding ATP and orienting the γ phosphate 
in a position to be attacked by the nucleophilic serine in a phosphoryl transfer reaction.  
The “DFG” loop binds and positions the metal ions that coordinate the phosphate 
oxygens of ATP and help orient the nucleotide.  The catalytic loop contains the 
conserved N and D residues necessary for catalysis and metal binding.  In typical protein 
kinases the sequence of the P-loop is GXGXXG.  In afRio2 the sequence is GEGKES, 
and in ctRio2 the sequence is GVGKES.  The sequence of the DFG loop in both afRio2 
and ctRio2 is IDFPQ.  In afRio2, the catalytic loop contains the catalytic D218 and the 
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metal binding residue N223.  It has the sequence DLSQYN.  For ctRio2, the catalytic 
residue is D232 and the metal binding residue is N237.  The sequence is DFNEFN.  
Figure 5.3 shows the labeled sequences of ctRio2. 
5.3.2:  Binding Role of the Extended C-terminus in CtRio2 
 
CtRio2 contains an extended C-terminus.  The C-termini of eukaryotic Rio2 
proteins differ widely.  Higher eukaryotes have an elongated C-terminus whereas lower 
eukaryotes have a shorter C-terminus.  The sequence alignment of the C-termini between 
lower and higher eukaryotes is poor.  Figure 5.4 shows the alignment of the most 
conserved segment of the C-terminus between Rio2 from different eukaryotic organisms.  
There is conservation in the region of αJ between these organisms.  Most of ribosomal 
processing is deduced from studies in yeast, thus Rio2p has been well studied.  Its C-
terminus contains a weak nuclear export signal (NES) within residues 318-425, which 
can supplement the endogenous NES of the Nmd3p adaptor protein (37).  Another study 
has assigned the NES signal in yeast specifically to residues 407-425 (52).  Rio2p 
temperature sensitive mutants show a 40S preribosomal subunit nuclear export 
impairment at the restrictive temperature.  Also leptomycin inhibits the export of NES 
containing cargo.  Upon leptomycin treatment of yeast cells, Rio2p accumulates in the 
nucleus (37).  
Human hRio2 protein also contains an NES signal in the C-terminus.  After 
depletion of hRio2, the 40S preribosome is stalled in the nucleus.  The 40S preribosomes 
get exported upon overexpression of hRio2 (but not hRio2) with a mutated or deleted 
NES signal (52).  Thus, by correlation, the extended C-termini of ctRio2 may simply be 
involved in export of the 40S preribosome from the nucleus. 
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The C-terminus of ctRio2 also contains an extra α helix that binds between the 
two lobes of the kinase domain, indicating that the extension of the C-terminal domain 
might have an inhibitory effect on the kinase activity.  This α helix is reminiscent of 
kinases with autoinhibitory domains.  The α subunit of the AMP-activated protein kinase 
(AMPK) from Schizosaccharomyces pombe  (Figure 5.5) contains a conventional 
serine/threonine kinase domain followed by an autoinhibitory domain (AID).  The AID 
consists of three α helices and interacts with both the N- and C- lobes of the kinase 
domain, and buries 1500 Å
2
 exposed surface area mainly through hydrophobic 
interactions.  Without the AID, kinase activity is tenfold higher (53).  CtRio2 has one α 
helix in the cleft between the two lobes of the kinase domain while the AID of AMPK 
binds to the back hinge region of the protein.  The interactions of the two proteins with 
their potential AIDs are very different. 
AMPK also contains an activation domain consisting of a single alpha helix 
similar to the one seen in ctRio2 that occupies the active site between the two lobes of the 
kinase domain.  The C-terminal alpha helix in ctRio2 could be an activation domain that 
has an inhibitory effect on kinase activity.  This kinase activity may be activated by 
phosphorylation of the helix or regions surrounding it. 
Another example of a kinase with an AID is twitchin kinase (Figure 5.6).  
Twitchin kinase contains an autoinhibitory C-terminus with 58 residues (54).  However, 
the AID of twitching kinase binds quite differently than the AID of AMPK and the α 
helix of ctRio2.  It binds extensively to the C-terminal lobe of the kinase domain and uses 
a long region to bind to the cleft between the two lobes.  This domain consists of a long α 
helix that occupies the peptide substrate binding site in the C-lobe of the kinase domain.  
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It also contains a long alpha helix followed by a short turn single α helix and a short β-
strand that binds between the two lobes in the ATP binding site.  In the case of twitchin 
kinase, structural changes occur upon binding to accommodate the AID.  Binding of the 
AID causes the two lobes of the kinase domain to rotate 30° (54).  It does not seem that 
the helix seen in the structure of ctRio2 causes structural changes to the kinase domain, as 
the positioning of lobes and helices is consistent with that of afRio2.  
5.3.3:  C-terminal αJ Interactions with the Kinase Domain 
 
 αJ from the extended C-terminus and the RIO domain are involved in many 
interactions in ctRio2.  The sequence of αJ in ctRio2 is K227, KMAKDLEAAIREAQ, 
Q341.  D232, L333, E334, A336, from ctRio2 are conserved in yeast (Figure 5.4).  The 
side chain of D232 hydrogen bonds with the side chain of Y156 from αC.  The side chain 
of L333 makes a hydrophobic interaction with the side chain of A161 from αC.  The side 
chain of E334 makes a hydrogen bond with the side chain of Y275 from αF and the side 
chain of H269 from the loop region close to αF.  The side chain of A336 makes a 
hydrophobic contact with the side chain of L157 from αC.  The side chain of I337 (V344 
in Rio2p) makes a hydrophobic contact with the side chains of P262 and N263 from the 
metal binding loop.  The side chain of E339 makes a salt bridge with the side chain of 
R149 form αC.  The side chain of Q340 hydrogen bonds to the backbone amide nitrogen 
of G132 from the flexible loop.  Thus αJ binds tightly to the RIO domain of ctRio2 and is 
not expected to be flexible.  Figure 5.8 illustrates the interactions of αJ with the kinase 
domain. 
5.3.4:  Binding of ATP to Rio2 
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In the structure of ctRio2 in a complex with ATP, Mg
2+
 is present in the active 
site.  As shown in Figure 5.9, the metal ion is coordinated by two phosphate oxygen 
atoms from the α and β phosphate groups, a conserved catalytic residue N237, and a 
conserved residue D260 in the metal binding loop.  Water molecules complete the 
coordination sphere of the metal ion.  Figure 5.10 shows that the γ phosphate is held in 
place by interaction with a conserved residue Q263 in the metal binding loop, and by a 
conserved residue E110 in the P-loop (bond lengths 3.24 Å and 2.46 Å respectively).   
The α phosphate is coordinated via a 2.08 Å bond to the metal ion (Figure 5.10).  
K127 is the conserved lysine present in all protein kinases and forms a 2.64 Å hydrogen 
bond with the α phosphate.  The 3’ hydroxyl of the ribose ring forms a 2.98 Å hydrogen 
bond with F236 of the catalytic loop.  The 6’ amino group of adenine forms a 2.85 Å 
hydrogen bond with S193. 
The β phosphate is coordinated via a 2.14 Å bond to the metal ion (Figure 5.11).  
The conserved S111 from the P-loop forms a 2.46 Å bond with the β phosphate and a 
3.17 Å bond with the bridging oxygen between the α and β phosphate.  K127 also forms a 
3.24 Å bond with the bridging oxygen between the β and γ phosphate. 
5.3.5:  Position of γ Phosphate of ATP in AfRio2 and CtRio2 
 
CtRio2 binds ATP in a different conformation than afRio2.  The position of the γ 
phosphate is significantly shifted relative to the position of the metal ion and the catalytic 
residues (Figure 5.12).  The structural alignment of afRio2 and ctRio2 reveals that the P-
loop of ctRio2 is positioned lower than in afRio2 (Figure 5.13).  As a result the γ 
phosphate of ATP in ctRio2 is positioned lower than in afRio2 (Figure 5.13).  Residues 
S111 and E110 of the P-loop coordinate the β and γ phosphates respectively of ctRio2. 
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The positioning of the γ-phosphate in afRio2 places the kinase catalytic base D 
218 too far away to be able to participate directly in phosphoryl transfer (Figure 5.14).  
Whereas, the distance between the carboxyl oxygen of D218 and the phosphorus atom is 
~4.48 Å in PKA, this distance is nearly 7.09 Å in afRio2.  In ctRio2 the positioning of the 
γ-phosphate relative to the catalytic base D232 is similar to the positioning seen in PKA 
and the distance between the γ phosphate and D232 is 4.66 Å.  Since the position of the γ 
phosphate in ctRio2 is like that of other ePKs such as PKA, it may represent an active 
state of the kinase while the position of the γ phosphate in afRio2, may represent an 
inactive state. 
Structural alignment showing the conserved active site residues, ATP, and metal 
ions of ctRio2 and afRio2 (Figure 5.13) reveal that while the conserved residues do not 
change positions dramatically, the second Mn ion of afRio2 occupies the position of the 
phosphorous atom of the γ phosphate of ctRio2.  Binding of the second Mn to afRio2 
may preclude the γ phosphate of afRio2 from assuming a catalytically active state.  
afRio2 may become active when only one metal ion is bound as in ctRio2.  Kinetic 
studies on afRio2 and ctRio2 have not been performed to determine whether excess Mg 
ion is inhibitory on kinase activity but based on this information, this is an obvious next 
step. 
5.3.6:  Structural Alignments 
 
Structural alignment of ctRio2 and afRio2 (rmsd 2.204 Å for 217 atoms) reveals 
that the winged helix domain is shifted between the two proteins.  This shift could be due 
to elongation of αC in ctRio2 (Figure 5.13).  Alignment was performed of the C-terminal 
lobe of the kinase domain between afRio2 and ctRio2 using Swiss PDB viewer.  The 
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alignment reveals a larger shift of the wing helix domain between the two proteins.  The 
alignment also reveals β8 and β9 are extended in ctRio2 as compared to afRio2 (Figure 
5.16). 
Alignment of the best-fit fragment between the two proteins in the Swiss PDB 
viewer shows that the most structurally conserved feature between the two proteins is the 
active site as expected.  The N-terminal lobe of the kinase domain and the active site 
portion of the C-terminal lobe of the kinase domain align, while the rest of the C-terminal 
lobe of the kinase domain and the N-terminal wing helix domain are shifted (Figure 
5.15).   
5.3.7:  Kinase Activity of CtRio2 
 
 LC/MS data show that ctRio2 is phosphorylated once (Figure 5.17).  The kinase 
activity was tested by incubating ctRio2 with γP
32
-labeled ATP (Figure 5.18).  Kinase 
activity was indicated by the autophosphorylation of ctRio2.  It produced a radioactive 
band at the molecular weight of the protein on SDS-PAGE gel.  Kinase activity was 
evident at 0.5 µM ATP with both 10 µg and 50 µg of ctRio2.   
5.4:  Summary 
 
The crystal structure of ctRio2 was determined and the structures of ctRio2 and 
afRio2 were compared.  The structure of ctRio2 in a complex with ATP aligns well with 
afRio2.  However, ctRio2 contains an extended C-terminus containing αJ.  αJ interacts 
with the kinase domain through both hydrophobic and hydrophilic interactions with αC, 
αF, the flexible loop and the metal binding loop.  Since αJ occupies the cleft between the 
two lobes of the kinase domain, it may have an inhibitory effect on kinase activity by 
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preventing peptide substrates from binding.  Examples of protein kinases containing 
inhibitory C-termini are AMP activated protein kinase (53) and twitchin kinase (54). 
AfRio2 has two Mn ions in the active site.  These metal ions coordinate all three 
phosphates of ATP.  The structure of ctRio2 shows only one Mg ion.  This Mg ion 
coordinates the α and β phosphates of ATP.  The γ phosphate in the structure of ctRio2 is 
still well bound as it makes polar interactions with two amino acids. 
The structural alignment reveals that the winged helix domain is shifted between 
afRio2 and ctRio2.  My analysis revealed the position of the γ phosphate in ctRio2 is 
closer to the catalytic aspartate than in afRio2.  The binding of the second Mn ion in 
afRio2 as well as the higher positioning of the P-loop may prevent the γ phosphate of 
ATP from binding in a productive manner.  The positioning of the γ phosphate in ctRio2 
closely mimics the position of the γ phosphate found in eukaryotic serine threonine 
protein kinases such as PKA.  Thus ctRio2 might share the same mechanism of catalysis 
as traditional eukaryotic protein kinases.   
 Figure 6.6 shows the alignment between Rio2 from different eukaryotic species.  
The conserved residues are mapped on a surface representation of ctRio2 (Figure 5.19).  
The conserved surface patches might indicate important rRNA or protein interactions 
made with the ribosome.  The crystal structure of ctRio2 allows us to postulate and study 





Table 5.1  Data Collection and current refinement statistics for apo ctRio2.  Crystal 
data:  space group H3 
  
 
a (Å)    117.40 
b (Å)     117.40 
c (Å)    71.29 
α=β (º)    90.00 
γ (º)    120.00 
Resolution (Å)  29.3-2.48  
Rsym (last shell)  0.074(0.516) 
Reflections (last shell) 12315(1255) 
Redundancy   2.9(2.9) 
Completeness (%)  97.9(99.1) 
Mean B-factor (Å)2  60.5 
R/Rfree (%)   21.78/28.51 
(Last shell)   29.13/38.71 
RMS deviations 
 Lengths (Å)   0.010 
 Angles (º)   1.38 
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Table 5.2  Data Collection and current refinement statistics for ATP bound ctRio2.  
Crystal data:  space group H3 
  
 
a (Å)    119.62 
b (Å)     119.62 
c (Å)    71.78 
α=β (º)    90.00 
γ (º)    120.00 
Resolution (Å)  34.5-2.20  
Rsym (last shell)  0.067(0.539) 
Reflections (last shell) 19451(1942) 
Redundancy   3.2(3.2) 
Completeness (%)  100(100) 
Mean B-factor (Å)2  55.3 
R/Rfree (%)   19.61/24.73 
(Last shell)   20.9/27.9 
RMS deviations 
 Lengths (Å)   0.009 





Table 5.3:  Apo CtRio2 Scalepack Logfile 
 
 
Shell       Average Redundancy Per Shell 
  Lower Upper       
  limit limit 
  50.00  5.38             3.0 
   5.38  4.27             2.9 
   4.27  3.73             2.9 
   3.73  3.39             2.9 
   3.39  3.15             2.9 
   3.15  2.96             2.9 
   2.96  2.82             2.9 
   2.82  2.69             2.9 
   2.69  2.59             2.9 
   2.59  2.50             2.9 
  All hkl                 2.9 
Shell            I/Sigma in resolution shells: 
  Lower Upper      % of of reflections with I / Sigma less than 
  limit limit     0     1     2     3     5    10    20   >20  total 
  50.00  5.38   0.0   0.1   0.4   0.9   1.9   5.8  54.0  41.4   95.4 
   5.38  4.27   0.0   0.4   0.7   1.5   3.4  17.8  95.1   1.3   96.4 
   4.27  3.73   0.2   1.0   1.9   2.9   5.6  21.6  97.5   0.3   97.8 
   3.73  3.39   0.7   2.5   4.8   8.5  14.9  40.7  98.1   0.1   98.2 
   3.39  3.15   2.3   6.9  13.2  18.7  29.8  56.0  95.9   1.7   97.6 
   3.15  2.96   5.5  11.1  19.3  27.5  42.0  73.4  98.6   0.2   98.8 
   2.96  2.82   7.2  17.2  30.6  41.2  59.4  82.1  96.6   1.6   98.2 
   2.82  2.69   8.9  23.8  38.5  52.7  69.7  91.2  98.2   0.6   98.8 
   2.69  2.59  12.5  31.0  49.2  64.6  81.4  95.0  98.8   0.1   98.9 
   2.59  2.50  14.4  36.1  59.5  74.5  90.9  98.0  99.1   0.0   99.1 
 All hkl        5.2  13.0  21.8  29.3  39.9  58.1  93.1   4.8   97.9 
 
 
Shell Lower Upper Average      Average     Norm. Linear Square 
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac 
      50.00   5.38   235.5    12.4     4.2  1.122  0.047  0.058 
       5.38   4.27   138.1    10.1     3.7  1.094  0.068  0.084 
       4.27   3.73    99.0     7.4     2.8  1.139  0.072  0.088 
       3.73   3.39    48.3     4.2     2.3  1.118  0.084  0.092 
       3.39   3.15    23.9     2.4     1.8  1.124  0.107  0.108 
       3.15   2.96    14.2     2.0     1.7  1.346  0.163  0.154 
       2.96   2.82     8.3     1.7     1.7  1.055  0.219  0.202 
       2.82   2.69     6.0     1.7     1.7  0.906  0.280  0.260 
       2.69   2.59     4.3     1.8     1.7  0.826  0.389  0.341 
       2.59   2.50     3.3     1.8     1.8  0.787  0.518  0.473 




Table 5.4:  ATP-CtRio2 Scalepack Logfile 
 
  
Shell       Average Redundancy Per Shell 
  Lower Upper       
  limit limit 
  40.00  4.74             3.2 
   4.74  3.76             3.2 
   3.76  3.29             3.2 
   3.29  2.99             3.2 
   2.99  2.77             3.2 
   2.77  2.61             3.2 
   2.61  2.48             3.2 
   2.48  2.37             3.2 
   2.37  2.28             3.2 
   2.28  2.20             3.2 




     Shell            I/Sigma in resolution shells: 
  Lower Upper      % of of reflections with I / Sigma less than 
  limit limit     0     1     2     3     5    10    20   >20  total 
  40.00  4.74   0.0   0.1   0.3   0.4   1.1   5.7  90.5   9.2   99.7 
   4.74  3.76   0.0   0.2   0.6   1.3   2.3   8.1  97.5   2.5  100.0 
   3.76  3.29   0.5   1.1   2.2   3.5   6.4  19.6  96.7   3.3  100.0 
   3.29  2.99   1.5   3.3   6.4   9.2  14.9  34.0  89.5  10.5  100.0 
   2.99  2.77   2.4   6.2  11.2  17.0  28.4  52.9  95.3   4.7  100.0 
   2.77  2.61   3.7   9.7  16.8  25.2  40.4  69.5  97.8   2.2  100.0 
   2.61  2.48   6.0  16.5  29.4  39.8  57.4  84.3  98.6   1.4  100.0 
   2.48  2.37   8.4  22.2  36.9  48.6  67.3  90.8  99.1   0.9  100.0 
   2.37  2.28   9.4  24.6  44.3  58.2  77.9  94.8  99.5   0.5  100.0 
   2.28  2.20  14.3  34.6  54.1  69.6  85.9  97.7  99.9   0.1  100.0 
 All hkl        4.6  11.9  20.2  27.3  38.2  55.7  96.4   3.5  100.0 
 
Shell Lower Upper Average      Average     Norm. Linear Square 
 limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac 
      40.00   4.74   357.8    22.1     5.9  0.949  0.041  0.048 
       4.74   3.76   295.7    19.9     5.1  0.973  0.052  0.060 
       3.76   3.29   147.9     9.7     3.9  1.017  0.061  0.067 
       3.29   2.99    68.6     4.6     3.0  0.972  0.071  0.073 
       2.99   2.77    34.2     3.1     2.6  0.901  0.103  0.101 
       2.77   2.61    22.3     2.8     2.6  0.794  0.144  0.141 
       2.61   2.48    14.4     2.7     2.6  0.837  0.224  0.215 
       2.48   2.37    11.3     2.8     2.8  0.903  0.296  0.277 
       2.37   2.28     9.0     3.0     2.9  0.870  0.385  0.370 
       2.28   2.20     7.0     3.2     3.1  0.917  0.539  0.504 




Figure 5.1:  Structure of the Winged Helix Domain of CtRio2 
The winged helix domain consists of four alpha helices followed by two beta sheets.  A fifth alpha helix 
(αR) is part of the RIO domain. The wing is labeled W1and is in magenta.  This cartoon representation was 





Figure 5.2:  Crystal Structure of CtRio2 
The crystal structure of CtRio2 shows a bilobal kinase domain (green and orange) connected to a N-
terminal winged helix domain (blue).  The “hinge” region connects the N- and C- terminal lobes of the 
kinase domain.  The ATP binding loop “P-loop”, metal binding loop used to bind Mg, and catalytic loop 




























       1             11        21        31        41              51  
afRio2 MNIAELYGKM----GKHSWRIMDAIFKNLWDYEYVPLQLISSHARIGEEKARN------ILK-YLSDLRV  
                     *            *      *     *   *              *   *   *  
                     *            *      *     *   *              *   *   *  
ctRio2 MKLDTRAMRHLTAEDWRVLTAVEMGSKNH-----EIVPTPLIE-KIARLRGGSSGVHKSIATLAKA-GLI  
       4         14        24             34         44        54         64  
                                                            P-loop 
                                                            XXXXXX 
                     61        71        81        91         101       111  
afRio2 -------------VQNRQKDYEGSTFTFIGLSLYSLHRLVRSGKVDAIGKLM-GEGKESAVFNCYSEKFG  
                    *                  *         * * * **   ***********  
                    *                  *         * * * **   ***********  
ctRio2 ARMKEAKYDGYRLTYGGL--------------DYLALHTHAARKDVYSVGSRIGVGKESDIMIVADEKGK  
              74        84                      94        104       114  
 
            121       134                  152       162         172       18  
afRio2 ECVVKFHKVGHTKVKE-----------FSVLAIRSARNEFRALQKLQ--GLAVPKVYAWEGNAVLMELID  
        ********                  ***************** **  ********  ***********  
        ********                  ***************** **  ********  ***********  
ctRio2 QKVLKIHRLGRISFRTVDYLRNRSTGSWMYLSRLAAIKEFAFMKALYEEGFPVPEPIAQSRHTIVMSLVD  
        124       134       148       158       168       178       188  
                                         Catalytic                  Metal 
                                          XXXXXX                    XXXXXX 
       2     192          202       212       222                  232  
afRio2 AKELYRVR-VENPDEVLDMILEEVAKFYHRGIVHGDLSQYNVLVSEE-----------GIWIIDFPQSVE  
       *******  *********************************** *            ************  
       *******  *********************************** *            ************  
ctRio2 ALPMRQVSSVPDPASLYADLIALILRLAKHGLIHGDFNEFNILIREEKDAEDESSITLTPIIIDFPQMVS  
        198       208       218       228       238       248       258  
 
       242       252       262       272       282  
afRio2 VGEEGWREILERDVRNIITYFSRTYRTEKDINSAIDRILQE  
       **  ** **********************     *   *  
       **  ** **********************     *   *  
ctRio2 MDHPNAEMYFDRDVQCIKRFFERRFHFVSTTPG-PFYKDAKKTVGKDGARLDAALEASGFTKKMAKDLEA  
        268       278       288       298        308       319       329  
 
ctRio2 AIREQQES  




Figure 5.3:  Alignment between AfRio2 and CtRio2.  
 Structural alignment was performed using sequences from A. fuligidus  (afRio2) and ctRio2.  Alignment 
positions marked with two asterisks are defined as "matching residues", i.e. corresponding C-alpha-atoms 
lie within 1.8Å .  The wing helix domain of afRio2 is highlighted in yellow, the N-terminal lobe in green 
and the C-terminal lobe in blue.  The C-terminal extension of Rio2p is in the boxed region encompassing 
residues 307-346.  The sequences of the ATP binding loop “P-loop”, metal binding loop used to bind Mg, 







 Figure 5.4:  Alignment Between CtRio2 and Eukaryotic Rio2 
Alignment was performed using sequences from Rio2p (scRio2), zea mays Rio2 (zmRio2),  human rio2 
(hsrio2), xenopus laevis Rio2(xlRio2), candida albicans Rio2 (caRio2) and ctRio2.  Identical, highly 
similar, and weakly similar residues are indicated by red, green, and blue letters respectively.  The position 
of αJ is indicated by x’s.  
ctrio2  251 LTPIIIDFPQMVSMDHPNAEMYFDRDVQCIKRFFERRFHFVSTT------PGPFYKDAKKTVG 
zmrio2  240 IT--VIDFPQMVSVSHRNAQMFFDRDIECIYKFFNKRFNLRSVKNE--EQAGSENDDEGNSRP 
hsrio2  242 IT--MIDFPQMVSTSHPNAEWYFDRDVKCIKDFFMKRFSYESELF-------PTFKDIRREDT 
xlrio2  242 IT--MIDFPQMVSTSHANAEWYFDRDVKCIRDFFLKRFNYESELY-------PTFKDIQRECS 
scrio2  247 CGFVVIDFPQCISIQHQDADYYFQRDVDCIRRFFKKKLKYEPKPDSSMLDTEGFGDGYKYAYP 
cario2  245 FDFVVIDFPQCVSIEHPDAKEYFDRDVQGIRDFFSKKFRYNPQHDPTMFDTDGYGDGYKYAYP 
                                          αJ 
                                  xxxxxx     xxxxxxxx 
ctrio2  308 -----KDGAKRLDAALEASGFTKKMAKD-----LEAAIREQQ-ESR--ND----EEDSDDY-E 
zmrio2  299 SFLSVEKGAGSLDKELAASGFTRKEKVD-----MDKYIEEV-VEG--H—DSS------SD-D- 
hsrio2  296 -----------LDVEVSASGYTKEMQAD-----DEL-LHPL-GPDD-KNIETKEGSEFSFS-D 
xlrio2  296 -----------LDVEIAASGFTKEMQED-----DEL-LQPS-GPSD-DEVEDDDDNDDDDN-D 
scrio2  310 DFKRDVKRTDNLDELVQASGFSKKHPGD---RGLETAVESM-RNAV-YNSDDDM--SNDEA-E 




Figure 5.5 :  Crystal Structure of AMP Activated Protein Kinase 
The cartoon structure was generated by PYMOL using PDB structure 3H4J  The N-terminal kinase 
domain, C-terminal kinase domain, activation domain, and inhibitory domain of AMPK are labeled in red, 









Figure 5.6:  Crystal Structure of Twitchin Kinase 
The cartoon structure was generated by PYMOL using PDB structure 1KOA. The N-terminal kinase 
domain, C-terminal kinase domain, and inhibitory domain of twitchin kinase are labeled in yellow, green, 









Figure 5.7:  The Interface Between αJ and the Kinase Domain 
 The interaction between αJ (in sticks) and the kinase domain of ctRio2 (in lines) are 
shown in A and B.  The figure was made using PYMOL.  A.  The 2Fo-Fc map of αJ is 








Figure 5.8:  Coordination Sphere of Mg 
Crystal structure of ctRio2 with 2Fo-Fc map contoured at 1σ.  Mg is coordinated by D260, N237, α and β 




Figure 5.9:  Polar Contacts with γ Phosphate of ATP 
Crystal structure of ctRio2 with 2Fo-Fc map contoured at 1σ.  The γ phosphate of ATP makes polar 





Figure 5.10:  Polar Contacts with α Phosphate of ATP 
Crystal structure of ctRio2 with 2Fo-Fc map contoured at 1σ.  The α phosphate of ATP makes polar 
contacts with K127 and is coordinated by the Mg ion.  The 6’amino group of adenine makes a polar contact 




Figure 5.11:  Polar Contacts with β Phosphate of ATP 
Crystal structure of ctRio2 with 2Fo-Fc map contoured at 1σ.  The β phosphate of ATP makes polar 




Figure 5.12:  Alignment Between Conserved Active Site Resides in AfRio2 and 
CtRio2 
The structures of afRio2and ctRio2are aligned, ctRio2residue numbering is used.  Residues for afRio2 are 
blue and for ctRio2 are green.  ATP for afRio2 is red and for ctRio2 is pink. The 2Fo-Fc map for ctRio2  is 




Figure 5.13:  Structural Alignment of CtRio2 and AfRio2 and Positioning of the P-
loop. 
AfRio2(cyan) and ctRio2(green) in complex with ATP are structurally aligned. Rmsd is 2.204A for 217 
atoms.  ATP for afRio2 is red and for ctRio2 is pink.  A. Wing helix domain is indicated.  B.  Close-up of 




Figure 5.14:  Alignment of CtRio2 and AfRio2 and Positioning of the γ Phosphate. 
AfRio2(cyan) and ctRio2(green) in complex with ATP are structurally aligned. Rmsd is 2.204A for 217 
atoms.  ATP for afRio2 is red and for ctRio2 is pink.  The γ phosphate of ctRio2 is 4.66 Å from the 




Figure 5.15:  Best Fit Alignment Between CtRio2 and AfRio2 
AfRio2(yellow) and ctRio2(green) in complex with ATP are structurally aligned using Swiss PDB Viewer.  
Alignment is for the best fit fragment between the two proteins.  ATP for afRio2 is red and for ctRio2 is 






Figure 5.16:  C-Terminal Lobe Alignment Between CtRio2 and AfRio2 
AfRio2(magenta) and ctRio2(green) in complex with ATP are structurally aligned using Swiss PDB 
Viewer.  Alignment is for the C-terminal lobe between the two proteins.  ATP for afRio2 is red and for 
ctRio2 is pink. 
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Figure 5.17:  Mass Spec of CtRio2 
1 mg/mL ctRio2 was incubated with 1mM ATP and 2.5 mM MgCl2 overnight at room temperature.  
LC/MS was taken of the sample.  The expected molecular weight of ctRio2 is 44799kDA.  The difference 










Figure 5.18:  Autophosphorylation of CtRio2 
10 µg or 50 µg of ctRio2 was incubated with 10 μCi γP32 labeled ATP and various concentrations of cold 
ATP and incubated at 37 °C for one hour.  The samples were loaded on a SDS-PAGE gel, dried and 
exposed overnight on a Phosphor imaging plate. 
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Figure 5.19:  Surface Representation of Conserved Resides on CtRio2 
A surface representation of ctRio2 is shown with identical, highly similar and weakly similar residues 




Chapter 6:  Role of the Winged Helix Domain in Binding to the Ribosome 
6.1:  Domain Contribution to Rio2 Ribosome Binding  
 
Previous research has shown that Rio2 binds tightly to the pre-40S ribosome.  
Rio2p is stably associated with the 43S preribosome in the nucleus and cytoplasm 
concomitantly with other late 40S processing factors and ribosomal proteins (35-37).  
Sucrose gradients of yeast expressing TAP-tagged Rio2p were performed to analyze 
ribosome profiles.  In sucrose gradients used to analyze ribosome profiles in yeast 
containing TAP tagged Rio2p, the 40S and 43S fractions were isolated and a TAP tag 
pull down of Rio2p showed that Rio2p was associated with other late 40S factors 
including Dim1p, Tsr1p, Enp1p, Hrr25p, Nob1p, and Yor145p.  The TAP tag pull down 
of Rio2p also showed the presence of many small subunit Rps proteins (35-37), 
characterizing Rio2p as a marker for late 40S pre-subunits.   
The results of the earlier work done by Hurt and others (35-37) were used as the 
basis for experiments performed in this Chapter.  Since we know that afRio2 consists of 
at least the N-terminal winged helix domain (wHTH) and the C-terminal RIO domain 
(Figure 1.2), I was interested in determining whether one domain, or the other, or both 
were involved in binding of Rio2p to the ribosome.  To address this question, I used tap-
tagged Rio2p constructs containing various domains or point mutations to pull-down and 
assay ribosome binding. 
6.2:  Development of an Assay to Determine if Rio2p Constructs can Pull Down the 
Ribosome 
 
An assay was developed to determine if Rio2p was attaching to the ribosome.  
The constructs of Rio2p full length (FL Rio2p), Rio2p minus the winged helix domain 
(Short Rio2p), and the winged helix domain alone (Rio2p WH) were cloned into 
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plasmids containing a C-terminal TAP tag and a HIS3 gene for histidine production to 
select for the plasmid.  The Short Rio2p consisted of FL Rio2p missing the first 78 amino 
acids.  Rio2p WH consisted of the first 103 amino acids.  The TAP tag consisted of C-
terminal protein A followed by a TEV cleavage site and a calmodulin binding protein 
construct (CBP) (Figure 6.1). 
The protein A tag allows the TAP tag fusion protein to bind to rabbit IgG beads.  
The TEV cleavage site allows the protein A tag to be cleaved so that Rio2p can be 
released from the column.  The CBP tag allows for further purification of Rio2p by 
calmodulin beads.  However, in this experiment the TEV cleavage site and the CBP tag 
were not used since my experiments showed that these were ineffective in purifying 
Rio2p from the supernatant in sufficiently large quantities.  These three constructs were 
transformed into yeast cells containing GST tagged Rps18a on a separate plasmid 
containing the URA3 gene, conferring the ability to produce uracil.  Rps18a is a 
constituent of the 40S small ribosomal subunit.  The Rio2p constructs were pulled down 
by their Protein A tag via rabbit IgG beads.  Rps18a was pulled down by Rio2p if the 40S 
preribosome in which Rps18a was incorporated also contained the Rio2p construct.  The 
IgG beads bound to Rio2p were then boiled with SDS loading dye to remove the protein 
bound to the beads.  The proteins extracted into the SDS dye were run on a gel.  The GST 
tag of the pull down small ribosomal protein Rps18a was detected by performing a 
Western blot using a polyclonal antibody against the GST tag.  In addition to binding the 
GST tag, the rabbit polyclonal antibody bound the protein A portion of the TAP tag.  It 
allowed TAP-tagged Rio2p constructs to be seen on the Western blot in the lysate, 
supernatant, and pull down elution fractions.   
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The Western blot was analyzed for the presence of the GST tagged protein to 
show whether Short Rio2p and FL Rio2p could bind to the ribosome (Figure 6.2).  The 
negative control for this assay was the yeast strain carrying the GST tagged Rps18a 
plasmid, which was needed to determine whether IgG beads alone could pull down 
Rps18a.  The FL Rio2p was used as the positive control to pull down the 40S pre-
ribosome and hence Rps18a. 
6.3:  Procedures 
6.3.1:  Transformation of Rio2p Constructs into Yeast Cells Containing GST 
Tagged Rps18a. 
 
The plasmid containing the GST tagged Rps18a and the URA3 gene pre-
transformed into a yeast cell was purchased from Operon (Cat # 166-044-C-10 with name 
YDR450W).  The genotype of the yeast strain was MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0.  The Rps18a gene was under the control of the galactose promoter.  The Rio2p 
constructs were cloned into pAG413GAL-ccdB-TAP.   This plasmid contained a HIS3 
gene.  In this plasmid the transcription of the inserted gene is under control of the 
galactose promoter.  The plasmids were transformed into the YDR450W cells using the 




Yeast cells were grown in 5 mL YPAD media (rich yeast media) for 12-16 hours.  
Then 2.5 × 10
8
 cells were added to 50 mL of pre-warmed 2×YPAD media.  Cell titer was 
determined by taking O.D. at 600 nm.  An O.D.600 reading of 0.1 corresponds to 1×10
6
 
cells/mL.  The titer of the inoculation solution should be 5×10
6
 cells/ml.  The flask was 
incubated while shaking at 30°C and 200 rpm for about 4 hours or until the cell titer was 
at least 2×10
7
 cells/mL.  A 1.0 mL sample of 2 mg/mL salmon sperm DNA was boiled 
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for five minutes and chilled on an ice bath.  The yeast cells were harvested by 
centrifugation at 3000g for 5 minutes and resuspended in 25 mL sterile water.  The cells 
were again centrifuged at 3000g for 5 minutes to pellet the cells.  This wash was repeated 
with 25 mL sterile water.  Then the cells were resuspended in 1.0 mL of sterile water.  
The cell suspension was transferred to a 1.5 mL microcentrifuge tube and centrifuged for 
30s at 13000g.  The supernatant was discarded and the cells were resuspended in 1.0 mL 
of sterile water.  100 μl of cell solution containing 10
8
 cells were pipetted into 1.5 mL 
microcentrifuge tubes, one for each transformation.  The cell solution was centrifuged at 
13000g for 30s and the supernatant was removed.  240 μl of 50% (w/v) PEG 3350, 35 μl 
1.0 M Lithium Acetate, 50 μl 2.0 mg/mL salmon sperm DNA, 34 μl plasmid DNA in 
sterile water was added to each cell pellet.  The plasmid DNA was approximately 1 μg.  
The tubes were vortexed for resuspension and then incubated for 40 minutes at 42ºC.  
The tubes were then centrifuged at 13000g for 30s and the supernatant was removed.  1.0 
mL of sterile water was pipetted into each transformation tube and the cell pellet was 
resuspended.  20 μL and 200 μl of the transformation mixture were plated onto agar 
plates made with synthetic complete media lacking uracil and histidine. 
6.3.2:  Procedure for Pull Down Assay of Rps18a. 
 
 The basic procedure for pull down of Rps18a from yeast cells is described in this 
section.  A yeast culture in 5mL of minimal media minus uracil and histidine was grown 
overnight at 30°C.  Next day, one mL of this culture at an O.D. 600 of 5.0 was used to 
inoculate 2 L of minimal media minus uracil and histidine.  The cultures were grown in 
flasks at 30°C with shaking at 220 rpm.  When the O.D. reached 2.0, the flasks were 
removed from the shaker and centrifuged at 4000 rpm for 20 minutes to sediment the 
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yeast cells.  The yeast cells were then washed with 500 mL of cold distilled water.  The 
cells were aliquoted into 15 mL falcon tubes so that each tube contained 0.5 g of dry 
yeast cell pellet.  These falcon tubes were frozen at -80°C.   
 One tube of cells was thawed and resuspended in 10 mL sterile Buffer A (10 mM 
K-HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF, 2 mM 
Benzamidine, ¼ EDTA free protease inhibitor tablet).  To Buffer A was added 20 µl 
Fisher Brand Optizyme Rnase Inhibitor, Porcine (33,300 U/ml).  The suspension was 
passed twice through a French Press at 1200 psi.  2 M KCl was added to the lysate to 
bring the final concentration to 0.2 M KCl.  A 200 μl sample of the lysate was taken and 
mixed with 80 μl 5x SDS loading dye and boiled for a Western blot sample.  The lysate 
was centrifuged at 20.5 Krpm for 30 minutes at 4°C.  The supernatant was transferred 
into clean 45Ti tubes and centrifuged again at 33.5 Krpm for 1 hour 24 minutes.  The 
supernatant was then dialyzed at 4°C for two hours against 2 L of Buffer D (20 mM K-
HEPES, 50 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 20% glycerol, 0.5 mM PMSF, and 2 
mM Benzamidine).  The volume of the supernatant was reduced in half after dialysis.  5 
mL of the dialysis buffer was added to the supernatant to return the volume back to 10 
mL.  A 200 μl sample of the supernatant was taken and mixed with 80 μl 5x SDS loading 
dye and boiled for a Western blot sample. 
 The supernatant was frozen at -80°C.  The next day the supernatant was thawed.  
A 200 μl sample of the supernatant was taken and mixed with 80 μl 5x SDS loading dye 
and boiled for a Western blot sample. To a small Bio-Rad column was added 400 μl of 
50% suspension of Rabbit IgG-Agarose beads from Sigma (A2909).  The beads were 
washed with 5 mL of sterile IPP150 buffer (10 mM Tris-Cl pH 8.0, 150 mM NaCl, and 
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0.1% NP40).  Fifty μl 2 M Tris-Cl pH 8.0 (10 mM final concentration), 200 μl 5 M NaCl 
(150 mM final concentration), 100 μl 10% NP40 (0.1% final concentration) was added to 
the supernatant. The beads were then added to the 10 mL supernatant in the 15 mL 
Falcon tube and shaken on a rocking platform at 4°C for two hours.  The bead and 
supernatant solution was then transferred back to the Bio-Rad column and the flow-
through was allowed to drain out.  200 μl of the flow-through was retained and mixed 
with 80 μl of 5x SDS loading dye and boiled for a Western blot sample.  The beads were 
washed with 40 mL IPP150 buffer and the last 10 mL of wash was collected.  200 μl of 
sample was removed and mixed with 80 μl of 5x SDS loading dye and boiled for a 
Western blot sample.   
 One mL of IPP150 buffer was added to the beads in the Bio-Rad column.   A 
suspension was made and it was transferred to a 1.5 mL eppendorf tube.  The suspension 
was centrifuged at 1000 rpm for 1 minute to settle the beads.  The IPP150 buffer was 
removed from the top of the beads and 100 μl of 5x loading dye was added to the beads.  
The beads were vortexed and then boiled for ten minutes.  The beads were vortexed again 
and then centrifuged at 13000 rpm for one minute to settle the beads.  The top dye was 
removed and put into a separate 1.5 mL eppendorf tube and marked eluate. 
 Polyclonal antibody against the GST tag was used for the Western blotting.  The 
antibody was purchased from Santa Cruz Biotechnology, Inc. (Cat.# SC-459 HRP).  The 
antibody was a primary antibody recognizing the GST tag directly, and was conjugated to 
horseradish peroxidase enzyme, which produced light in the presence of 
chemiluminescent substrate.  Dilutions of the samples of lysate, supernatant, wash, and 
eluate were run on Invitrogen NuPage 4-12% Bis-Tris Gels, 15 well alongside a sample 
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of Invitrogen “Novex Sharp Prestained Protein Standards” ladder.  The gel was then 
transferred to a PVDF membrane (Millipore Immobilon-P membrane Cat No. 
lSEQ07850) at 30V for 1 hour.   The ladder was completely transferred to the PVDF 
membrane after transfer.   The PVDF membrane was blocked with 1% blocking solution 
of powdered skim milk in 1X TBST buffer (25 mM Tris, pH 7.5, 100 mM NaCl, 0.05% 
Tween 20).  Blocking took place for one hour at room temperature on a shaking platform. 
The blocking solution was removed and a 1/200 dilution of antibody in blocking solution 
was added to the PVDF membrane.  The antibody was incubated with the membrane 
while rocking for one hour.  The membrane was then rinsed with 40 mL TBST and 
washed 4×2 minutes with 40 mL of TBST.  Excess TBST was drained by placing one 
edge of the membrane on a Kimwipe.  Then the membrane was incubated with “Lumi-
Light Western Blotting Substrate” (Cat. No. 12015200001) while rocking for five 
minutes.  
 The membrane was exposed for one minute in a dark box.  The antibody was 
conjugated to HRP, which in the presence of chemiluminescent substrate produced light.  
A photo was taken.  A photo was also taken of the protein standards ladder with the 
lightbox on.   
6.4:  Results of First Three Constructs Made in Pull Down Assay 
 
Initially three constructs were cloned—FL Rio2p, Short Rio2p and Rio2p WH.  
Samples of the lysate, supernatant, thawed sample, flow-through, wash, and elution were 
diluted for each of the constructs before running on a Western blot to maximize the signal 
seen for the pull down protein, Rps18a, without overloading the Western blot.  GST 
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tagged Rps18a has a molecular weight of 43kDa, TAP tagged FL Rio2p has a molecular 
weight of 95kDA and TAP tagged Short Rio2p has a molecular weight of 86kDa. 
The Western blot showed that FL Rio2p was more soluble than Short Rio2p, 
which showed only a faint band in the supernatant fraction (Figure 6.3).  No protein 
eluted in the flow through and wash of FL Rio2p and Short Rio2p,  indicating that entire 
protein in the supernatant became bound to the column.  The elution lane showed well-
defined bands for the TAP tagged protein in both the Western blots of FL Rio2p and 
Short Rio2p.  Both also had well-defined bands for the GST tagged Rps18a. 
 Rio2p WH was expressed at low levels in the yeast cell, so no dilutions of the 
lysate, supernatant, and elution were made.  The Western blot shows that Rio2p WH was 
weakly expressed in the lysate and was slightly soluble in the supernatant as compared to 
the lysate (Figure 6.4).  The elution showed a band for Rio2p WH and no band for the 
GST tagged Rps18a.  The negative control was completely blank. 
The experiment showed that the ribosome was equally pulled down with Short 
Rio2p as with FL Rio2p.  Rio2p WH did not pull down GST-tagged Rps18a, perhaps due 
to low expression of Rio2p WH.  The negative control did not show any signal for 
Rps18a, confirming that the Western blot band for Rps18a was authentic.  The negative 
results with Rio2p WH suggested that the TAP tag alone was not interacting with and 
pulling down Rps18a.   
  From the data we can draw the following conclusion: Though the wHTH may 
make direct contacts with the ribosome, the RIO domain or the C-terminus may make 
equally strong or stronger contacts with the ribosome.  The wHTH does have all of the 
interactions between  Rio2p and the 40S preribosome. 
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The exterior surface of the wHTH was positively charged in Rio2 suggesting that 
the wHTH interacted with the negatively charged phosphate backbone of RNA.  The 
closest structures found with the DALI server to wHTH were the transcription factors 
MarR and SlyA and histone linker protein GH5 (34).  All of these are known to interact 
directly with DNA.  Crosslinking experiments have shown that Rio2p binds to a small 
part of the rRNA of the ribosome close to the site D cleavage (114).  However, it is not 
known if the wHTH of Rio2p makes these contacts to the rRNA or some other part of the 
RIO domain binds to the rRNA sequence.  The true extent of the rRNA contacts are not 
known.  The crosslinking experiment may represent only the partial binding site of Rio2p 
to the rRNA.  It may be possible that the wHTH does not contact rRNA and may simply 
interact with the protein complex of the preribosome or have some altogether different 
function.  
6.5:  Results of Point Mutations Made in the Rio2p Pull Down Assay 
 
The structure was reexamined to determine what other portions of Rio2p might 
bind to the rRNA sequence of the 40S preribosome.  The structure showed patches of 
positively charged surface containing conserved positively charged residues.  Three 
conserved positively charged residues were chosen to be mutated in Rio2p.  The residues 
in AF Rio2 corresponded to K102, R253, and R264 (Figure 6.5) and are conserved 
surface residues among eukaryotes (Figures 6.6). 
These conserved residues were mutated to alanine to see whether they were 
involved in the binding of Rio2p to the rRNA of the ribosome.  Three residues (K105A , 
R271A, and K282A) were mutated in FL Rio2p (FL R271A, FL K282A, and FL K105A) 
and Short Rio2p (Short R271A, Short K282A, and Short K105A) to determine pull down 
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of the 40S preribosome in either construct.  The fractions of lysate, supernatant, thawed 
sample, flow-through, wash, and elution were diluted for each mutated construct to 
visualize the pull down of Rps18a.  In some cases the fractions had to be diluted 
extensively to prevent saturation of the Western blot with the signal for Rps18a.  In other 
cases the fractions required less dilution because Rps18a was present only in small 
amounts.   
The Western blot showed that Short K105A was only weakly expressed in the 
lysate, requiring no dilution of fractions (Figure 6.7).  FL K105A and Short K105A were 
not very soluble.  They showed a faint band or no band in the supernatant fraction.  No 
protein eluted in the wash.  The elution showed a strong band for the TAP tagged protein 
in both the Western blot of the FL K105A and the Short K105A.  Only FL K105A 
showed a well-defined band for the GST tagged Rps18a. 
The Western blot showed that Short R271A was only weakly expressed in the 
lysate.  It required 1/5 dilution of fractions (Figure 6.80).  FL R271A and Short R271A 
were equally soluble and showed bands in the supernatant fraction that were equal in 
strength to the lysate fraction.  No protein eluted in the wash.  The elution showed a 
strong band for the TAP tagged protein in both the Western blot of the FL R271A and the 
Short R271A.  Only FL R271A showed a well-defined band for the GST tagged Rps18a. 
The Western blot showed that Short K282A was weakly expressed in the lysate, 
requiring no dilution of fractions (Figure 6.9).  FL K282A was very soluble.  It showed a 
band in the supernatant fraction that was equal in strength to the band in the lysate 
fraction.  No protein eluted in the flow through and wash indicating that all the protein in 
the lysate did bind.  The elution showed a strong band for the TAP tagged protein in both 
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the Western blot of FL K282A and Short K282A.  Both FL K282A and Short K282A 
showed weak bands for the GST tagged Rps18a. 
A Western blot with all supernatants from different constructs was run on the 
same gel.  The supernatant was diluted in order to allow the band of the tagged protein to 
be seen at about equal levels.  A separate Western blot was run with all elutions for 
different constructs of the GST tagged Rps18a at relatively same dilution as the 
supernatants.  The elutions from different constructs could then be compared and 
contrasted (Figure 6.10). 
FL Rio2p, Short Rio2p, FL K282A, and Short K282A pull down the 40S 
preribosome.  FL K105A pulled down pre-40S ribosome weakly.  Short K105A was 
barely soluble, so it was difficult to determine if it pulls down the pre40S ribosome.  
However, Short R271A though soluble, does not pull down the ribosome at the dilution 
chosen to compare with the other constructs.  Short Rio2p and Short R271A have similar 
amounts of protein in the supernatants.  However, Short Rio2p pulled down Rps18a 
while Short R271A does not.  In the earlier Western blot, the FL R271A construct did 
pull down the pre-40S ribosome at 1/5 dilution.  This would indicate that FL R271A 
pulled down the pre-40S ribosome most weakly of all the constructs.   
 R271 is analogous to R253 in Rio2 from afRio2.  This residue is part of α helix F 
or the second to last helix in the sequence.  Helix F is part of the C-terminal lobe of AF 
Rio2 and contains three other positively charged arginines that are not part of the 
conserved sequence.  In the yeast sequence this helix would have five other positively 
charged residues.  This makes Helix F ideal for making contacts with the negatively 
charged backbone of rRNA.  However, whether it actually interacts with the rRNA is not 
131 
known.  The point mutation does not appear to prevent Rio2p from folding properly as 
FL R271A and Short R271A are soluble and show up in the supernatant. 
  A true test of the proper folding of the protein would be to analyze its serine 
kinase enzymatic activity.  Since AF Rio2 is shown to autophorphorylate, similar activity 
most likely exists with Rio2p.  Though the natural peptide substrates of Rio2p are not 
known, it can be tested for its ability to autophosphorylate.   
6.6:  Conclusions of Rio2p TAP Tag Pull Down 
 
 A TAP tag pull down assay was performed with different constructs of Rio2p to 
determine if the winged helix domain was necessary for binding of Rio2p to the 
ribosome.  Without the winged helix domain, Rio2p still bound to the ribosome so it is 
not absolutely required for ribosomal binding.  Three different point mutations were 
made to FL Rio2p and Short Rio2p to determine what specific residue might interact with 
the ribosome.   R271 was implicated in binding of Rio2p to the ribosome.  R271 is a 
surface residue strictly conserved among eukaryotes (Figure 6.6).  It might be important 
for the binding of Rio2p to other ribosomal processing factors, to ribosomal proteins, or 






N’ Rio2p CBP TEV 
Cleavage  
Protein A C’ 
 
Figure 6.1:  TAP tagged Rio2 Construct 
A schematic of the C-terminal TAP tag is shown.  It consists of calmodulin binding peptide (CBP) 




Figure 6.2:  Assay for Pull Down of Ribosome 
This figure illustrates the pull down assay with Rio2. Both Rps18a with a GST tag (pink) and TAP tagged 
Rio2 (blue) attach to the ribosome and and are pulled down together with IgG beads(green) which bind to 
the TAP tag.  After the pull down, the IgG beads are boiled in SDS buffer, and the eluate is Western blotted 
















Figure 6.3:  Tap Tag Pull Down of Rio2p 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed (lysate), centrifuged to 
remove the supernatant, frozen and thawed the next day.  The thawed supernatant was rotated with IgG 
beads, the IgG beads were collected and the flow-through removed, and the beads washed with binding 
buffer.  The beads were boiled in 5xSDS-loading dye and the dye was removed (“eluate”).  The Western 
blot was probed with polyclonal antibody against the GST tag conjugated to HRP.  This figure represent 
the fractions of FL Rio2p TAP tag pull down at 1/20 dilutions.  This figure also represents the fractions of 













































































Figure 6.4:  TAP Tag Pull Down of Wing Helix Domain and Negative Control 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed (lysate), centrifuged to 
remove the supernatant, frozen and thawed the next day.  The thawed supernatant was rotated with IgG 
beads, the IgG beads were collected and the flow-through removed, and the beads washed with binding 
buffer.  The beads were boiled in 5xSDS-loading dye and the dye was removed (“eluate”).  The Western 
blot was probed with polyclonal antibody against the GST tag conjugated to HRP.  This figure represent 
the fractions of the Rio2p WH TAP tag pull down at no dilution.  This figure also represent the fractions of 













































































Figure 6.5:  Electrostatic Properties of AfRio2 
 This figures represents the electrostatic properties of the surface of AF Rio2.  Blue represent positively 
charged electron density and red represents negatively charged electron density.  The three point mutations 
K102 (K105A in yeast), R253 (R271A in yeast), and R264A (K282A in yeast), all lie in the positively 








Figure 6.6:  Sequence Alignment of Eukaryotic Rio2 and Rio2p 
Alignment was performed with the program CLUSTALW using sequences from Dictyostelium discoideum 
(ddRio2), Danio rerio (ddRio2), Homo sapiens (hsRio2), Sacchoromyces cerevisae (Rio2p), Arabidopsis 
thaliana (atRio2). Chaetomium thermophilum (ctRio2), Drosophila melanogaster (dsRio2), and Xenopus 
laevis (xlRio2).  Identical, highly similar, and weakly similar residues are indicated by red, green, and blue 
letters respectively.  Yellow highlighted residues represent the placements of the K105A, R271A, and 
K282A mutations in yeast.  
                    10        20        30        40        50        60 
                      |         |         |         |         |         | 
ddRio2       -MKLDPKALRYLSKDDFRTLVAVEMGMKNHELVPVSLICTIANLKY--GGTKKSIQTLHK 
atRio2       -MKLDVNVLRYLSKDDFRVLTAVEMGMRNHEIVPSELVERIACLKH--GGTYKVLKNLLK 
rio2p        -MKLDTSHMRYLTTDDFRVLQAVEQGSRSHEVVPTPLIHQISGMRS-QSGTNRAISDLAK 
ctRio2       -MKLDTRAMRHLTAEDWRVLTAVEMGSKNHEIVPTPLIEKIARLRGGSSGVHKSIATLAK 
drrio2       MGKLNVVILRYLSRDDFRVLTAVEMGMKNHEIVPVSLIASIASLKH--GGCNKVLRELVK 
xlrio2       MGKLNVLLLRYLSREDFRVLTAVEMGMKNHEIVPASLIASIASLKH--GGCNKILRELVK 
hsrio2       MGKVNVAKLRYMSRDDFRVLTAVEMGMKNHEIVPGSLIASIASLKH--GGCNKVLRELVK 
dmrio2       MGKLNVTVLRYLTKEDFRVLTAIEMGMKNHELVPGPLAAAIANLKS--GGVHKLLKELCK 
 
                     70        80        90       100       110       120 
                      |         |         |         |         |         | 
ddRio2       FKLLFHD-GRNYDGYKLTYLGYDFLALKTLVSRGVCSYVGNQIGVGKESDIYIVANDDNQ 
atRio2       YKLLHHD-SSKYDGFRLTYLGYDFLAIKTLVNRGIFTGVGRQIGVGKESDIFEVAQEDGT 
rio2p        LSLISKMRNVKYDGYRLTYNGIDYLALKTMLNRDTVYSVGNTIGVGKESDIYKVSDKNGN 
ctRio2       AGLIARMKEAKYDGYRLTYGGLDYLALHTHAARKDVYSVGSRIGVGKESDIMIVADEKGK 
drrio2       HKLLAYERSKTVQGYRLNYGGYDYLALKTLSSRDVILSVGNQMGVGKESDIYIVANAEEQ 
xlrio2       HKLIAYDRTKTVQGYRLIYGGYDYLALKTLSSREVVTSVGNQMGVGKESDIYIVANEDEN 
hsrio2       HKLIAWERTKTVQGYRLTNAGYDYLALKTLSSRQVVESVGNQMGVGKESDIYIVANEEGQ 
dmrio2       HKLLAYERGKKYDGYRLTNTGYDYLALKSLTLRGSVSSFGNQIGIGKESNIYVVADEEGT 
 
                    130       140       150       160       170       180 
                      |         |         |         |         |         | 
ddRio2       EMVLKLHRLGRVSFKTIKNNRDYLKHRKSAS-WLYLSRLAALKEFAYMKALYENGFPVPT 
atRio2       ILAMKLHRLGRTSFRAVKSKRDYLRHRSSFS-WLYLSRLAALKEFAFMKALEEHDFPVPK 
rio2p        PRVMKIHRLGRTSFHSVRNNRDYLKKSNQGANWMHLSRLAANKEYQFMSMLYSKGFKVPE 
ctRio2       QKVLKIHRLGRISFRTVKANRDYLRNRSTGS-WMYLSRLAAIKEFAFMKALYEEGFPVPE 
drrio2       QFALKLHRLGRTSFRNLKNKRDYHKHRNNMS-WLYLSRLSAMKEFAYMKALYDRGFPVPK 
xlrio2       QMALKLHRLGRTSFRNLKNKRDYHKHRHKMS-WLYLSRLAAMKEFAYMKALYDTGFPVPK 
hsrio2       QFALKLHRLGRTSFRNLKNKRDYHKHRHNVS-WLYLSRLSAMKEFAYMKALYERKFPVPK 
dmrio2       PICLKLHRLGRTCFRNVKAKRDYHGRRHKAS-WLYLSRISATREFAYMSALYDRGFPVPK 
 
                    190       200       210       220       230       240 
                      |         |         |         |         |         | 
ddRio2       PIDYNRHCIVMSRARGYPLTQIVQLRHPSKVYSDLMNLIVKLASYGLIHGDFNEFNILIN 
atRio2       AIDCNRHCVIMVQVK--------QLQNPETIFEKIIGIVVRLAEHGLIHCDFNEFNIMID 
rio2p        PFDNSRHIVVMELIEGYPMRRLRKHKNIPKLYSDLMCFIVDLANSGLIHCDFNEFNIMIK 
ctRio2       PIAQSRHTIVMSLVDALPMRQVSSVPDPASLYADLIALILRLAKHGLIHGDFNEFNILIR 
drrio2       PVDYNRHAVVMELINGYPLCQVREIQDPAALYSEIMELIVKLANHGLIHGDFNEFNLMLD 
xlrio2       PHDYNRHAVVMELINGYPLCQIRQLEDPASLYSELMDLIVKLANHGLIHGDFNEFNLMLD 
hsrio2       PIDYNRHAVVMELINGYPLCQIHHVEDPASVYDEAMELIVKLANHGLIHGDFNEFNLILD 
dmrio2       PIDFNRHCVLMDLVKGWPMTQVHELLDAPQVYDDLMNLIVRLGNSGVIHGDFNEFNLMVT 
 
                    250       260       270       280       290       300 
                      |         |         |         |         |         | 
ddRio2       D----EEEITL------IDFPQMVSTSHLNAEMYFDRDVTCIRVFFEKRFNFIGERWPKF 
atRio2       D----EEKITM------IDFPQMVSVSHRNAQMYFDRDIECIFKFFRKRFN--------- 
rio2p        DKLEDENDCGF----VVIDFPQCISIQHQDADYYFQRDVDCIRRFFKKKLK--------- 
ctRio2       EEKDAEDPSSITLTPIIIDFPQMVSMDHPNAEMYFDRDVQCIKRFFERRFH--------- 
drrio2       D----NDHVTM------IDFPQMVSTSHINAEWYFDRDVKCIRDFFIKRFNYESELYPTF 
xlrio2       E----EDHVTM------IDFPQMVSTSHANAEWYFNRDVKCIRDFFLRRFNYESELYPTF 
hsrio2       E----SDHITM------IDFPQMVSTSHPNAEWYFDRDVKCIKDFFMKRFSYESELFPTF 















Figure 6.7:  TAP Tag Pull Down of K105A Construct 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed (lysate), centrifuged to 
remove the supernatant, frozen and thawed the next day.  The thawed supernatant was rotated with IgG 
beads, the IgG beads were collected and the flow-through removed, and the beads washed with binding 
buffer.  The beads were boiled in 5xSDS-loading dye and the dye was removed (“eluate”).  The Western 
blot was probed with polyclonal antibody against the GST tag conjugated to HRP.  The figure represent the 
fractions of FL K105A TAP tag pull down at 1/20 dilution. The figure also represent the fractions of Short 




































































Figure 6.8:  TAP Tag Pull Down of R271A Construct 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed (lysate), centrifuged to 
remove the supernatant, frozen and thawed the next day.  The thawed supernatant was rotated with IgG 
beads, the IgG beads were collected and the flow-through removed, and the beads washed with binding 
buffer.  The beads were boiled in 5xSDS-loading dye and the dye was removed (“eluate”).  The Western 
blot was probed with polyclonal antibody against the GST tag conjugated to HRP.  This figure represent 
the fractions of the Fl R271A TAP tag pull down at 1/5dilutions.  This figure also represent the fractions of 












































































Figure 6.9:  TAP Tag Pull Down of K282A Construct 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed (lysate), centrifuged to 
remove the supernatant, frozen and thawed the next day.  The thawed supernatant was rotated with IgG 
beads, the IgG beads were collected and the flow-through removed, and the beads washed with binding 
buffer.  The beads were boiled in 5xSDS-loading dye and the dye was removed (“eluate”).  The Western 
blot was probed with polyclonal antibody against the GST tag conjugated to HRP. This represent the 
fractions of the FL K282A TAP tag pull down at 1/20dilutions. This figure also represent the fractions of 














































































Figure 6.10:  TAP Tag Pull Down of All Constructs 
Yeast cells containing both GST tagged Rps18a and TAP tagged Rio2p were lysed, centrifuged to 
remove the supernatant and frozen.  The thawed “supernatants” indicated TAP tagged Rio2p.  The thawed 
supernatant was rotated with IgG beads, the IgG beads were collected and the flow-through removed, and 
the beads washed with binding buffer.  The beads were boiled in 5xSDS-loading dye and the dye was 
removed (“eluates”). The Western blot was probed with polyclonal antibody against the GST tag 
conjugated to HRP.  The eluates indicated GST tagged Rps18a.   
The supernatant of the wing helix domain was undiluted, the supernatant of Rio2p FL, the 
supernatant of Short Rio2p, and the supernatant of FL 105A was diluted 1/5.  The supernatant of Short 
K105A was undiluted.  The supernatant of FL R271A was diluted 1/5.  The supernatant of Short R271A 
was undiluted.  The supernatant of Fl K282A was diluted 1/5.  The supernatant of Short K105A was 
undiluted.   
The eluate of the wing helix domain was undiluted.  The eluate of Rio2p , the supernatant of Short 
Rio2p, and the eluate of FL 105A was diluted 1/20.  The eluate of Short K105A was undiluted.  The eluate 
of FL R271A was diluted 1/20.  The eluate of Short R271A was diluted 1/5.  The eluate of Fl K282A was 









































































Chapter 7:  Crystal Structure of MphR(A) with and without the Drug 
Erythromycin 
7.1:  Statement of Authorization 
 This research was originally published under the title Structure and Function of 
the Macrolide Biosensor Protein, MphR(A), with and without Erythromycin in Journal of 
Molecular Biology  (2009; 387:1250-1260).  The scientists who collaborated on the study 
were: Jianting Zheng, Vatsala Sagar, Adam Smolinsky, Chase Bourke, Nicole LaRonde-
LeBlanc, and T. Ashton Cropp.   
 7.2:  Overview 
 Dr. Jianting Zheng and I were co-first authors of the paper on the crystal structure 
of MphR(A) and my role in the work we did together was as follows: I supervised Dr. 
Jianting Zheng and worked closely with him to set up crystal trays.  I then did all the 
computer work to determine and refine the structure of MphR(A).  My supervisor Dr. 
Nicole LaRonde-LeBlanc guided me in this endeavor.  The paper also describes 
mutagenesis done by Dr. Jianting Zheng. 
7.3:  Introduction to MphR(A) 
Macrolide antibiotics are used to treat many bacterial infections.  Some macrolide 
antibiotics include erythromycin, azithromycin, and clarithromycin (Figure 7.1).  
However, bacteria have developed resistance to these antibiotics by various mechanisms, 
including modifying the drug target, using efflux pumps, and modifying the drug itself 
(56-58).  Our study examined the repressor of the mphA gene whose transcribed gene 
product phosphorylates the 2’ hydroxyl group on the desosamine sugar of the antibiotic 
143 
(59).  This modification prevents the drug from interacting with the drug target—the 
ribosome. 
MphR(A) is regulated by the presence of erythromycin (60).  When erythromycin 
is present, it can no longer bind to the promoter region of the gene cassette containing 
mphA, mrx, and MphR(A) and transcription of mph(A) is de-repressed.  The MphR(A) 
binding site completely overlaps that of the PmphA promoter (60) and is 2173 basepairs 
upstream of its own start codon.  The MphR(A) binding site is 35 base pairs in length. 
Thus MphR(A) has a negative feedback loop of its own expression (60).  This gene 
cassette has been found in many clinical and environmental sources and as such is mobile 
(61, 62). 
 MphR(A) is predicted to be part of the TetR class of transcriptional regulators 
based on the sequence of the N-terminal helix turn helix motif (63).  The dimeric motif is 
responsible for binding of Tet repressors to the promoter region.  Thus it is predicted for 
MphR(A) that its similar N-terminal motif is responsible for binding to the promoter 
region.   While the C-terminal domains of the MphR(A) and TetR classes of repressors 
differ in sequence, they both function to bind their respective ligand antibiotics.  
 MphR(A) can bind to various different ligands of different sizes including 12- 
14-, and 16-membered macrolactone antibiotics.  MphR(A) binds to these ligands 
irrespective of the ligand’s function.  MphR(A) can bind erythromycin, azithromycin, 
methymycin, and josamycin.  While these ligands all contain a macrocyclic lactone and a 
desosamine sugar, they differ in aspects of size and shape.  This brings us to the focus of 
this study, which was to determine the structure of MphR(A) in order to know how it can 
bind ligands of different sizes.  Once this is known, it is possible that MphR(A) can be 
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engineered to bind to and detect ligands other than the lactones to which it is known to 
bind. 
The gene for MphR(A) and the section of promoter to which it binds have also 
been utilized for many screens.  It has been fused to other genes to control expression of 
those genes in mammalian tissue culture and mice (63, 65).  The same fusion has been 
employed in vitro to determine the presence of erythromycin in milk (66, 67).  These 
fusions have also been used to determine the presence of macrolide antibiotics in 
Streptomyces fermentation extracts (68).  Thus in future, this type of gene system could 
be used to quickly and accurately screen soil and culture extracts for macrolide 
antibiotics .   
 Towards this end the structure of MphR (with and without the ligand 
erythromycin) was determined.  The protein was expressed as a selenomethionine 
derivative and its liganded structure was determined by the single wavelength anomalous 
diffraction (SAD) method.  The apo structure was then determined by molecular 
replacement. 
7.4:  Experimental Procedures  
7.4.1:  Crystallization 
In the crystallization trials, 10% glycerol was added to the MphR(A) solutions to 
stabilize the protein.  The final concentration of protein screened was 10 mg/ml.  For 
ligand screens, 10 mM erythromycin was added.  The first screens for crystal hits were 
performed using the sitting drop vapor diffusion method and encompassed 480 different 
conditions at three protein-to-well solution ratios.  Those ratios included one-to-one 
protein-to-well solution, two-to-one protein-to-well solution, and one-to-two protein-to-
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well solution.  Crystals were optimized by mixing 2 µl of protein solution with 1 µl of 
well solution in hanging drops.  The apo form of MphR(A) crystallized in a solution of 
18-22% (w/v) polyethylene glycol 3350, 0.2 M ammonium acetate, and 0.1 M Bis-Tris 
pH 5.5  MphR(A) bound to erythromycin crystallized in 35-40% (w/v) polyethylene 
glycol 3350, 0.2 M MgCl2, and Bis-Tris, pH 5.5.  Crystals were flash frozen in well 
solution containing 20% glycerol. 
7.4.2:  Data Collection, Phasing and Refinement 
 Data was processed using HKL2000(46), and the MphR(A)-erythromycin 
structure was determined using the program HKL2MAP to locate the selenium atoms and 
calculate the phases from selenium SAD.  The map was put through heavy-atom position 
refinement, density modification, and model building using autoSHARP (69).  Additional 
model building was performed using Coot (70).  Molecular replacement with the ligand-
bound MphR(A) was used to find the phases for the apo MphR(A) structure using 
MolRep.  Refmac (50) was used for refinement.  TLS refinement was used by setting 
each monomer as a separate TLS group (71). 
7.5:  Structure of MphR(A) with Erythromycin 
 The first structures were determined with the liganded MphR(A) because it was 
easier to crystallize.  The first crystals appeared after three days.  Selenomethionione was 
incorporated in the protein to determine phases by SAD.  Crystal and refinement statistics 
are shown in Table 7.1.  Each asymmetric unit contained a dimer.  Electron density was 
visible for residues 5-189 in one subunit and 6-189 in the second subunit with each 
subunit containing 194 residues.  There was clear electron density for erythromycin A 
binding in a central cavity in each subunit.  We found that MphR(A) contains nine α-
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helices per monomer (Figure 7.2) as characteristic of the structure of proteins in the same 
class—TetR (72), EthR (73), and QacR (74), etc.  The α-helices of MphR(A) encompass 
residues 9-22 (α1), 30-37 (α2), 41-48(α3), 51-72 (α4), 80-90 (α5), 99-111 (α6), 118-133 
(α7), 145-160 (α8), and 165-181(α9).  Structural alignment of the coordinates using the 
Secondary Structure Matching (SSM) (75) search algorithm revealed the closest 
homology (rmsd of 2.49Å for 156 matched Cα atoms in the monomer) to the regulator, 
IcaR from Staphylococcus epidermidis (76) (Protein Data Bank entry 2ZCM), thought the 
sequence identity was only 14.8%.   The purpose of IcaR is thought to be “antibiotic 
sensing.”  However, IcaR recognizes a different class of antibiotics, gentamicins, and is 
also important in controlling biofilm formation.  Structurally similar proteins that align 
their tertiary structure with MphR(A) include TetR (3.26 Å, 135 matched C
α
 atoms), 
EthR (2.98 Å, 147 matched C
α
 atoms), and QacR (2.76 Å, 144 matched C
α 
atoms). 
 The N-terminal residues of MphR(A) are responsible for binding to the DNA 
promoter region.  Residues 8-50 form a helix-turn-helix motif.  The two helix-turn-helix 
motifs (HTH) that are part of the dimer are separated by a distance of 46.3Å as measured 
from the two C
α
 atoms of L44.  L44 is a conserved residue of the TetR family.  The same 
distance between N termini is seen in QacR and Act—44 and 46Å distances respectively.  
Dissociation of MphR(A) from the promoter, which likely occurs upon ligand binding, is 
due to the large increase in distance between the N-termini.  The portion of the HTH 
motif that comes into contact with the promoter contains hydrophobic and conserved 
positively charged residues to bind to the negatively charged phosphate backbone.  The 
residues include K35, R41, and R51.   
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 Each monomer of MphR(A) binds one molecule of erythromycin.  Since 
erythromycin is largely hydrophobic so is the binding pocket for it.  The cavity is 
spanned by residues from helices α4-α8 and includes the dimeric interface of the other 
monomer.  The pocket is large enough to accommodate the entire ligand, including the 
desosamine and cladinose sugar residues.  To enter the central cavity the ligand has to 
traverse a short tunnel (Figure 7.2).  The cavity is lined with 17 residues of mainly 
hydrophobic nature that make close contact with the erythromycin.  The side chains are 
within 4Å of erythromycin (Figure 7.3).  The cavity also contains a small portion of 
positively charged residues to counteract a negatively charged portion on erythromycin.  
These residues consist of R122, N123, and H147.  Hydrogen bonds are formed between 
N123 and the C-9 and C-11 oxygen atoms of erthryomycin, H147 and the C-9 carbonyl, 
and R122 and the C1-carbonyl.  A water-mediated reaction involving the C-12 hydroxyl 
group of erythromycin and the backbone carbonyl of A151 and the hydroxyl of Y103 
further stabilizes negative charges on erythromycin.  A chloride ion was placed at a 
position of high electron density that was greater than 10 σ in the difference density map.  
The chloride ion interacts between the desosamine moiety of the erythromycin and the 
backbone amide of N94.  Only one of the monomers shows a hydrogen bond between 
K21 and the erythromycin cladinose O-6 and the 2’hydroxyl, and between S106 and the 
C-1carbonyl.  The 2’ hydroxyl of the desosamine residue of erythromycin is the target for 
MphA phosphotransferase protein that conveys resistance of the organism to 
erythromycin.  The Ɛ-nitrogen of K21 is located 4.6Å from this hydroxyl group in the 
second monomer.  Thus the phosphorylated product would be stabilized by this 
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interaction between its 2’-O-phosphate and the positively charged NH3 group, leading to 
the hypothesis that the phosphorylated erythromycin is a better ligand for MphR(A).   
7.6:  Structural Effects of Ligand Binding 
 Once the liganded structure of MphR(A) was determined, the apo form could be 
solved by molecular replacement.  Clear electron density was seen for residues 8-94, and 
101-190 for one monomer, and for residues 6-95 and 99-186 for the second monomer.  
The electron density was too weak to model residues 95-200 for the first monomer and 
residues 96-98 for the second monomer.  Both erythromycin-bound and apo structures of 
MphR(A) were aligned as dimers.  Their overlap had an rmsd of 0.86Å for 298 C
α 
atoms 
as determined by least squares method.  When one monomer was aligned the rmsd 
changed to 1.028Å for 173 atoms.  This occurs because when the rmsd is greater than 4Å, 
it is excluded as an outlier.  Thus the rmsd between atoms when the dimer is overlapped 
with a dimer contains more of these outliers than the rmsd calculated when one monomer 
is overlapped with the dimer.  It appears as if a large shift between monomers occurs 
upon ligand binding such that the distance between N-termini in the apo form becomes 
shorter.  This distance between the two C
α
 atoms of L44 is shorter and is only 42.9Å 
(Figure 7.4).  This shorter distance allows for correct positioning of the N-termini of the 
repressor on the promoter for optimal binding.  When erythromycin is bound, this 
distance increases and the hold on the promoter is lost, resulting in de-repression.  The 
apo form of MphR(A) also contains a larger cavity volume than the erythromycin-bound 
MphR(A).  As calculated by VOIDOO, the two cavities in the liganded-dimer are 1183 
and 1234Å
3
 and in apo MphR(A) dimer are 2273 and 1756Å
3
. Thus the cavity closes 
around the bound ligand, and brings the N-terminal HTH closer towards the cavity, 
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increasing the distance between termini.  The changes in structure can be accounted for 
by introduction of new bonds between MphR(A) and the ligand.  Hydrophobic residues 
T17 and L20 on helix 1, in the apo form, are more spaced out.  When erythromycin 
binds, these residues converge to make contacts with the hydrophobic region on the 
cladinose sugar residue.  Also on helix 1 are residues E14 and R61 that converge to form 
a strong ionic interaction when erythromycin is bound.   
7.7:  Discussion 
The TetR family of proteins is known for its role in antibiotic resistance.  However, these 
proteins may also have a role in secondary metabolism.  Some TetR family members 
have a role in secondary metabolism and as such are activated by metabolic intermediates 
and precursor ligands (77).  In fact, when a BLAST-P search is done with MphR(A), it 
reveals homologues that are part of the TetR family members including those from 
Myxococcus, Salinispora, and Streptomyces species.  10% of the genome of these species 
is involved in secondary metabolism.  Alignment shows that these homologues might 
function similarly as they share many conserved residues (Figure 7.5).  Importantly, they 
share a hydrophobic residue that in MphR(A) is L20 and is involved in the interaction of 
helix one with the binding pocket of erythromycin.  In addition proteins from 
Myxococcus and Rhodopseudomonas both have the anionic side chain of E14 (or D14) 
and the cationic side chain of R61 that form an ionic interaction between helices 1 and 4 
when the ligand is bound.  Conserved residues include R122 and N123 that in MphR(A) 
form favorable contacts with erythromycin.  It may be that proteins from these organisms 
recognize the same ligands as MphR(A).  Thus these proteins may have a dual function to 
protect the organism from environmental toxins and to regulate secondary metabolism.   
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 In addition to binding erythromycin, MphR(A) binds to larger ligands with extra 
sugar residues.  Those sugar residues might hang outside the entrance tunnel since the 
binding pocket snugly fits erythromycin with no extra room.  MphR(A) does not make 
any polar contacts with the desosamine sugar of erythromycin.  It probably does not 
make direct contacts to sugar molecules.  The sugar molecules are not critical to ligand 
recognition.  The polar contacts to the oxygen atoms at C-1, C-9, and C-11 suggest these 
must be the critical points of anchoring the ligand to the binding site.  If the 
phosphorylated erythromycin does indeed serve as a better ligand for MphR(A), it would 
create a cascade effect for activation of the operon.   
 Mutations to MphR(A) might be able to allow a different ligand to bind to 
MphR(A) or improve the sensitivity of MphR(A) for its natural ligands.  Such changes 
could lead to amplifying the MphR(A) response to the ligand creating a more pronounced 
activation of the operon.  Including multiple copies of the MphR(A) binding site might 
slow the response to ligands and give a positive signal for ligands when large 
concentrations are present.  Alternatively, the promoter could be modified to create a 
cascade response to detect smaller amounts of ligand.  Thus the MphR(A) regulatory 
system can be modified to create responses to different ligands, and to different 





Figure 7.1:  MphR(A) Ligands (64) 
The structures of known ligands of MphR(A) and order of genes.  MphA is the erythromycin 2’-





Figure 7.2:  Model of MphR(A) (64) 
This figure shows MphR(A) with and without erythromycin.  Space filling models show the tunnel 













Protein Data Bank code  3FRQ 3G56 
Data collection 
Space group P212121 P212121 P21 
Cell dimensions 
a, b, c (Å) 44.4, 61.1, 134.7 44.3, 61.2, 134.6 37.4, 113.8, 43.4 
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 93.9, 90.0 
Molecules per asymmetric unit 2 2 2 
Wavelength (Å) 0.9795 0.9795 1.000 
Resolution (Å) 50–2.0 50–1.76 50–2.1 
Rsym (last shell) 0.070 (0.321) 0.064 (0.419) 0.040 (0.467) 
I/σI (last shell) 51.2 (8.1) 30.0 (4.6) 30.2 (2.1) 
Completeness (%) (last shell) 99.7 (97.4) 99.5 (97.9) 98.5 (90.7) 
Redundancy (last shell) 7.3 (7.0) 7.8 (7.4) 4.1 (3.6) 
No. of reflections 45,208 35,182 20,802 
Refinement 
Resolution (Å)  30–1.76 57–2.1 
Rwork/Rfree (%)  18.1/22.1 22.0/28.4 
No. of protein residues in monomers A/B/C/D/E/F/G/H  184/183 176/179 
No. of non-protein atoms 
Ligand  102 0 
Solvent  273 84 
Mean B-factors (Å
2
)  30.0 48.1 
RMSD 
Bond lengths (Å)  0.017 0.015 




Figure 7.3:  Interactions of MphR(A) (64) 
(a) The figure is a stereo image of the ligand binding site of MphR(A) with erythromycin.  Polar contacts 
within 4Å are shown as dotted lines.  (b)  The surface charge of Mphr(A) as seen from the bottom HTH.  
Surface resiudes are labeled.  (c)  The 2Fo-Fc electron density map of the erythromycin bound to the ligand 











Figure 7.5:  CLUSTALW alignment of homologues of MphR (64).   
Mx, Myxococcus Xanthus (accession no. YP_633146); Rp, Rhodopseudomonas palustris (accession no. 
YP_ABE4088); St, Salinispora tropica (accession no. YP_001159116); Ec, TetR from E.coli.  Black boxes 
represent complete identity, open boxes represent similar residues, and arrows indicate the residues 





Chapter 8:  Crystal Structure of N-Acetyl-L-glutamate Synthase from Neisseria 
gonorrhoeae  
8.1:  Overview 
 This chapter contains work published along with Dr. Dashuang Shi, Dr. Norma 
Allewell and Dr.Mendel Tuchman.  As author of this dissertation manuscript, it is my 
responsibility to discuss those portions of the project I completed and what was 
contributed by other authors.  Cloning, purification, and crystallization of Neisseria 
gonorrhoeae N-acetylgluatamate synthase (NAGS) was done solely by me.  I also 
completed the activity assays.  Computer manipulations of the x-ray diffraction data to 
determine the actual structure of N. gonorrhoeae NAGS was done by Dr. Dashuang Shi. 
8.2:  Statement of Authorization 
 This research was originally published in The Journal of Biological Chemistry by 
Dashuang Shi, Vatsala Sagar, Zhongmin Jin, Xiaolin Yu, Ljubica Caldovic, Hiroki 
Morizono, Norma M. Allewell, and Mendel Tuchman.  The paper was titled: The Crystal 
Structure of N-Acetly-L-glutamate Synthase from Neisseria gonorrhoeae Provides 
Insights into Mechansims of Catalysis and Regulation.  The Journal of Biological 
Chemistry.  2008; 283(11):  7176-7184. © the American Society for Biochemistry and 
Molecular Biology. 
8.3:  Introduction 
The first step in the synthesis of arginine is the acetylation of glutamate by N-
acetylgluatamate synthase (NAGS) to create N-acetlyglutamate (NAG).  NAG is then 
phosphorylated by NAG kinase (NAGK) to become NAG phosphate and then 
transformed into N-acetylornithine.  In organisms such as fungi, plants, and many 
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bacteria, NAG can also be generated by transferring the acetyl group from N-acetyl 
ornithine to glutamate by ornithine acetyl transferase (OAT) (80, 81).  If organisms 
possess OAT they mainly use this enzyme to produce NAG in which process feedback 
inhibition by arginine usually targets NAGK and, to a much lesser extent, NAGS.  
However, if organisms do not possess OAT, then arginine mainly inhibits NAGS and 
does not at all inhibit NAGK (82).  Neisseria gonorrhoeae, in addition to having NAGS, 
contains an OAT that can use both acetyl CoA and N-acetylornithine as substrates to 
transfer the acetyl group (83).  However, NAG and OAT have little sequence similarity 
(82).   
 In mammals NAG acts as an obligatory allosteric activator of carbamylphosphate 
syntheatase I in the urea cycle (84).  Contrary to microorganisms, arginine is used by 
mammals to activate NAGS.  Without the production of NAG by NAGS, 
hyperammonemia ensues due to a dearth of carbamylphosphate synthetase I that causes a 
block in ureagenesis (85). 
 While enzymes of the arginine cycle usually show similar sequence similarity 
across phyla, the NAGS enzyme differs among mammals, fungi, and bacteria (86-88).  It 
is thought that the modern day NAGS was generated from the fusion of two genes 
containing NAGK and N-acetyltranferase (NAT).  Support for this hypothesis comes 
from the existence of enzymes that are bifunctional as kinases and acetyl transferases 
(88).  The existence of enzymes that are considerably shortened in some bacteria also 
favors this hypothesis (89). 
 While several NAGK and many NAT related structures have been solved, no 
NAGS structure from any organism had been solved until now (90-95).  This is probably 
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because NAGS proteins are usually unstable and not crystallizable (94).  The first look at 
a three-dimensional structure of a NAGS protein comes from the crystal structure of 
NAGS from Neisseria gonorrhoeae.  The structure reveals two domains that are 
connected but fold independently.  The domains are an N-terminal amino acid kinase 
domain and a C-terminal GCN5-related NAT domain.  Two structures have been solved 
with Acetyl Coenzyme A (AcCoA) bound and with both CoA and NAG bound.  The 
structures reveal aspects of the catalytic process and the allosteric effects of arginine.   
8.4:  Experimental Procedures 
8.4.1:  PCR of N. gonnorrhoeae NAGS 
 PCR of the argA gene was done using N. gonnorrhoeae genomic DNA (ATCC 
53420).  The primers used were CGGCATATGAACGCGCCCGACAGCTTTGT and 
CTTCTCGAGATATCAGCGGTGCAGGCGAC.  The PCR product was cloned into a 
pET28a expression vector (Novagen).  The gene was sequenced and contained three 
point variations that resulted in V312I, D336N, and P427S amino acid substitutions.  
These three amino acids are found in the NAT domain sequence of Neisseria 
meningitides NAGS (accession codes NP_274872, AAF42210 or CAM07850).  The 
construct that was cloned is the AAK domain of N. gonorrhoeae and the NAT domain of 
N. meningitides.   
8.4.2:  Protein Purification and Crystallization of NAGS 
Protein was expressed in Eschrichia coli BL21(DE3) cells (Invitrogen).  The 
protein was first purified on a Ni affinity column and subsequently on a DEAE column 
(GE Healthcare).  The protein was concentrated to 10 mg/ml.  It was incubated for 30 
minutes with 23 mM AcCoA or AcCoA with 100 mM L-glutamate.  CsCl was then 
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added to 100 mM of the concentrate.  The hanging drop method was used for crystal 
formation.  2 µl of well solution containing 100 mM CsCl, 6% polyethylene glycol 2250 
and 100 mM sodium citrate at pH 5.8 was mixed with 2 µl of the protein mixture to make 
the hanging drop.  The selenomethione- (SeMet) substituted protein was made using 
Overnight Auto-induction System 2 (Novagen) (94, 95).  The same procedure was used 
to make the SeMet crystals.  AcCoA and glutamate formed the reaction product CoA and 
NAG when incubated and these products crystallized with the protein. 
8.4.3:  Activity of NAGS 
 NAGS activity was measured in a solution containing 50 mM Tris-HCl buffer, pH 
8.5, 100 mM NaCl, 10 mM L-glutamate, and 2.5 mM AcCoA and 0.16 ug of enzyme in 
100 µl (88).  The reaction was incubated at 30°C for five minutes and terminated with 
100 µl of 30% trichloroacetic acid.  The amount of NAG produced was determined using 
liquid chromatography-mass spectroscopy as described (86, 87).  NAGK activity was 
measured colorimetrically.  1.0 µg of enzyme was mixed in 100 µl 100 mM Tris-HCl, pH 
8.5, 100 mM NaCl, 100 mM NAG, 20 mM ATP, 40 mM MgCl2 and 400mM 
hydroxylamine at room temperature for 20 minutes.  The reaction was terminated and the 
color was developed by adding 100 µl of 5% FeCl3, 8% trichloracetic acid, and 0.3 M 
HCl.  The absorbance of product was measured at 540nm.  Inhibition of NAGS activity 
was measured over 0.01 mM -10 mM L-arginine concentrations.  
8.5:  Enzymatic Activity  
The enzyme had a specific NAGS activity of 29.1 µmol/min/mg protein.  The 
activity is about 10 times lower than the NAGS activity of NAGS/K enzyme from 
Xanthomonas campestris and 4 times lower than NAGS from E. coli (96).  
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 N. gonorrhoeae NAGS activity is inhibited by arginine with 50% inhibition with 
0.15mM arginine.  The enzyme has no NAGK activity, in line with the fact that N. 
gonorrhoeae contains a separate gene encoding NAGK (accession number YP_207961). 
8.6:  Linkage of the AAK and NAT Domains 
The monomeric  N. gonorrhoeae NAGS consists of two domains that are linked 
together by three amino acids (10Å) (Figure 8.3).  The N-terminal Amino Acid Kinase 
(AAK) domain and the C-terminal GCN5-related NAT domain share no other 
monomeric contacts.  The AAK domain consists of an eight-stranded parallel β sheet 
bracketed by α helices on both sides.  Proteins with similar folds include NAGK (92, 93), 
carbamate kinase (98), carbamate kinase-like CPS (99), UMP kinase (100, 101), 
aspartokinase (102), and 5-glutamate kinase (103).  The NAGK structure of Thermotoga 
maritima, and Pseudomonas aeruginosa, when overlayed with the AAK domain of N. 
gonorrhoeae, have a root mean square deviation of 1.7 and 1.6Å for the 238 and 234 
equivalent C
α
 atoms.  The amino acid sequence of the AAK domain from N. gonorrhoeae 
has 25.9 and 27.4% sequence identity to T. maritima and P. aeruinosa NAGK, 
respectively.  Differences between organisms occur in the N-terminal lobe, which is 
responsible for binding different substrates and making dimer contacts.  The C-terminal 
lobe, since it is responsible for binding the same ATP molecule, is similar (101, 103).  
Among different organisms NAGK mainly varies in the β3-β4 loop.  Different 
conformations lead to either opening or closing of the active site.  For the AAK domain 
of N. gonorrhoeae the active site is closed similar to the state of Mycobacterium 
tuberculosis NAGK without substrate.  
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 The C-terminal NAT domain on the other hand contains a central anti-parallel β 
sheets surrounded by α helices on both sides.  The β sheets are divided to form a V shape 
with AcCoA binding inside the V.  On the N-terminus of the V is a four-stranded anti-
parallel β sheet surrounded by three α helices.  On the C-terminus of the V is a three-
stranded anti-parallel β sheet surrounded by two α helices.  At the closure of the V, the β 
strands share four hydrogen bonds between two parallel strands (β22 and β23).  The 
bulge caused by A355 and C356 causes the V to split.  According to a DALI data base 
search, the NAT domain of N. gonorrhoeae is most similar to the GCN5 histone 
acetyltransferase (Protein Data Bank code 1M1D) with a z score of 16.4 (104).  




8.7:  NAGS Monomers Form a Hexameric Ring  
 Crystals of NAGS from N. gonorrhoeae have one molecule in the asymmetric 
unit.  The crystals have a three-fold crystallographic symmetry axis that aligns with the 
molecular three-fold axis, and a two-fold crystallographic symmetry axis that aligns with 
the molecular two-fold axis.  Thus it can be said that the hexamer consists of either three 
dimers or two trimers.   
 The AAK domain of one monomer makes contacts with the NAT domain of a 
neighboring monomer.  Two stacked trimers form a ring with outer diameter 100Å and 
inner diameter 20Å and a height of 110Å (Figure 8.4A).  The width of the inside ring is 
smaller than the 26-32Å arginine sensitive NAGK structures, which change ring size 
depending on whether arginine is bound or not (92).   
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 When the three dimensional structure of the hexamer is viewed perpendicularly to 
the 3-fold axis, the AAK domains form a zigzag stripe across the middle of the molecule.  
The NAT domains are at the top and bottom of this stripe (Figure 8.4A).  Each AAK 
domain makes contacts with two other AAK domains.  The hexamers in the crystal are 
packed together along the c axis to form long tubes of alternating AAK and NAT layers. 
8.8:  Interactions Across the Dimer Interface 
 The AAK domain can make two types of dimer contacts with other AAK domains 
along the zigzag stripe across the middle of the molecule (Figure 8.4, B and C).  The first 
is the dimer contact between K1 and K4 (Figure 8.4C).  The contacts occur amongst 
residues from strand 5, helix 4, helix 5, and the loop between strands 11 and 12 in the N-
terminal lobes of both subunits.  The contacts are planar with α helices flanking strand 5.  
Strand 5 makes antiparallel β strand contacts with strand 5 from the neighboring subunit 
and transforms the 8-stranded β sheet from each monomer into an extended 16-stranded β 
sheet.  The interactions that occur are mainly the formation of hydrogen bonds including 
the main chain atoms of L125, S127, and N129.  The α helices interact principally 
through hydrophilic contacts including the side chains of Q96, R103, S104, E107, N129, 
Q161 and H175.  There are also some hydrophic interactions involving V126, F160, and 
A164 in the dimer interface.  The strength of the many hydrogen bonds and hydrophic 
contacts suggests that the crystal structure represents the natural dimeric interface. 
 Another dimer contact occurs between K1 and K5 and involves interlacing helices 
(Figure 8.4B).  The helix bends at conserved P16 and is divided into an N-terminal helix 
and a C-terminal helix.  The N-terminal helix is 15 residues long and amphipathic with 
charges on one side and hydrophobic residues on the other side.  The C-terminal helix is 
164 
five residues long and thought to be responsible for binding arginine at a place similar to 
that where ariginine binds in NAGK enzyme (92).  Y16, which aligns with Y15 and Y21 
in the sequence of T. maritima and P. aeruginosa NAGK, is in this C-terminal helix.  F7, 
F11, A14, I18, and H10 form hydrophobic contacts across the N-terminal helices creating 
a two-fold dimer axis.  Since the N-terminal helix is amphipathic, it is lined with R12, 
R19, and R22 on the other side and these residues also make contacts between K1 and 
K5.  Hexamer formation is likely to be reliant on the N-terminal helix.  This helix is 
probably responsible for the arginine regulatory response and formation of the hexamer is 
likely to be key to the arginine response.  Thus hexamer formation probably also occurs 
in nature (92).   
 The dimeric contacts between K1-K4 and K1-K5 occupy a buried surface area of 
1206 and 1340 Å
2
.  This indicates that the hexamer is most likely to occur both in 
solution and in the crystal structure. 
8.9:  The Interaction of AAK and NAT Domains  
 Though the AAK domain and the NAT domain of a monomer do not interact, the 
AAK domain and the NAT domain of adjacent monomers do interact (Figure 8.4D).  
These contacts are polar and involve the side chains of R134, D140, D143, R151, K152 
and the main chain oxygen or nitrogen atoms of I136, V138, and G141 from the AAK 
domain interacting with N393, T394, N426, and H428 from the NAT domain.  The 
AcCoA bound to the NAT domain also makes contacts with the AAK domain via atoms 
O2*, O3*, and OAQ and R134, R151, and K152 from the AAK domain (Figure 8.4D).   
8.10:  The AAK Domain Cannot Catalyze a Reaction 
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Though NAGK proteins and AAK proteins share significant sequence similarity 
(20-27%), the AAK domain lacks several key residues that would allow it to bind ATP 
and NAG and enable phosphorylation of NAG.  K8 is one such residue that is conserved 
in all NAGK sequences including X. campestris NAGS/K and in the AAK domain of N. 
gonorrhoeae NAGS is changed to G29.  Furthermore, the side chain of M186 occupies 
the place where the K8 side chain would lie.  All NAGK enzymes have a conserved 
N160-A161-D162 (E. coli NAGK numbering), but the AAK domain contains D185-
M186-V187 in its place.  Finally the important K217 is replaced by L241 in the AAK 
domain.  These replacements would suggest that the NAGK domain of N. gonorrhoeae 
NAGS is inactive (88). 
8.11:  The Catalytic Mechanism 
 The densities of AcCoA, CoA, and NAG delineate the active site of the NAT 
domain (Figures 8.1 and 8.2A).  AcCoA and CoA bind to the NAT domain using the 
loop-joining strands 22 and 12 to engage the pyrophosphate group.  The sequence N364-
E365-G366-G367-Y368-G369 in the loop agrees with the (R/N)-Xaa-Xaa-G-Xaa-(G/A) 
sequence for binding AcCoA in the GCN5-related NAT superfamily members (105).  
However, as previously mentioned, the side chains of R134, R151, and K152 from the 
adjacent AAK domain also take part in binding AcCoA (Figure 8.4D).  The adenosine 
ring is anchored via hydrogen bonds to the side chain of E397.  AcCoA bends about 180° 
at the pyrophosphate group so that the CoA chain is parallel to the adenosine ring.  It also 
bends 90° at the CBO atom of pantetheine to bury the acetyl group in the core of the 
NAT domain.  The acetyl group is bound in a hydrophobic pocket that is lined by the side 
chains of A355, L357, and F399.  The acetyl carbonyl hydrogen atom bonds to the main 
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chain nitrogen atoms of C356 and L357 and positions the acetyl group towards the 
opening of the V created by the B bulge of A355-C356 (Figure 8.1).  The same hydrogen 
bonding between the acetyl carbonyl group and the NH group of the residue aligning with 
L357 have been shown in other GCN5-related NAT proteins (106).  What is missing in 
the case of the acetyl group is a conserved tyrosine that interacts with the sulfur or 
carbonyl atom of AcCoA in other NAT proteins (91, 107).  S392 is the closest alternative 
but its side chain oxygen atom is 3.7Å away from the sulfur atom of AcCoA.  However, 
S392 does form a hydrogen bond with the sulfur atom of CoA (3.3Å).  The side chain of 
S392 appears to form a hydrogen bond with the main chain nitrogen atom of T395, 
preventing its locomotion.  The pantetheine moiety of AcCoA and CoA form hydrogen 
bonds to the NH group of V359 (NH) and carbonyl group of L357, similar to the 
hydrogen bonding in an anti-parallel β-sheet.  The carbonyl atoms of AcCoA and CoA 
make hydrogen bonds with the side chains of T395 and Q364. 
 Since the acetyl group of AcCoA is buried deep within the protein, the glutamate 
molecule must enter the active site from a passageway at the other end of the protein.  
This passageway allows AcCoA access to the solvent.  The ternary complex of AcCoA 
and glutamate shows that glutamate or the NAGS carboxyl group form bonds with R316, 
R425, S427, and the main chain nitrogen atoms of C356 and L314.  The hydrophobic 
side chains of L314 and L391 make interactions with the methylene groups in the side 
chain of glutamate.  The acetyl carbonyl atom of the NAG hydrogen bonds to the main 
chain nitrogen atoms of C356 and L357.  The side chain of A416 has a fixed position due 
to hydrogen bonding with the side chain of conserved E353 and it also may contribute to 
the positive charge stabililizing the negative caroboxyl group of L-glutamate or NAG. 
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 Compared to the crystal structure with bound AcCoA, where both CoA and NAG 
are bound, the side chain of R316 swings 8Å closer to the active site (Figure 8.2A).  This 
movement might be critical for catalysis. 
 There are two schools of thought on how NAGS enzymes accomplish catalysis.  
The first is the two-step ping-pong method in which the acetyl group of AcCoA is first 
transferred to a cysteine group on the enzyme (108-110).  Then the L-glutamate binds 
and the acetyl group is transferred to it.  According to the crystal structure, the potential 
acceptor of the acetyl group, C356, is 8.4Å away from the sulfur atom of AcCoA making 
covalent attachment less likely.  The other hypothesis is that the active site 
accommodates both substrates simultaneously and that the acetyl group is directly 
transferred from AcCoA to L-glutamate.  Most members of the GCN5-related NAT 
family use this mechanism of acetyl group transfer (90).  A possible scenario for catalysis 
can be modeled based on the two solved structures (Figure 8.2B).  In this scenario the α-
amino nitrogen atom of L-glutamate is 2.5Å from the carbon atom of the acetyl group.  
The nitrogen atom is positioned to attack the carbonyl atom directly to form a S-
configured tetrahedral transition state.  The carbonyl atom of the acetyl group would be 
hydrogen bonded to the main chain nitrogen atoms of C356 and L357 imparting a slight 
positive charge to the carbon atom.  The products of CoA and NAG form and the sulfur 
atom of CoA moves 0.9Å towards the side chain of Ser392 for protonation before release.  
The plane of the acetyl group of NAG rotates almost 90° from the acetyl group of 
AcCoA.  At the same time, the side chain of R316 moves away to allow room for NAG 
to leave the active site.  The main chain carbonyl oxygen atom of L391 hydrogen bonds 
to the amino nitrogen atom of NAG and is close to the sulfur atom of CoA.  This 
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positioning may help proton transfer from the amino group of glutamate to the sulfur 
atom of CoA.   
8.12:  Classes of NAGS Protein  
 There are four different known types of NAGS.  The first class is the “classical” 
E.coli-like NAGS.  The second class is the bifunctional vertebrate-like NAGS-K.  The 
third class is the “short” NAGS.  The fourth class is the argH-argA fusion NAGS (111).  
The first two classes consist of an AAK domain and a NAT domain comprised of 
approximately 440 amino acids (87).  From the current crystal structure, it can be 
deduced that the AAK domain plays a regulatory role and the NAT domain plays a 
catalytic role.  This is consistent with the fact that the AAK domain can be removed and 
the NAT domain will still be functional, and that the AAK domain is not functional in all 
NAGS.  Sometimes the AAK domain may be part of an argH encoded argininosuccinate 
lyase (111).  Contrary to prevalent thought, this crystal structure shows that the AAK 
domain does not contribute to glutamate binding (92, 112).  
Aspartate transcarbamoylase is similar to NAGS as follows: the catalytic trimer is active 
alone and when combined with inactive dihydroorotase, or regulatory units, or even when 







Figure 8.1:  AcCoA Binding Site (97) 
The 2Fo-Fc electron density map is shown for the AcCoA binding site at 1.0 σ contour. The carbon atoms 
for AcCoA are represented by pink sticks.  The carbon atoms for the protein are represented by blue sticks 




Figure 8.2:  Ribbon Diagram of the the NAT domain for the AcCoA and CoA and 
NAG complexed structures and the reaction model. (97) 
  (a) A stereo diagram of the structures of NAGS with AcCoA in light blue and NAGS with CoA and NAG 
in green are superimposed. The bound CoA and NAG are shown as an 2Fo-Fc electron density map at 1.0 σ 
contour.  The carbon atoms of AcCoA are shown as pink sticks while the carbon atoms of NAG are shown 
as yellow sticks.  The side chains of R316 and R425 are shown as sticks because they are involved in NAG 
or glutamate binding.  (b)  The reaction model for the attack of the nitrogen of the α amino group of 
glutamate on the carbon atom of the acetyl group.  The nitrogen and carbon atoms are 2.5Å away and 




Figure 8.3:  Ribbon diagram for a NAGS monomer(A, shown in stereo) and its 
AAK(B) and NAT (C) domains. (97)   







Figure 8.4:  Molecular hexamer of N. gonorrhoeae NAGS and its interfaces.  (97) 
(a) Quaternary interactions between the subunits are shown.  (b) Dimer interface between the AAK domain 
of K1 and K5 is shown.  (c) Dimer interface between the AAK domain of K1 and K4 is shown.  (d)  Trimer 
interface between the AAK domain of K2 and the NAT domain of S1 is shown.  Each subunit is shown in a 




Chapter 9:  Future Studies 
Now that the crystal structure of a eukaryotic Rio2 kinase is known, we can begin 
to examine the role of residues that appear important to the function of Rio2.  Recent 
papers have been published by Karbstein and colleagues that elucidate the binding site of 
Rio2 in the ribosome and human Rio2’s  potential binding interactions with other 
ribosomal 43S processing factors (115, 116).  In-vitro binding assays with ribosomal 
processing factors and ribosomal proteins indicate yeast Rio2 seems to directly interact 
with Rps15, Rps5, Pno1, Tsr1, Dim1, Nob1, and indirectly interacts with Ltv1 and 
Enp1(116).  In addition, cryoEM studies were done of purified pre40S ribosomal 
particles pulled down by TAP tagged Rio2 in which various ribosomal processing factors 
were depleted or deleted to determine the exact positioning of these assembly factors in 
the ribosome (115).  Future studies of Rio2 might involve docking the eukaryotic 
structure of Rio2 into the electron density seen by cryoEM and observing whether 
conserved surface residues on ctRio2 might be involved in binding to other ribosomal 
processing factors or binding to the rRNA or proteins of the ribosome.  The surface 
residues can be mutated and TAP tagged Rio2 can be pulled down to view if it remains 
associated with the ribosome and with all the known ribosomal processing factors.  
Sucrose gradients can be run to observe whether mutated TAP tagged Rio2 is associating 
with the pre 40S ribosomal particle.  In vitro experiments can be performed to determine 
if purified Rio2 with various point mutations can bind to MBP tagged ribosomal 
processing factors as done previously by Karbstein (116).  Northern blots can be 
performed to determine if the point mutations have any affect on rRNA processing of 20S 
rRNA to 18S rRNA.   
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 The dependence of rRNA processing on the catalytic activity of Rio2 can be 
addressed.  Based on the crystal structure, mutations can be made to Rio2 that do not 
affect binding of ATP but affect catalysis.  A Northern blot can be run to witness the 
effect of the mutation on 20S rRNA processing.  Similarly TAP tagged Rio2 with the 
catalytic mutation can be pulled down to determine if catalytic activity has any effect on 
binding to the ribosome or association of ribosomal assembly factors.   
The future direction of the studies of the wing helix domain and Rio2p would be 
to dock ctRio2 into the cryoEM of the pre40S particle.  I would look for support of the 
data thus collected that extensive contacts besides the wing helix domain are made 
between Rio2 and the ribosomal particle.  I would also look for the position of R271 to 
suggest how it interacts with the ribosome or ribosomal processing factors.   The 
mutation of R271 on ribosomal binding could be tested in vivo by Northern blots to see if 
it affects ribosomal rRNA processing.  It can also be tested by sucrose gradient to support 
that mutated Rio2p is not associating with the ribosome.  The effect of the mutation of 
R271 on folding of Rio2p can be tested in vivo by CD of purified Rio2p or tested by 
proof of autophosphorylation of the mutated Rio2p. 
Cancer cells exhibit enhanced ribosomal production as discussed in Chapter 1.  
Inhibitors of human Rio2 might be potential anticancer drugs.  The study of inhibitors of 
yeast Rio2 is also advantageous because most of the studies of ribosome biogenesis have 
been in yeast.  Since I have purified human Rio2 and yeast Rio2 the next step would be to 
study the binding of various kinase inhibitors with a thermo fluorescence assay to 
determine melting point.  In this assay, purified protein is incubated with the inhibitor and 
then mixed with fluorescent dye which binds to hydrophobic residues.  The sample is put 
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in a thermocycler which increments the temperature slowly while monitoring 
flourescence.  When the protein become denatured, a spike in fluorescence is seen.  The 
inflection point of the fluorescent change marks the melting temperature of the protein.  
The binding of the kinase inhibitors to Rio2 can be determined by an increase in melting 
temperature.  The enzyme kinetics of human Rio2 and yeast Rio2 can be studied by 
autophoshphorylation rate with and without inhibitors.  When a potential inhibitor for 
human Rio2 has been identified, it can be cocrystallized with ctRio2 to observe how it 
binds and whether it can be used as a drug specific to Rio2. 
Crystallization of ctRio2 will help us make advances to the understanding of 
eukaryotic ribosomal biogenesis.  The presence of Rio2 is necessary for maturation of the 
43S preribosome and cleavage of the 20S rRNA to18S rRNA (21-23).  At least in vitro, 
Rio2 makes direct or indirect contacts with many of the 43S preribsomal processing 
factors and might be critical to their function (116).  As of now, the catalytic mechanism 
of Rio2 is not known, nor are its substrates or how it is important for cleavage of the 20S 
rRNA.  Understanding of how Rio2 structure relates to function is the next step of study.   
Understanding ribosomal biogenesis is also critical to the field of cancer therapeutics.  
Cancer cells have upregulated ribosomal biogenesis because of their rapid proliferation 
and need for increased protein production for the new daughter cells (1-4).  Ribosomal 
biogenesis is also correlated to cell cycle control and loss of cell cycle control in cancer 
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